Regulatory polynucleotides
By designing an AAV vector encoding a targeted siRNA and introducing targeted polynucleotides into cells, the problems of insufficient specificity of target expression strategies and off-target effects in the prior art are solved, and efficient inhibition of target genes is achieved.
Patent Information
- Application Number
- CN202411018854.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-06-15
- Filing Date
- 2018-05-04
- Publication Date
- 2024-11-08
AI Technical Summary
Existing target expression strategies have insufficient specificity and off-target effects when regulating gene expression, making it difficult to effectively inhibit the expression of specific genes.
These polynucleotides were designed and used to inhibit the expression of the target gene by AAV particles, including adeno-associated virus (AAV) vectors encoding molecules targeting small interfering RNA (siRNA) to introduce these polynucleotides into cells through AAV particles.
It achieves efficient and specific inhibition of target gene expression, reduces interference from non-target genes, and improves the therapeutic effect.
Smart Images

Figure CN118910166A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 2018800425347, application date May 4, 2018, and invention name “Regulatory Polynucleotides”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Provisional Patent Application No. 62 / 501,787, filed May 5, 2017, U.S. Provisional Patent Application No. 62 / 507,923, filed May 18, 2017, and U.S. Provisional Patent Application No. 62 / 520,093, filed June 15, 2017, the contents of each of which are incorporated herein by reference in their entirety.
[0004] Reference Sequence Listing
[0005] This application is submitted with a sequence listing in electronic format as an ASCII text file. The sequence listing is provided as an ASCII text file, titled 14482_155_228_SEQ_LIST_LISTING.txt, created on May 3, 2018, and 6,853,639 bytes in size. The sequence listing is incorporated herein by reference in its entirety. Field of the Invention
[0006] The present invention relates to compositions, methods and processes for the design, preparation, manufacture, use and / or formulation of AAV particles comprising regulatory polynucleotides, such as polynucleotides encoding at least one small interfering RNA (siRNA) molecule that targets at least one target gene. Targeting a target gene may interfere with gene expression and the resulting protein production. AAV particles comprising regulatory polynucleotides encoding at least one siRNA molecule can be inserted into a recombinant adeno-associated virus (AAV) vector. Methods of using AAV particles to inhibit the expression of a target gene in a subject are also disclosed. Background of the Invention
[0008] MicroRNA (or miRNA or miR) is a small, non-coding, single-stranded ribonucleic acid molecule (RNA) typically 19-25 nucleotides in length. More than one thousand microRNAs have been identified in mammalian genomes. Mature microRNAs primarily bind to the 3' untranslated region (3'-UTR) of target messenger RNA (mRNA) by partially or completely pairing with the complementary sequence of the target mRNA, thereby promoting the degradation of the target mRNA at the post-transcriptional level and, in some cases, inhibiting the initiation of translation. MicroRNAs play a vital role in many key biological processes, such as regulating the cell cycle and growth, apoptosis, cell proliferation, and tissue development.
[0009] miRNA genes are typically transcribed as long primary transcripts of miRNA (i.e., pri-miRNAs). The pri-miRNAs are cleaved into miRNA precursors (i.e., pre-miRNAs), which are then further processed to generate mature, functional miRNAs.
[0010] Although many target expression strategies utilize nucleic acid-based formats, there remains a need for improved nucleic acid formats with greater specificity and fewer off-target effects.
[0011] The present invention provides such improved forms in the form of artificial pri-, pre-, and mature microRNA constructs and methods for their design. These novel constructs can be synthesized as stand-alone molecules or encoded in plasmids or expression vectors for delivery to cells. Such vectors include, but are not limited to, adeno-associated viral vectors, such as vector genomes of any AAV serotype, or other viral delivery vectors, such as lentiviruses. Summary of the Invention
[0012] Described herein are methods, processes, compositions, kits, and devices for administering AAV particles comprising a regulatory polynucleotide encoding at least one siRNA molecule for treating, preventing, ameliorating, and / or ameliorating a disease and / or condition.
[0013] The details of various embodiments of the present invention are set forth in the following description. Other features, objects, and advantages of the present invention will become apparent from the description and drawings, and from the claims.
[0014] Set forth below are non-limiting embodiments that represent the subject matter described herein:
[0015] 1. An adeno-associated virus (AAV) viral genome comprising a nucleic acid sequence located between two inverted terminal repeats (ITRs), wherein the nucleic acid inhibits or represses the expression of a target gene in a cell when expressed, wherein the nucleic acid sequence comprises, in 5' to 3' order: a first region encoding a first sense strand sequence, a second region encoding a first antisense strand sequence, a third region encoding a second sense strand sequence, and a fourth region encoding a second antisense strand sequence, wherein the first and second sense strand sequences comprise at least 15 consecutive nucleotides, and the first and second antisense strand sequences are complementary to mRNA produced by the target gene and comprise at least 15 consecutive nucleotides, and wherein the first sense strand sequence and the first antisense strand sequence share a complementary region of at least 4 nucleotides in length, and the second sense strand sequence and the second antisense strand sequence share a complementary region of at least 4 nucleotides in length.
[0016] 2. An adeno-associated virus (AAV) viral genome comprising a nucleic acid sequence located between two inverted terminal repeats (ITRs), wherein the nucleic acid, when expressed, inhibits or represses the expression of a first target gene and a second target gene in a cell, wherein the nucleic acid sequence comprises, in 5' to 3' order: a first region encoding a first sense strand sequence, a second region encoding a first antisense strand sequence, a third region encoding a second sense strand sequence, and a fourth region encoding a second antisense strand sequence, wherein the first and second sense strand sequences comprise at least 15 consecutive nucleotides, and the first antisense strand sequence is complementary to the mRNA produced by the first target gene, and the second antisense strand sequence is complementary to the mRNA produced by the second target gene and comprises at least 15 consecutive nucleotides, and wherein the first sense strand sequence and the first antisense strand sequence share a complementary region of at least 4 nucleotides in length, and the second sense strand sequence and the second antisense strand sequence share a complementary region of at least 4 nucleotides in length.
[0017] 3. The AAV viral genome of embodiment 2 further comprises, in 5' to 3' order, a fifth region encoding a third sense strand sequence and a sixth region encoding a third antisense strand sequence, wherein the third sense strand sequence comprises at least 15 consecutive nucleotides, and the third antisense strand sequence is complementary to the mRNA produced by the third target gene and comprises at least 15 consecutive nucleotides, and wherein the third sense strand sequence and the third antisense strand sequence share a complementary region of at least 4 nucleotides.
[0018] 4. The AAV viral genome of embodiment 3 further comprises, in 5' to 3' order, a seventh region encoding a fourth sense strand sequence and an eighth region encoding a fourth antisense strand sequence, wherein the fourth sense strand sequence comprises at least 15 consecutive nucleotides, and the fourth antisense strand sequence is complementary to the mRNA produced by the fourth target gene and comprises at least 15 consecutive nucleotides, and wherein the fourth sense strand sequence and the fourth antisense strand sequence share a complementary region of at least 4 nucleotides.
[0019] 5. The AAV viral genome of embodiment 2, wherein the first target gene is the same as the second target gene.
[0020] 6. The AAV viral genome of embodiment 3, wherein the third target gene is the same as the first target gene.
[0021] 7. The AAV viral genome of embodiment 3, wherein the third target gene is the same as the second target gene.
[0022] 8. The AAV viral genome of embodiment 3, wherein the first target gene, the second target gene, and the third target gene are the same.
[0023] 9. The AAV viral genome of embodiment 4, wherein the fourth target gene is the same as the first target gene.
[0024] 10. The AAV viral genome of embodiment 4, wherein the fourth target gene is the same as the second target gene.
[0025] 11. The AAV viral genome of embodiment 4, wherein the fourth target gene is the same as the third target gene.
[0026] 12. The AAV viral genome of embodiment 4, wherein the fourth target gene is the same as the first target gene and the second target gene.
[0027] 13. The AAV viral genome of embodiment 4, wherein the fourth target gene is the same as the second target gene and the third target gene.
[0028] 14. The AAV viral genome of embodiment 4, wherein the fourth target gene is the same as the first target gene, the second target gene, and the third target gene.
[0029] 15. The AAV viral genome of any one of embodiments 1-14, wherein the first target gene, the second target gene, the third target gene and / or the fourth target gene is the Huntington gene.
[0030] 16. The AAV viral genome of any one of embodiments 1-14, wherein the first target gene, the second target gene, the third target gene and / or the fourth target gene is SOD1.
[0031] 17. The AAV viral genome of any one of embodiments 1-14, wherein the first target gene, the second target gene, the third target gene and / or the fourth target gene is Huntington's gene or SOD1.
[0032] 18. The AAV viral genome of embodiment 1 or 2, wherein the region of complementarity between the first sense strand and the first antisense strand is at least 12 nucleotides in length.
[0033] 19. The AAV viral genome of embodiment 18, wherein the length of the complementary region between the first sense strand and the first antisense strand is 14 to 21 nucleotides.
[0034] 20. The AAV viral genome of embodiment 19, wherein the length of the complementary region between the first sense strand and the first antisense strand is 19 nucleotides.
[0035] 21. The AAV viral genome of embodiment 1 or 2, wherein the region of complementarity between the second sense strand and the second antisense strand is at least 12 nucleotides in length.
[0036] 22. The AAV viral genome of embodiment 21, wherein the length of the complementary region between the second sense strand and the second antisense strand is 14 to 21 nucleotides.
[0037] 23. The AAV viral genome of embodiment 22, wherein the length of the complementary region between the second sense strand and the second antisense strand is 19 nucleotides.
[0038] 24. The AAV viral genome of embodiment 3, wherein the region of complementarity between the third sense strand and the third antisense strand is at least 12 nucleotides in length.
[0039] 25. The AAV viral genome of embodiment 24, wherein the length of the complementary region between the third sense strand and the third antisense strand is 14 to 21 nucleotides.
[0040] 26. The AAV viral genome of embodiment 25, wherein the length of the complementary region between the third sense strand and the third antisense strand is 19 nucleotides.
[0041] 27. The AAV viral genome of embodiment 4, wherein the region of complementarity between the fourth sense strand and the fourth antisense strand is at least 12 nucleotides in length.
[0042] 28. The AAV viral genome of embodiment 27, wherein the length of the complementary region between the fourth sense strand and the fourth antisense strand is 14 to 21 nucleotides.
[0043] 29. The AAV viral genome of embodiment 25, wherein the length of the complementary region between the fourth sense strand and the fourth antisense strand is 19 nucleotides.
[0044] 30. The AAV viral genome of embodiment 1 or 2, wherein the first sense strand sequence, the second sense strand sequence, the first antisense strand sequence, and the second antisense strand sequence are independently 30 nucleotides or less.
[0045] 31. The AAV viral genome of embodiment 3, wherein the first sense strand sequence, the second sense strand sequence, the third sense strand sequence, the first antisense strand sequence, the second antisense strand sequence, and the third antisense strand sequence are independently 30 nucleotides or less.
[0046] 32. The AAV viral genome of embodiment 4, wherein the first sense strand sequence, the second sense strand sequence, the third sense strand sequence, the fourth sense strand sequence, the first antisense strand sequence, the second antisense strand sequence, the third antisense strand sequence, and the fourth antisense strand sequence are independently 30 nucleotides or less.
[0047] 33. The AAV viral genome of embodiment 1 or 2, wherein at least one of the first sense strand sequence and the first antisense strand sequence or the second sense strand sequence and the second antisense strand sequence comprises a 3' overhang of at least 1 nucleotide.
[0048] 34. The AAV viral genome of embodiment 1 or 2, wherein at least one of the first sense strand sequence and the first antisense strand sequence or the second sense strand sequence and the second antisense strand sequence comprises a 3' overhang of at least 2 nucleotides.
[0049] 35. The AAV viral genome of embodiment 3, wherein the third sense strand sequence and the third antisense strand sequence comprise a 3' overhang of at least 1 nucleotide.
[0050] 36. The AAV viral genome of embodiment 3, wherein the third sense strand sequence and the third antisense strand sequence comprise a 3' overhang of at least 2 nucleotides.
[0051] 37. The AAV viral genome of embodiment 4, wherein the fourth sense strand sequence and the fourth antisense strand sequence comprise a 3' overhang of at least 1 nucleotide.
[0052] 38. The AAV viral genome of embodiment 4, wherein the fourth sense strand sequence and the fourth antisense strand sequence comprise a 3' overhang of at least 2 nucleotides.
[0053] 39. The AAV viral genome of any one of embodiments 1-38, wherein the first region comprises a promoter 5' of the first sense strand sequence, followed by the first sense strand sequence, and the second region comprises a first antisense strand sequence, followed by a promoter terminator 3' of the first antisense strand sequence; or the third region comprises a promoter 5' of the second sense strand sequence, followed by the second sense strand sequence, and the fourth region comprises a second antisense strand sequence, followed by a promoter terminator 3' of the second antisense strand sequence.
[0054] 40. The AAV viral genome of any one of embodiments 1-38, wherein the first region comprises a promoter 5' of the first sense strand sequence, followed by the first sense strand sequence, and the second region comprises a first antisense strand sequence, followed by a promoter terminator 3' of the first antisense strand sequence; and the third region comprises a promoter 5' of the second sense strand sequence, followed by the second sense strand sequence, and the fourth region comprises a second antisense strand sequence, followed by a promoter terminator 3' of the second antisense strand sequence.
[0055] 41. The AAV viral genome of any one of embodiments 3-40, wherein the fifth region comprises a promoter 5' of the third sense strand sequence, followed by the third sense strand sequence, and the sixth region comprises a third antisense strand sequence, followed by a promoter terminator 3' of the third antisense strand sequence.
[0056] 42. The AAV viral genome of any one of embodiments 4-41, wherein the seventh region comprises a promoter 5' of the fourth sense strand sequence, followed by the fourth sense strand sequence, and the eighth region comprises a fourth antisense strand sequence, followed by a promoter terminator 3' of the fourth antisense strand sequence.
[0057] 43. The AAV viral genome of embodiment 3, wherein the fifth region is 3′ to the fourth region.
[0058] 44. The AAV viral genome of embodiment 4, wherein the seventh region is 3′ to the sixth region.
[0059] 45. The AAV viral genome of any one of embodiments 39-44, wherein the promoter is a Pol III promoter and the promoter terminator is a Pol III promoter terminator.
[0060] 46. The AAV viral genome of embodiment 45, wherein the Pol III promoter is U3, U6, U7, 7SK, H1 or MRP, EBER, selenocysteine tRNA, 7SL, adenovirus VA-1 or telomerase gene promoter, and the Pol III promoter terminator is U3, U6, U7, 7SK, H1 or MRP, EBER, selenocysteine tRNA, 7SL, adenovirus VA-1 or telomerase gene promoter terminator.
[0061] 47. The AAV viral genome of embodiment 46, wherein the Pol III promoter is an H1 promoter, and the Pol III promoter terminator is an H1 promoter terminator.
[0062] 48. The AAV viral genome of any one of embodiments 1-47, wherein the AAV viral genome is a monospecific polycistronic AAV viral genome.
[0063] 49. The AAV viral genome of any one of embodiments 1-47, wherein the AAV viral genome is a bispecific polycistronic AAV viral genome.
[0064] 50. The AAV viral genome of embodiment 1 or 2, wherein the first region and the second region encode a first siRNA molecule, and the third region and the fourth region encode a second siRNA molecule, wherein the first and second siRNA molecules target different target genes.
[0065] 51. The AAV viral genome of embodiment 3, wherein the fifth region and the sixth region encode a third siRNA molecule, wherein the first siRNA molecule, the second siRNA molecule, and the third siRNA molecule each target a different target gene.
[0066] 52. The AAV viral genome of embodiment 4, wherein the seventh region and the eighth region encode a fourth siRNA molecule, wherein the first siRNA molecule, the second siRNA molecule, the third siRNA molecule, and the fourth siRNA molecule each target a different target gene.
[0067] 53. An adeno-associated virus (AAV) viral genome comprising a nucleic acid sequence located between two inverted terminal repeats (ITRs), wherein the nucleic acid sequence comprises a first molecular scaffold region and a second molecular scaffold region, wherein the first molecular scaffold region comprises a first molecular scaffold nucleic acid sequence encoding:
[0068] (a) a first stem and a loop to form a first stem-loop structure, the sequence of the first stem-loop structure comprising from 5' to 3':
[0069] i. a first UG motif located at or near the base of the first 5' stem of the first stem-loop structure;
[0070] ii. a first 5' stem arm comprising a first sense strand and optionally a first 5' spacer, wherein the first 5' spacer, when present, is located between the first UG motif and the first sense strand;
[0071] iii. a first loop region comprising a first UGUG motif at the 5' end of the first loop region;
[0072] iv. a first 3' stem arm comprising a first antisense strand and optionally a first 3' spacer, wherein uridine is present at the 5' end of the first antisense strand, and wherein the first 3' spacer, when present, has a length sufficient to form one helical turn;
[0073] (b) a first 5' flanking region located 5' to the first stem-loop structure; and
[0074] (c) a first 3' flanking region located 3' to the first stem-loop structure, wherein the first 3' flanking region comprises a CNNC motif, and
[0075] The second molecular scaffold region comprises a second molecular scaffold nucleic acid sequence encoding
[0076] (d) a second stem and a loop to form a second stem-loop structure, the sequence of the second stem-loop structure comprising from 5' to 3':
[0077] v. a second UG motif located at or near the base of the second 5' stem of the second stem-loop structure;
[0078] vi. a second 5' stem arm comprising a second sense strand and optionally a second 5' spacer, wherein the second 5' spacer, when present, is located between the second UG motif and the second sense strand;
[0079] vii. a second loop region comprising a second UGUG motif at the 5' end of the second loop region;
[0080] viii. a second 3' stem arm comprising a second antisense strand and optionally a second 3' spacer, wherein uridine is present at the 5' end of the second antisense strand, and wherein the second 3' spacer, when present, has a length sufficient to form one helical turn;
[0081] ix. a second 5' flanking region located 5' to the second stem-loop structure; and
[0082] (e) a second 3' flanking region located 3' to the second stem-loop structure, wherein the second 3' flanking region comprises a CNNC motif, and
[0083] wherein the first antisense strand and the first sense strand form a first siRNA duplex, and the second antisense strand and the second sense strand form a second siRNA duplex, wherein the first siRNA duplex, when expressed, inhibits or represses expression of a first target gene in a cell, and the second siRNA duplex, when expressed, inhibits or represses expression of a second target gene in a cell, wherein the first and second sense strand sequences comprise at least 15 nucleotides, the first antisense strand sequence is complementary to mRNA produced by the first target gene, and the second antisense strand sequence is complementary to mRNA produced by the second target gene, and wherein the first sense strand sequence and the first antisense strand sequence share a complementary region of at least 4 nucleotides in length, and the second sense strand sequence and the second antisense strand sequence share a complementary region of at least 4 nucleotides in length.
[0084] 54. An adeno-associated virus (AAV) viral genome comprising a nucleic acid sequence located between two inverted terminal repeats (ITRs), wherein the nucleic acid sequence comprises a first molecular scaffold region and a second molecular scaffold region, wherein the first molecular scaffold region comprises a first molecular scaffold nucleic acid sequence encoding:
[0085] (a) a first stem and a loop to form a first stem-loop structure, the sequence of the first stem-loop structure comprising from 5' to 3':
[0086] i. a first UG motif located at or near the base of the first 5' stem of the first stem-loop structure;
[0087] ii. a first 5' stem arm comprising a first antisense strand and optionally a first 5' spacer, wherein the first 5' spacer, when present, is located between the first UG motif and the first antisense strand;
[0088] iii. a first loop region comprising a first UGUG motif at the 5' end of the first loop region;
[0089] iv. a first 3' stem arm comprising a first sense strand and optionally a first 3' spacer, wherein uridine is present at the 5' end of the first sense strand, and wherein the first 3' spacer, when present, has a length sufficient to form one helical turn;
[0090] (b) a first 5' flanking region located 5' to the first stem-loop structure; and
[0091] (c) a first 3' flanking region located 3' to the first stem-loop structure, wherein the first 3' flanking region comprises a CNNC motif, and
[0092] The second molecular scaffold region comprises a second molecular scaffold nucleic acid sequence encoding
[0093] (d) a second stem and a loop to form a second stem-loop structure, the sequence of the second stem-loop structure comprising from 5' to 3':
[0094] v. a second UG motif located at or near the base of the second 5' stem of the second stem-loop structure;
[0095] vi. a second 5' stem arm comprising a second antisense strand and optionally a second 5' spacer, wherein the second 5' spacer, when present, is located between the second UG motif and the second antisense strand;
[0096] vii. a second loop region comprising a second UGUG motif at the 5' end of the second loop region;
[0097] viii. a second 3' stem arm comprising a second antisense strand and optionally a second 3' spacer, wherein uridine is present at the 5' end of the second antisense strand, and wherein the second 3' spacer, when present, has a length sufficient to form one helical turn;
[0098] (e) a second 5' flanking region located 5' to the second stem-loop structure; and
[0099] (f) a second 3' flanking region located 3' to the second stem-loop structure, wherein the second 3' flanking region comprises a CNNC motif, and
[0100] wherein the first antisense strand and the first sense strand form a first siRNA duplex, and the second antisense strand and the second sense strand form a second siRNA duplex, wherein the first siRNA duplex, when expressed, inhibits or represses expression of a first target gene in a cell, and the second siRNA duplex, when expressed, inhibits or represses expression of a second target gene in a cell, wherein the first and second sense strand sequences comprise at least 15 nucleotides, the first antisense strand sequence is complementary to mRNA produced by the first target gene, and the second antisense strand sequence is complementary to mRNA produced by the second target gene, and wherein the first sense strand sequence and the first antisense strand sequence share a complementary region of at least 4 nucleotides in length, and the second sense strand sequence and the second antisense strand sequence share a complementary region of at least 4 nucleotides in length.
[0101] 55. The AAV viral genome of embodiment 53 or 54, wherein the first antisense strand sequence or the second antisense strand sequence inhibits or represses the expression of the Huntington gene.
[0102] 56. The AAV viral genome of embodiment 53 or 54, wherein the first antisense sequence and the second antisense sequence inhibit or repress the expression of the Huntington gene.
[0103] 57. The AAV viral genome of embodiment 53 or 54, wherein the first antisense strand sequence or the second antisense strand sequence inhibits or represses the expression of SOD1.
[0104] 58. The AAV viral genome of embodiment 53 or 54, wherein the first antisense strand sequence and the second antisense strand sequence inhibit or repress the expression of SOD1.
[0105] 59. The AAV viral genome of embodiment 53 or 54, wherein the first 5' flanking region is selected from the sequences listed in Table 10.
[0106] 60. The AAV viral genome of embodiment 53 or 54, wherein the second 5' flanking region is selected from the sequences listed in Table 10.
[0107] 61. The AAV viral genome of embodiment 59, wherein the second 5' flanking region is selected from the sequences listed in Table 10.
[0108] 62. The AAV viral genome of embodiment 53 or 54, wherein the first loop region is selected from the sequences listed in Table 11.
[0109] 63. The AAV viral genome of embodiment 53 or 54, wherein the second loop region is selected from the sequences listed in Table 11.
[0110] 64. The AAV viral genome of embodiment 62, wherein the second loop region is selected from the sequences listed in Table 11.
[0111] 65. The AAV viral genome of embodiment 53 or 54, wherein the first 3' flanking region is selected from the sequences listed in Table 12.
[0112] 66. The AAV viral genome of embodiment 53 or 54, wherein the second 3' flanking region is selected from the sequences listed in Table 12.
[0113] 67. The AAV viral genome of embodiment 65, wherein the second 3' flanking region is selected from the sequences listed in Table 12.
[0114] 68. The AAV viral genome of embodiment 53 or 54, wherein the nucleic acid sequence comprises a promoter sequence between the first molecular scaffold nucleic acid sequence and the second molecular scaffold nucleic acid sequence.
[0115] 69. The AAV viral genome of embodiment 53 or 54, further comprising a promoter 5' of the first 5' flanking region followed by the first 5' flanking region in (b), and a first 3' flanking region followed by the promoter terminator 3' of the first 3' flanking region in (c), and a promoter 5' of the second 5' flanking region followed by the second 5' flanking region in (d), and a second 3' flanking region followed by the promoter terminator 3' of the second 3' flanking region in (e).
[0116] 70. The AAV viral genome of embodiment 69, wherein the promoter is a Pol III promoter.
[0117] 71. The AAV viral genome of embodiment 70, wherein the Pol III promoter sequence is U3, U6, U7, 7SK, H1 or MRP, EBER, selenocysteine tRNA, 7SL, adenovirus VA-1 or telomerase gene promoter.
[0118] 72. The AAV viral genome of embodiment 71, wherein the Pol III promoter is an H1 promoter.
[0119] 73. The AAV viral genome of embodiment 53, wherein the nucleic acid sequence further comprises a third molecular scaffold region, wherein the third molecular scaffold region comprises a third molecular scaffold nucleic acid sequence encoding:
[0120] (g) a third stem and a loop to form a third stem-loop structure, the sequence of the third stem-loop structure comprising from 5' to 3':
[0121] ix. a third UG motif located at or near the base of the third 5' stem of the third stem-loop structure;
[0122] x. a third 5' stem arm comprising a third sense strand and optionally a third 5' spacer, wherein the third 5' spacer, when present, is positioned between the third UG motif and the third sense strand;
[0123] xi. a third loop region comprising a third UGUG motif at the 5' end of the third loop region;
[0124] xii. a third 3' stem arm comprising a third antisense strand and optionally a third 3' spacer, wherein uridine is present at the 5' end of the third antisense strand, and wherein the third 3' spacer, when present, has a length sufficient to form one helical turn;
[0125] (h) a third 5' flanking region located 5' to the third stem-loop structure; and
[0126] (i) a third 3' flanking region located 3' to the third stem-loop structure, the third 3' flanking region comprising a CNNC motif, and
[0127] wherein the third antisense strand and the third sense strand form a third siRNA duplex, wherein the third siRNA duplex inhibits or represses expression of a third target gene in a cell when expressed, wherein the third sense strand sequence comprises at least 15 nucleotides, the third antisense strand sequence is complementary to the mRNA produced by the third target gene, and wherein the third sense strand sequence and the third antisense strand sequence share a complementary region of at least 4 nucleotides in length.
[0128] 74. The AAV viral genome of embodiment 73, further comprising a promoter 5' of the third 5' flanking region in (h), followed by a third 5' flanking region, and comprising a third 3' flanking region in (i), followed by a promoter terminator 3' of the third 3' flanking region.
[0129] 75. The AAV viral genome of embodiment 74, wherein the promoter is a Pol III promoter.
[0130] 76. The AAV viral genome of embodiment 75, wherein the Pol III promoter sequence is U3, U6, U7, 7SK, H1 or MRP, EBER, selenocysteine tRNA, 7SL, adenovirus VA-1 or telomerase gene promoter.
[0131] 77. The AAV viral genome of embodiment 76, wherein the Pol III promoter is an H1 promoter.
[0132] 78. The AAV viral genome of embodiment 73, wherein the nucleic acid sequence further comprises a fourth molecular scaffold region, wherein the fourth molecular scaffold region comprises a fourth molecular scaffold nucleic acid sequence encoding
[0133] (j) a fourth stem and a loop to form a fourth stem-loop structure, the sequence of the fourth stem-loop structure comprising from 5' to 3':
[0134] xiii. a fourth UG motif located at or near the base of the fourth 5' stem of the fourth stem-loop structure;
[0135] xiv. a fourth 5' stem arm comprising a fourth sense strand and optionally a fourth 5' spacer, wherein the fourth 5' spacer, when present, is positioned between the fourth UG motif and the fourth sense strand;
[0136] xv. a fourth loop region comprising a fourth UGUG motif at the 5' end of the fourth loop region;
[0137] xvi. a fourth 3' stem arm comprising a fourth antisense strand and optionally a fourth 3' spacer, wherein a uridine is present at the 5' end of the fourth antisense strand, and wherein the fourth 3' spacer, when present, has a length sufficient to form one helical turn;
[0138] (k) a fourth 5' flanking region located 5' to the fourth stem-loop structure; and
[0139] (1) a fourth 3' flanking region located 3' to the fourth stem-loop structure, the fourth 3' flanking region comprising a CNNC motif, and
[0140] wherein the fourth antisense strand and the fourth sense strand form a fourth siRNA duplex, wherein the fourth siRNA duplex, when expressed, inhibits or represses expression of a fourth target gene in a cell, wherein the fourth sense strand sequence comprises at least 15 nucleotides, the fourth antisense strand sequence is complementary to mRNA produced by the fourth target gene, and wherein the fourth sense strand sequence and the fourth antisense strand sequence share a complementary region of at least 4 nucleotides in length.
[0141] 79. The AAV viral genome of embodiment 78, further comprising a promoter 5' of the fourth 5' flanking region in (k), followed by a fourth 5' flanking region, and comprising a fourth 3' flanking region in (1), followed by a promoter terminator 3' of the fourth '3' flanking region.
[0142] 80. The AAV viral genome of embodiment 79, wherein the promoter is a Pol III promoter.
[0143] 81. The AAV viral genome of embodiment 80, wherein the Pol III promoter sequence is U3, U6, U7, 7SK, H1 or MRP, EBER, selenocysteine tRNA, 7SL, adenovirus VA-1 or telomerase gene promoter.
[0144] 82. The AAV viral genome of embodiment 81, wherein the Pol III promoter is an H1 promoter.
[0145] 83. The AAV viral genome of any one of embodiments 53-82, wherein the first target gene is the same as the second target gene.
[0146] 84. The AAV viral genome of any one of embodiments 53-82, wherein the third target gene is the same as the first target gene.
[0147] 85. The AAV viral genome of any one of embodiments 53-82, wherein the third target gene is the same as the second target gene.
[0148] 86. The AAV viral genome of any one of embodiments 53-82, wherein the first target gene, the second target gene, and the third target gene are the same.
[0149] 87. The AAV viral genome of any one of embodiments 53-82, wherein the fourth target gene is the same as the first target gene.
[0150] 88. The AAV viral genome of any one of embodiments 53-82, wherein the fourth target gene is the same as the second target gene.
[0151] 89. The AAV viral genome of any one of embodiments 53-82, wherein the fourth target gene is the same as the third target gene.
[0152] 90. The AAV viral genome of any one of embodiments 53-82, wherein the fourth target gene is the same as the first target gene and the second target gene.
[0153] 91. The AAV viral genome of embodiments 53-82, wherein the fourth target gene is the same as the second target gene and the third target gene.
[0154] 92. The AAV viral genome of embodiments 53-82, wherein the fourth target gene is the same as the first target gene and the third target gene.
[0155] 93. The AAV viral genome of any one of embodiments 53-82, wherein the fourth target gene is the same as the first target gene, the second target gene, and the third target gene.
[0156] 94. The AAV viral genome of any one of embodiments 53-93, wherein the first target gene, the second target gene, the third target gene and / or the fourth target gene is the Huntington gene.
[0157] 95. The AAV viral genome of any one of embodiments 53-93, wherein the first target gene, the second target gene, the third target gene and / or the fourth target gene is SOD1.
[0158] 96. The AAV viral genome of any one of embodiments 53-93, wherein the first target gene, the second target gene, the third target gene and / or the fourth target gene is Huntington gene or SOD1.
[0159] 97. A method of inhibiting gene expression of a target gene in a cell, the method comprising administering to the cell a composition comprising the AAV viral genome of any one of embodiments 1-96.
[0160] 98. The method of embodiment 97, wherein the cell is a mammalian cell.
[0161] 99. The method of embodiment 98, wherein the mammalian cell is a medium spiny neuron.
[0162] 100. The method of embodiment 98, wherein the mammalian cells are cortical neurons.
[0163] 101. The method of embodiment 98, wherein the mammalian cell is a motor neuron.
[0164] 102. The method of embodiment 98, wherein the mammalian cells are astrocytes.
[0165] 103. A method of treating a disease and / or condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition comprising the AAV viral genome of any one of embodiments 1-96.
[0166] 104. The method of embodiment 103, wherein the expression of the target gene is inhibited or repressed.
[0167] 105. The method of embodiment 104, wherein the expression of the target gene of interest is inhibited or repressed by about 30% to about 70%.
[0168] 106. The method of embodiment 104, wherein expression of the target gene is inhibited or repressed by about 50% to about 90%.
[0169] 107. A method of inhibiting expression of a target gene in a cell, wherein the target gene results in a gain of function in the cell, the method comprising administering to the cell a composition comprising the AAV viral genome of any one of embodiments 1-96.
[0170] 108. The method of embodiment 107, wherein the cell is a mammalian cell.
[0171] 109. The method of embodiment 108, wherein the mammalian cell is a medium spiny neuron.
[0172] 110. The method of embodiment 108, wherein the mammalian cells are cortical neurons.
[0173] 111. The method of embodiment 108, wherein the mammalian cell is a motor neuron.
[0174] 112. The method of embodiment 108, wherein the mammalian cells are astrocytes. BRIEF DESCRIPTION OF THE DRAWINGS
[0176] The foregoing and other objects, features and advantages will be apparent from the following description of certain embodiments of the invention, as illustrated in the accompanying drawings, which are not necessarily to scale, emphasis instead being placed upon illustrating the principles of various embodiments of the invention.
[0177] Figure 1 is a schematic diagram of the viral genome of the present invention.
[0178] Figure 2 is a schematic diagram of the viral genome of the present invention.
[0179] Figure 3 is a schematic diagram of the viral genome of the present invention.
[0180] Figure 4 is a schematic diagram of the viral genome of the present invention.
[0181] Figure 5 is a schematic diagram of the viral genome of the present invention.
[0182] Figure 6 is a schematic diagram of the viral genome of the present invention.
[0183] Figure 7 is a schematic diagram of the viral genome of the present invention.
[0184] Figure 8 is a schematic diagram of the viral genome of the present invention.
[0185] Figure 9 is a schematic diagram of the viral genome of the present invention.
[0186] The details of one or more embodiments of the present invention are set forth in the following accompanying description. Although any materials and methods similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred materials and methods are now described. By description, other features, objects and advantages of the present invention will be apparent. In the specification, the singular also includes the plural, unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs. In the event of conflict, this specification shall prevail. Detailed Description of the Invention
[0188] I. Composition of the Invention
[0189] According to the present invention, compositions for delivering regulatory polynucleotides and / or regulatory polynucleotide-based compositions via adeno-associated viruses (AAVs) are provided. The AAV particles of the present invention can be provided to cells, tissues, organs, or organisms in vivo, ex vivo, or in vitro by any of several routes.
[0190] As used herein, an "AAV particle" is a virus comprising a viral genome having at least one payload region and at least one inverted terminal repeat (ITR) region.
[0191] As used herein, "viral genome" or "vector genome" or "viral vector" refers to the nucleic acid sequence encapsulated in AAV particles. The viral genome contains at least one payload region encoding a polypeptide or fragment thereof.
[0192] As used herein, "payload" or "payload region" is any nucleic acid molecule encoding one or more polypeptides of the present invention. The payload region comprises at least nucleic acid sequences encoding sense and antisense sequences (a siRNA-based composition) or fragments thereof, but may also optionally comprise one or more functional or regulatory elements to promote transcriptional expression and / or translation of the polypeptide.
[0193] The nucleic acid sequences and polypeptides disclosed herein can be engineered to include assembled modular elements and / or sequence motifs that enable expression of the regulatory polynucleotides and / or regulatory polynucleotide-based compositions of the present invention. In some embodiments, the nucleic acid sequence comprising the payload region may include one or more of a promoter region, an intron, a Kozak sequence, an enhancer, or a polyadenylation sequence. The payload region of the present invention typically encodes at least one sense and antisense sequence (a composition based on siRNA) or fragments thereof that are bound to each other or to other polypeptide moieties.
[0194] The payload region of the present invention can be delivered to one or more target cells, tissues, organs or organisms within the viral genome of an AAV particle.
[0195] Adeno-associated virus (AAV) and AAV particles
[0196] The viruses of the Parvoviridae family are small, non-enveloped icosahedral capsid viruses characterized by a single-stranded DNA genome. The Parvoviridae family consists of two subfamilies: the Parvovirinae that infect vertebrates and the Densovirinae that infect invertebrates. Due to its relatively simple structure, it is easy to operate using standard molecular biology techniques, so this virus family can be used as a biological tool. The genome of the virus can be modified so that it comprises the minimum components for assembling a functional recombinant virus or virion, which is loaded with or engineered to express or deliver the desired payload, which can be delivered to target cells, tissues, organs or organisms.
[0197] Parvoviruses and other members of the Parvoviridae family are generally described in Kenneth I. Berns, "Parvoviridae: The Viruses and Their Replication" (FIELDS VIROLOGY) (3rd ed. 1996), Chapter 69, the contents of which are incorporated by reference in their entirety.
[0198] The Parvoviridae family includes the genus Dependovirus, which includes adeno-associated viruses (AAV) capable of replicating in vertebrate hosts, including but not limited to humans, primates, cattle, dogs, horses, and sheep.
[0199] The AAV viral genome is a linear single-stranded DNA (ssDNA) molecule with a length of approximately 5,000 nucleotides (nt). The AAV viral genome may include a payload region and at least one inverted terminal repeat (ITR) or ITR region. Traditionally, ITR is located on the flanks of the coding nucleotide sequences of non-structural proteins (encoded by the Rep gene) and structural proteins (encoded by the capsid gene or Cap gene). Although not wishing to be bound by theory, the AAV viral genome typically comprises two ITR sequences. The AAV viral genome comprises a characteristic T-shaped hairpin structure, which is limited by the self-complementary end 145nt at the 5' and 3' ends of the ssDNA that forms an energy-stabilized double-stranded region. The double-stranded hairpin structure comprises multiple functions, including but not limited to being used as a starting point for DNA replication by acting as a primer for the endogenous DNA polymerase complex of the host viral replication cell.
[0200] In addition to the encoded heterologous payload, the AAV vector may also contain, in whole or in part, any naturally occurring and / or recombinant AAV serotype nucleotide sequence or variant viral genome. AAV variants may have sequences with significant homology at the nucleic acid (genome or capsid) and amino acid levels (capsid) to produce constructs that are generally physically and functionally equivalent, replicate by similar mechanisms, and assemble by similar mechanisms. Chiorini et al., J. Vir. 71: 6823-33 (1997); Srivastava et al., J. Vir. 45: 555-64 (1983); Chiorini et al., J. Vir. 73: 1309-1319 (1999); Rutledge et al., J. Vir. 72: 309-319 (1998); and Wu et al., J. Vir. 74: 8635-47 (2000), the contents of each of which are incorporated herein by reference in their entirety.
[0201] In one embodiment, the AAV particles of the present invention are replication-defective recombinant AAV vectors that lack sequences encoding functional Rep and Cap proteins in their viral genome. These defective AAV vectors may lack most or all of the parental coding sequences and essentially carry only one or two AAV ITR sequences and a target nucleic acid for delivery to a cell, tissue, organ, or organism.
[0202] In one embodiment, the viral genome of the AAV particles of the present invention comprises at least one control element that provides for the replication, transcription and translation of the coding sequence encoded therein. It is not always necessary for all control elements to be present, as long as the coding sequence is capable of replication, transcription and / or translation in an appropriate host cell. Non-limiting examples of expression control elements include sequences for transcription initiation and / or termination, promoter and / or enhancer sequences, efficient RNA processing signals (e.g., splicing and polyadenylation signals), sequences that stabilize cytoplasmic mRNA, sequences that enhance translation efficiency (e.g., Kozak consensus sequences), sequences that enhance protein stability and / or sequences that enhance protein processing and / or secretion.
[0203] According to the present invention, AAV particles for therapeutic and / or diagnostic use comprise viruses that have been distilled or reduced to the minimum components required to transduce a nucleic acid payload or cargo of interest. In this manner, AAV particles are engineered as vectors for specific delivery while lacking the deleterious replication and / or integration characteristics found in wild-type viruses.
[0204] The AAV vectors of the present invention can be recombinantly produced and can be based on a parent or reference sequence of an adeno-associated virus (AAV). As used herein, a "vector" is any molecule or entity that transports, transduces, or otherwise acts as a vehicle for a heterologous molecule (e.g., a nucleic acid as described herein).
[0205] In addition to single-stranded AAV viral genomes (e.g., ssAAV), the present invention also provides self-complementary AAV (scAAV) viral genomes. The scAAV viral genome comprises DNA strands that anneal together to form double-stranded DNA. By skipping second-strand synthesis, scAAV can be rapidly expressed in cells.
[0206] In one embodiment, the AAV particle of the invention is a scAAV.
[0207] In one embodiment, the AAV particle of the invention is ssAAV.
[0208] Methods for producing and / or modifying AAV particles, such as pseudotyped AAV vectors, are disclosed in the art (PCT Patent Publication Nos. WO200028004; WO200123001; WO2004112727; WO 2005005610 and WO 2005072364, the contents of each of which are herein incorporated by reference in their entirety).
[0209] AAV particles can be modified to enhance delivery efficiency. Such modified AAV particles can be efficiently packaged and used to successfully infect target cells with high frequency and minimal toxicity. In some embodiments, the capsid of the AAV particle is engineered according to the methods described in U.S. Publication No. US20130195801, the contents of which are incorporated herein by reference in their entirety.
[0210] In one embodiment, AAV particles comprising a payload region encoding a polypeptide of the invention can be introduced into mammalian cells.
[0211] AAV serotypes
[0212] The AAV particles of the present invention may comprise or be derived from any natural or recombinant AAV serotype. According to the present invention, the AAV particles may utilize or be based on a serotype selected from any of the following: AAV1, AAV2, AAV2G9, AAV3, AAV3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV5, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2, AAV8, AAV9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV12, AAV16.3 , AAV24.1, AAV27.3, AAV42.12, AAV42-1b, AAV42-2, AAV42-3a, AAV42-3b, AAV42-4, AAV42-5a, AAV42-5b, AAV42-6b, AAV42-8, AAV42-10, AAV42-11 , AAV42-12, AAV42-13, AAV42-15, AAV42-aa, AAV43-1, AAV43-12, AAV43-20, AAV43-21, AAV43-23, AAV43-25, AAV43-5, AAV44.1, AAV44.2, AAV44.5, AAV223.1, AAV223.2, AAV223.4, AAV223.5, AAV223.6, AAV223.7, AAV1-7 / rh.48, AAV1-8 / rh.49, AAV2-15 / rh.62, AAV2-3 / rh.61, AAV2-4 / rh.50, A AV2-5 / rh.51, AAV3.1 / hu.6, AAV3.1 / hu.9, AAV3-9 / rh.52, AAV3-11 / rh.53, AAV4-8 / r11.64, AAV4-9 / rh.54, AAV4-19 / rh.55, AAV5-3 / rh.57, AAV5 -22 / rh.58, AAV7.3 / hu.7, AAV16.8 / hu.10, AAV16.12 / hu.11, AAV29.3 / bb.1, AAV29.5 / bb.2, AAV106.1 / hu.37, AAV114.3 / hu.40, AAV127.2 / hu.41 , AAV127.5 / hu.42, AAV128.3 / hu.44, AAV130.4 / hu.48, AAV145.1 / hu.53, AAV145.5 / hu.54, AAV145.6 / hu.55, AAV161.10 / hu.60, AAV161.6 / hu.61,AAV33.12 / hu.17、AAV33.4 / hu.15、AAV33.8 / hu.16、AAV52 / hu.19、AAV52.1 / hu.20、AAV58.2 / hu.25、AAVA3.3、AAVA3.4、AAVA3.5、AAVA3.7、AAVC1、AAV C2、AAVC5、AAV-DJ、AAV-DJ8、AAVF3、AAVF5、AAVH2、AAVrh.72、AAVhu.8、AAVrh.68、AAVrh.70、AAVpi.1、AAVpi.3、AAVpi.2、AAVrh.60、AAVrh.44、AAVrh. .65、AAVrh.55、AAVrh.47、AAVrh.69、AAVrh.45、AAVrh.59、AAVhu.12、AAVH6、AAVLK03、AAVH-1 / hu.1、AAVH-5 / hu.3、AAVLG-10 / rh.40、AAVLG-4 / rh.38、AAVLG-9 / hu.39、AAVN721-8 / rh.43、AAVCh.5、AAVCh.5R1、AAVcy.2、AAVcy.3、AAVcy.4、AAVcy.5、AAVCy.5R1、AAVCy.5R2、AAVCy.5R3、AAVCy.5R4、AAVc y.6、AAVhu.1、AAVhu.2、AAVhu.3、AAVhu.4、AAVhu.5、AAVhu.6、AAVhu.7、AAVhu.9、AAVhu.10、AAVhu.11、AAVhu.13、AAVhu.15、AAVhu.16、AAVhu.17、AA Vhu.18、AAVhu.20、AAVhu.21、AAVhu.22、AAVhu.23.2、AAVhu.24、AAVhu.25、AAVhu.27、AAVhu.28、AAVhu.29、AAVhu.29R、AAVhu.31、AAVhu.32、AAVhu. 34、AAVhu.35、AAVhu.37、AAVhu.39、AAVhu.40、AAVhu.41、AAVhu.42、AAVhu.43、AAVhu.44、AAVhu.44R1、AAVhu.44R2、AAVhu.44R3、AAVhu.45、AAVhu.4 6、AAVhu.47、AAVhu.48、AAVhu.48R1、AAVhu.48R2、AAVhu.48R3、AAVhu.49、AAVhu.51、AAVhu.52、AAVhu.54、AAVhu.55、AAVhu.56、AAVhu.57、AAVhu.58、AAVhu.60, AAVhu.61, AAVhu.63, AAVhu.64, AAVhu.66, AAVhu.67, AAVhu.14 / 9, AAVhu.t19, AAVrh.2, AAVrh.2R, AAVrh.8, AAVrh.8R, AAVrh.10, AAVrh.12, AAVrh.13, AAVrh.13R, AAVrh.14, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.20, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrh.37R2, AAVrh.38, AAVrh.39, AAVrh.40, AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49, AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54, AAVrh.56, AAVrh.57, AAVrh.58, AAVrh.61, AAVrh.64, AAVrh.64R1, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74, AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV, BAAV, goat AAV, bovine AAV, sheep AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14, AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhEr1.35, AAVhEr1.7, AAVhEr1.36, AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36, AAVhER1.23, AAVhEr3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV-LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV-LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-LK16, AAV-LK17, AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6,AAV-PAEC7, AAV-PAEC8, AAV-PAEC11, AAV-PAEC12, AAV-2-pre-miRNA-101, AAV-8h, AAV-8b, AAV-h, AAV-b, AAV SM 10-2, AAV Shuffled 100-1, AAV Shuffled 100-3, AAV Shuffled 100-7, AAV Shuffled 10-2, AAV Shuffled 10-6, AAV Shuffled 10-8, AAV Shuffled 100-2, AAV SM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10, BNP in AAV61, BNP in AAV62, BNP in AAV63, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.11, AAVhu.53, AAV4-8 / rh.64, AAVLG-9 / hu.39, AAV54.5 / hu.23, AAV54.2 / hu.22, AAV54.7 / hu.24, AAV54.1 / hu.21, AAV54.4R / hu.27, AAV46.2 / hu.28, AAV46.6 / hu.29, AAV128.1 / hu.43, authentic AAV (ttAAV), UPENN AAV 10, Japanese AAV 10 serotype, AAV CBr-7.1, AAV CBr-7.10, AAV CBr-7.2, AAV CBr-7.3, AAV CBr-7.4, AAV CBr-7.5, AAV CBr-7.7, AAV CBr-7.8, AAV CBr-B7.3, AAV CBr-B7.4, AAV CBr-E1, AAV CBr-E2, AAV CBr-E3, AAV CBr-E4, AAV CBr-E5, AAV CBr-e5, AAVCBr-E6, AAV CBr-E7, AAV CBr-E8, AAV CHt-1, AAV CHt-2, AAV CHt-3, AAVCHt-6.1, AAVCHt-6.10, AAV CHt-6.5, AAV CHt-6.6, AAV CHt-6.7, AAV CHt-6.8, AAVCHt-P1, AAV CHt-P2, AAV CHt-P5, AAV CHt-P6, AAV CHt-P8, AAV CHt-P9, AAV CKd-1, AAV CKd-10, AAV CKd-2, AAV CKd-3, AAV CKd-4, AAV CKd-6, AAV CKd-7, AAVCKd-8, AAV CKd-B1, AAV CKd-B2, AAVCKd-B3AAV CKd-B4、AAV CKd-B5、AAVCKd-B6、AAV CKd-B7、AAV CKd-B8、AAV CKd-H1、AAVCKd-H2、AAV CKd-H3、AAV CKd-H4、AAV CKd-H5、AAV CKd-H6、AAV CKd-N3、AAV CKd-N4、AAVCKd-N9、AAV CLg-F1、AAV CLg-F2、AAV CLg-F3、AAV CLg-F4、AAV CLg-F5、AAV CLg-F6、AAVCLg-F7、AAV CLg-F8、AAV CLv-1、AAV CLv1-1、AAV Clv1-10、AAV CLv1-2、AAV CLv-12、AAVCLv1-3、AAV CLv-13、AAV CLv1-4、AAV Clv1-7、AAV Clv1-8、AAVClv1-9、AAV CLv-2、AAVCLv-3、AAV CLv-4、AAV CLv-6、AAV CLv-8、AAV CLv-D1、AAV CLv-D2、AAV CLv-D3、AAV CLv-D4、AAV CLv-D5、AAV CLv-D6、AAV CLv-D7、AAV CLv-D8、AAV CLv-E1、AAV CLv-K1、AAV CLv-K3、AAV CLv-K6、AAV CLv-L4、AAV CLv-L5、AAV CLv-L6、AAV CLv-M1、AAV CLv-M11、AAV CLv-M2、AAV CLv-M5、AAV CLv-M6、AAV CLv-M7、AAV CLv-M8、AAV CLv-M9、AAV CLv-R1、AAVCLv-R2、AAV CLv-R3、AAV CLv-R4、AAV CLv-R5、AAV CLv-R6、AAV CLv-R7、AAV CLv-R8、AAVCLv-R9、AAV CSp-1、AAV CSp-10、AAV CSp-11、AAV CSp-2、AAV CSp-3、AAVCSp-4、AAV CSp-6、AAV CSp-7、AAV CSp-8、AAV CSp-8.10、AAV CSp-8.2、AAV CSp-8.4、AAV CSp-8.5、AAVCSp-8.6、AAV CSp-8.7、AAV CSp-8.8、AAV CSp-8.9、AAV CSp-9、AAV.hu.48R3、AAV.VR-355、AAV3B、AAV4、AAV5、AAVF1 / HSC1, AAVF11 / HSC11, AAVF12 / HSC12, AAVF13 / HSC13, AAVF14 / HSC14, AAVF15 / HSC15, AAVF16 / HSC16, AAVF17 / HSC17, AAVF2 / HSC2, AAVF3 / HSC3, AAVF4 / HSC4, AAVF5 / HSC5, AAVF6 / HSC6, AAVF7 / HSC7, AAVF8 / HSC8, AAVF9 / HSC9, AAV-PHP.B (PHP.B), AAV-PHP.A (PHP.A), G2B-26, G2B-13, TH1.1-32, TH1.1-35, AAVPHP.B2, AAVPHP.B3, AAVPHP.N / PHP.B-DGT, AAVPHP.B-EST, AAVPHP.B-GGT, AAVPHP.B-ATP, AAVPHP.B-ATT-T, AAVPHP.B-DGT-T, AAVPHP.B-GGT-T, AAVPHP.B-SGS, AAVPHP.B-AQP, AAVPHP.B-QQP, AAVPHP.B-SNP(3), AAVPHP.B-SNP, AAVPHP.B-QGT, AAVPHP.B-NQT, AAVPHP.B-EGS, AAVPHP.B-SGN, AAVPHP.B-EGT, AAVPHP.B-DST, AAVPHP.B-DST, AAVPHP.B-STP, AAVPHP.B-PQP, AAVPHP.B-SQP, AAVPHP.B-QLP, AAVPHP.B-TMP, AAVPHP.B-TTP, AAVPHP.S / G2A12, AAVG2A15 / G2A3, AAVG2B4, AAVG2B5 and their variants.
[0213] In some embodiments, the AAV serotype may be or have a sequence as described in U.S. Publication No. US20030138772, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV1 (SEQ ID NOs: 6 and 64 of US20030138772), AAV2 (SEQ ID NOs: 7 and 70 of US20030138772), AAV3 (SEQ ID NOs: 8 and 71 of US20030138772), AAV4 (SEQ ID NO: 63 of US20030138772), AAV5 (SEQ ID NO: 114 of US20030138772), AAV6 (SEQ ID NO: 65 of US20030138772), AAV7 (SEQ ID NOs: 1-3 of US20030138772), AAV8 (SEQ ID NOs: 1-4 of US20030138772), AAV9 (SEQ ID NOs: 2-3 of US20030138772), AAV10 (SEQ ID NOs: 3-4 of US20030138772), AAV11 (SEQ ID NOs: 4-5 of US20030138772), AAV12 (SEQ ID NOs: 5-6 of US20030138772), AAV13 (SEQ ID NOs: 6-7 of US20030138772), AAV14 (SEQ ID NO: 63 of US20030138772), AAV15 (SEQ ID NO: 114 of US20030138772), AAV16 (SEQ ID NO: 65 of US20030138772), AAV17 (SEQ ID NOs: 1- NO: 4 and 95), AAV9 (SEQ ID NO: 5 and 100 of US20030138772), AAV10 (SEQ ID NO: 117 of US20030138772), AAV11 (SEQ ID NO: 118 of US20030138772), AAV12 (SEQ ID NO: 119 of US20030138772), AAVrh10 (amino acids 1 to 738 of SEQ ID NO: 81 of US20030138772), AAV16.3 (US20030138772 SEQ ID NO: 10), AAV29.3 / bb.1 (US20030138772 SEQ ID NO: 11), AAV29.4 (US20030138772 SEQ ID NO: 12). NO:12), AAV29.5 / bb.2 (US20030138772 SEQ ID NO:13), AAV1.3 (US20030138772 SEQ ID NO:14), AAV13.3 (US20030138772 SEQ ID NO:15), AAV24.1 (US20030138772 SEQ ID NO:16), AAV27.3 (US20030138772 SEQ ID NO:17), AAV7.2 (US20030138772 SEQ ID NO:18), AAVC1 (US20030138772 SEQ ID NO:19), AAVC3 (US20030138772 SEQ ID NO:20), AAVC5(US20030138772 SEQ ID NO: 21), AAVF1 (US20030138772 SEQ IDNO:22)、AAVF3(US20030138772 SEQ ID NO:23)、AAVF5(US20030138772 SEQ ID NO:24)、AAVH6(US20030138772 SEQ ID NO:25)、AAVH2(US20030138772 SEQ ID NO:26)、AAV42-8(US20030138772 SEQ ID NO:27)、AAV42-15(US20030138772 SEQ ID NO:28)、AAV42-5b(US20030138772 SEQ ID NO:29)、AAV42-1b(US20030138772 SEQ ID NO:30)、AAV42-13(US20030138772 SEQ ID NO:31)、AAV42-3a(US20030138772 SEQ ID NO:32)、AAV42-4(US20030138772 SEQ ID NO:33)、AAV42-5a(US20030138772 SEQ ID NO:34)、AAV42-10(US20030138772 SEQ ID NO:35)、AAV42-3b(US20030138772 SEQ ID NO:36)、AAV42-11(US20030138772 SEQ ID NO:37)、AAV42-6b(US20030138772 SEQ ID NO:38)、AAV43-1(US20030138772 SEQ ID NO:39)、AAV43-5(US20030138772 SEQ ID NO:40)、AAV43-12(US20030138772 SEQ ID NO:41)、AAV43-20(US20030138772 SEQ ID NO:42)、AAV43-21(US20030138772 SEQ ID NO:43)、AAV43-23(US20030138772 SEQ ID NO:44)、AAV43-25(US20030138772 SEQ ID NO:45)、AAV44.1(US20030138772 SEQ ID NO:46)、AAV44.5(US20030138772 SEQ ID NO:47)、AAV223.1(US20030138772 SEQ ID NO:48)、AAV223.2(US20030138772 SEQ IDNO: 49), AAV223.4 (US20030138772 SEQ ID NO: 50), AAV223.5 (US20030138772 SEQ ID NO: 51), AAV223.6 (US20030138772 SEQ ID NO: 52), AAV223.7 (US20030138772 SEQ ID NO: 53), AAVA3.4 (US20030138772 SEQ ID NO: 54), AAVA3.5 (US20030138772 SEQ ID NO: 55), AAVA3.7 (US20030138772 SEQ ID NO: 56), AAVA3.3 (US20030138772 SEQ ID NO: 57), AAV42.12 (US20030138772 SEQ ID NO: 58), AAV44.2 (US20030138772 SEQ ID NO: 59), AAV42-2 (US20030138772 SEQ ID NO: 9) or variants thereof.
[0214] In some embodiments, the AAV serotype can be or have a sequence as described in U.S. Publication No. US20150159173, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV2 (SEQ ID NOs: 7 and 23 of US20150159173), rh20 (SEQ ID NO: 1 of US20150159173), rh32 / 33 (SEQ ID NO: 2 of US20150159173), rh39 (SEQ ID NOs: 3, 20, and 36 of US20150159173), rh46 (SEQ ID NOs: 4 and 22 of US20150159173), rh73 (SEQ ID NO: 5 of US20150159173), rh74 (SEQ ID NO: 6 of US20150159173), AAV6.1 (SEQ ID NO: 7 of US20150159173), rh80 (SEQ ID NO: 8 of US20150159173), rh91 (SEQ ID NO: 9 of US20150159173), rh10 (SEQ ID NO: 10 of US20150159173), rh110 (SEQ ID NO: 11 of US20150159173), rh120 (SEQ ID NO: 12 of US20150159173), rh131 (SEQ ID NO: 13 of US20150159173), rh132 (SEQ ID NO: 14 of US20150159173), rh143 (SEQ ID NO: 15 of US20150159173), rh151 (SEQ ID NO: 16 of NO:29), rh.8 (SEQ ID NO:41 of US20150159173), rh.48.1 (SEQ ID NO:44 of US20150159173), hu.44 (SEQ ID NO:45 of US20150159173), hu.29 (SEQ ID NO:42 of US20150159173), hu.48 (SEQ ID NO:38 of US20150159173), rh54 (SEQ ID NO:49 of US20150159173), AAV2 (SEQ ID NO:7 of US20150159173), cy.5 (SEQ ID NOs:8 and 24 of US20150159173), rh.10 (SEQ ID NO:43 of US20150159173), NO: 9 and 25), rh.13 (SEQ ID NO: 10 and 26 of US20150159173), AAV1 (SEQ ID NO: 11 and 27 of US20150159173), AAV3 (SEQ ID NO: 12 and 28 of US20150159173), AAV6 (SEQ ID NO: 13 and 29 of US20150159173), AAV7 (SEQ ID NO: 14 and 30 of US20150159173), AAV8 (SEQ ID NO: 15 and 31 of US20150159173), hu.13 (SEQ ID NO: 16 and 32 of US20150159173), hu.26 (SEQ ID NO: 17 and 33 of US20150159173), hu.37 (SEQ ID NO: 18 and 29 of US20150159173), ID NO:18 and 34), hu.53 (SEQ ID NO: 19 and 35 of US20150159173), rh.43 (SEQ ID NO: 21 and 37 of US20150159173), rh2 (SEQ ID NO: 39 of US20150159173), rh.37 (SEQ ID NO: 40 of US20150159173), rh.64 (SEQ ID NO: 43 of US20150159173), rh.48 (SEQ ID NO: 44 of US20150159173), ch.5 (SEQ ID NO: 46 of US20150159173), rh.67 (SEQ ID NO: 47 of US20150159173), rh.58 (SEQ ID NO: 49 of US20150159173), NO:48) or variants thereof, including but not limited to Cy5R1, Cy5R2, Cy5R3, Cy5R4, rh.13R, rh.37R2, rh.2R, rh.8R, rh.48.1, rh.48.2, rh.48.1.2, hu.44R1, hu.44R2, hu.44R3, hu.29R, ch.5R1, rh64R1, rh64R2, AAV6.2, AAV6.1, AAV6.12, hu.48R1, hu.48R2 and hu.48R3.
[0215] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Patent No. US 7198951, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV9 (SEQ (SEQ ID NOs: 1-3 of US 7198951), AAV2 (SEQ ID NO: 4 of US 7198951), AAV1 (SEQ ID NO: 5 of US 7198951), AAV3 (SEQ ID NO: 6 of US 7198951), and AAV8 (SEQ ID NO: 7 of US 7198951).
[0216] In some embodiments, the AAV serotype can be or have a mutation in the AAV9 sequence as described by N Pulicherla et al. (Molecular Therapy 19(6):1070-1078 (2011), incorporated herein by reference in its entirety), such as but not limited to AAV9.9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84.
[0217] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Patent No. 6156303, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV3B (SEQ ID NOs: 1 and 10 of U.S. 6156303), AAV6 (SEQ ID NOs: 2, 7, and 11 of U.S. 6156303), AAV2 (SEQ ID NOs: 3 and 8 of U.S. 6156303), AAV3A (SEQ ID NOs: 4 and 9 of U.S. 6156303), or derivatives thereof.
[0218] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Publication No. US20140359799, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV8 (SEQ ID NO: 1 of US20140359799), AAVDJ (SEQ ID NO: 2 and 3 of US20140359799), or variants thereof.
[0219] In some embodiments, the serotype can be AAVDJ (AAV-DJ) or a variant thereof, such as AAVDJ8 (or AAV-DJ8), as described by Grimm et al. (Journal of Virology 82(12):5887-5911 (2008), incorporated herein by reference in its entirety). The amino acid sequence of AAVDJ8 can comprise two or more mutations to remove the heparin binding domain (HBD). As a non-limiting example, the AAV-DJ sequence described as SEQ ID NO: 1 in U.S. Patent No. 7,588,772 (the contents of which are incorporated herein by reference in their entirety) can comprise two mutations: (1) R587Q, wherein the arginine (R; Arg) at amino acid 587 is changed to glutamine (Q; Gln) and (2) R590T, wherein the arginine (R; Arg) at amino acid 590 is changed to threonine (T; Thr). As another non-limiting example, three mutations may be included: (1) K406R, wherein the lysine (K; Lys) at amino acid 406 is changed to arginine (R; Arg), (2) R587Q, wherein the arginine (R; Arg) at amino acid 587 is changed to glutamine (Q; Gln), and (3) R590T, wherein the arginine (R; Arg) at amino acid 590 is changed to threonine (T; Thr).
[0220] In some embodiments, the AAV serotype can be or have an AAV4 sequence as described in International Publication No. WO 1998011244, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV4 (SEQ ID NOs: 1-20 of WO 1998011244).
[0221] In some embodiments, the AAV serotype may be or have a mutation in the AAV2 sequence to produce AAV2G9, as described in International Publication No. WO2014144229, which is herein incorporated by reference in its entirety.
[0222] In some embodiments, the AAV serotype may be or have a sequence as described in International Publication No. WO2005033321, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV3-3 (SEQ ID NO: 217 of WO2005033321), AAV1 (SEQ ID NO: 219 and 202 of WO2005033321), AAV106.1 / hu.37 (SEQ ID No: 10 of WO2005033321), AAV114.3 / hu.40 (SEQ ID No: 11 of WO2005033321), AAV127.2 / hu.41 (SEQ ID NO: 6 and 8 of WO2005033321), AAV128.3 / hu.44 (SEQ ID NO: 129 of WO2005033321), AAV129.4 / hu.50 (SEQ ID NO: 230 of WO2005033321), AAV130.5 / hu.51 (SEQ ID NO: 231 of WO2005033321), AAV131.6 / hu.52 (SEQ ID NO: 233 of WO2005033321), AAV132.7 / hu.53 (SEQ ID NO: 234 of WO2005033321), AAV133.8 / hu.54 (SEQ ID NO: 235 of WO2005033321), AAV134.9 / hu.55 (SEQ ID NO: 236 of WO2005033321), AAV135.1 / hu.56 (SEQ ID NO: 237 of WO2005033321), AAV136.1 / 3321), AAV145.1 / hu.53 (SEQ ID NOs: 176 and 177 of WO2005033321), AAV145.6 / hu.56 (SEQ ID NOs: 168 and 192 of WO2005033321), AAV16.12 / hu.11 (SEQ ID NOs: 153 and 57 of WO2005033321), AAV16.8 / hu.10 (SEQ ID NOs: 156 and 56 of WO2005033321), AAV161.10 / hu.60 (SEQ ID NO: 170 of WO2005033321), AAV161.6 / hu.61 (SEQ ID NOs: 168 and 192 of WO2005033321), AAV16.12 / hu.11 (SEQ ID NOs: 153 and 57 of WO2005033321), AAV16.8 / hu.10 (SEQ ID NOs: 156 and 56 of WO2005033321), AAV161.10 / hu.60 (SEQ ID NO: 170 of WO2005033321), AAV161.6 / hu.61 (SEQ ID NOs: 168 and 192 of WO2005033321), 33 of WO2005033321), AAV2-15 / rh.62 (SEQ ID NOs: 33 and 114 of WO2005033321), AAV2-3 / rh.61 (SEQ ID NO: 21 of WO2005033321), AAV2-4 / rh.50 (SEQ ID NOs: 23 and 108 of WO2005033321), AAV2-5 / rh.51 (SEQ ID NOs: 21 and 221 of WO2005033321), AAV2-6 / rh.72 (SEQ ID NOs: 21 and 222 of WO2005033321), AAV2-7 / rh.73 (SEQ ID NOs: 21 and 223 of WO2005033321), AAV2-8 / rh.80 (SEQ ID NOs: 23 and 108 of WO2005033321), AAV2-9 / rh.91 (SEQ ID NOs: 21 and 224 of WO2005033321), AAV2-10 / rh.92 (SEQ ID NOs: 21 and 225 of WO2005033321), AAV2-11 / rh. NO: 104 and 22), AAV3.1 / hu.6 (SEQ ID NO: 5 and 84 of WO2005033321), AAV3.1 / hu.9 (SEQ ID NOs: 155 and 58 of WO2005033321), AAV3-11 / rh.53 (SEQ ID NOs: 186 and 176 of WO2005033321), AAV3-3 (SEQ ID NO: 200 of WO2005033321), AAV33.12 / hu.17 (SEQ ID NO: 4 of WO2005033321), AAV33.4 / hu.15 (SEQ ID No: 50 of WO2005033321), AAV33.8 / hu.16 (SEQ ID No: 51 of WO2005033321), AAV3-9 / rh.52 (SEQ ID NOs: 96 and 18 of WO2005033321), AAV4-19 / rh.55 (SEQ ID NO: 190 of WO2005033321), AAV4-23 / rh.56 (SEQ ID NO: 231 of WO2005033321), AAV4-33 / hu.57 (SEQ ID NO: 233 of WO2005033321), AAV4-43 / hu.58 (SEQ ID NO: 234 of WO2005033321), AAV4-5 NO: 117), AAV4-4 (SEQ ID NOs: 201 and 218 of WO2005033321), AAV4-9 / rh.54 (SEQ ID NO: 116 of WO2005033321), AAV5 (SEQ ID NOs: 199 and 216 of WO2005033321), AAV52.1 / hu.20 (SEQ ID NO: 63 of WO2005033321), AAV52 / hu.19 (SEQ ID NO: 133 of WO2005033321), AAV5-22 / rh.58 (SEQ ID NO: 27 of WO2005033321), AAV5-3 / rh.57 (SEQ ID NO: 105 of WO2005033321), AAV5-3 / rh.57 (SEQ ID NO: 116 of WO2005033321), AAV5 3321), AAV58.2 / hu.25 (SEQ ID No: 49 of WO2005033321), AAV6 (SEQ ID NOs: 203 and 220 of WO2005033321), AAV7 (SEQ ID NOs: 222 and 213 of WO2005033321), AAV7.3 / hu.7 (SEQ ID No: 55 of WO2005033321), AAV8 (SEQ ID NOs: 223 and 214 of WO2005033321), AAVH-1 / hu.1 (SEQ ID No: 46 of WO2005033321), AAVH-5 / hu.3 (SEQ ID No: 44 of WO2005033321), AAVhu.1 (SEQ ID NOs: 203 and 220 of WO2005033321), AAV7.3 / hu.7 (SEQ ID NOs: 203 and 214 of WO2005033321), NO: 144), AAVhu.10 (SEQ ID NO: 156 of WO2005033321), AAVhu.11 (SEQ ID NO:153 of WO2005033321), AAVhu.12 (WO2005033321 SEQ ID NO:59), AAVhu.13 (SEQ ID NO:129 of WO2005033321), AAVhu.14 / AAV9 (SEQ ID NO:123 and 3 of WO2005033321), AAVhu.15 (SEQ ID NO:147 of WO2005033321), AAVhu.16 (SEQ ID NO:148 of WO2005033321), AAVhu.17 (SEQ ID NO:83 of WO2005033321), AAVhu.18 (SEQ ID NO:149 of WO2005033321), AAVhu.19 (SEQ ID NO:133 of WO2005033321), AAVhu.2 (SEQ ID NO:143 of WO2005033321), AAVhu.20 (SEQ ID NO:134 of WO2005033321), AAVhu.21 (SEQ ID NO:135 of WO2005033321), AAVhu.22 (SEQ ID NO:138 of WO2005033321), AAVhu.23.2 (SEQ ID NO:137 of WO2005033321), AAVhu.24 (SEQ ID NO:136 of WO2005033321), AAVhu.25 (SEQ ID NO:146 of WO2005033321), AAVhu.27 (SEQ ID NO:140 of WO2005033321), AAVhu.29 (SEQ ID NO:132 of WO2005033321), AAVhu.3 (SEQ ID NO:145 of WO2005033321), AAVhu.31 (SEQ ID NO:121 of WO2005033321), AAVhu.32 (SEQ ID NO:122 of WO2005033321), AAVhu..34 (SEQ ID NO:125 of WO2005033321), AAVhu.35 (SEQ ID NO:164 of WO2005033321), AAVhu.37 (SEQ ID NO:88 of WO2005033321), AAVhu.39 (SEQ ID NO:102 of WO2005033321), AAVhu.4 (SEQ ID NO:141 of WO2005033321), AAVhu.40 (SEQ ID NO:87 of WO2005033321), AAVhu.41 (SEQ ID NO:91 of WO2005033321), AAVhu.42 (SEQ ID NO:85 of WO2005033321), AAVhu.43 (SEQ ID NO:160 of WO2005033321), AAVhu.44 (SEQ ID NO:144 of WO2005033321), AAVhu.45 (SEQ ID NO:127 of WO2005033321), AAVhu.46 (SEQ ID NO:159 of WO2005033321), AAVhu.47 (SEQ ID NO:128 of WO2005033321), AAVhu.48 (SEQ ID NO:157 of WO2005033321), AAVhu.49 (SEQ ID NO:189 of WO2005033321), AAVhu.51 (SEQ ID NO:190 of WO2005033321), AAVhu.52 (SEQ ID NO:191 of WO2005033321), AAVhu.53 (SEQ ID NO:186 of WO2005033321), AAVhu.54 (SEQ ID NO:188 of WO2005033321), AAVhu.55 (SEQ ID NO:187 of WO2005033321), AAVhu.56 (SEQ ID NO:192 of WO2005033321), AAVhu.57 (SEQ ID NO:193 of WO2005033321), AAVhu.58 (SEQ ID NO:194 of WO2005033321), AAVhu.6 (SEQ ID NO:84 of WO2005033321), AAVhu.60 (SEQ ID NO:184 of WO2005033321), AAVhu.61 (SEQ ID NO:185 of WO2005033321), AAVhu.63 (SEQ ID NO:195 of WO2005033321), AAVhu.64 (SEQ ID NO:196 of WO2005033321), AAVhu.66 (SEQ ID NO:197 of WO2005033321), AAVhu.67 (SEQ ID NO:198 of WO2005033321), AAVhu.7 (SEQ ID NO:150 of WO2005033321), AAVhu.8 (SEQ ID NO:12 of WO2005033321), AAVhu.9 (SEQ ID NO:155 of WO2005033321), AAVLG-10 / rh.40 (SEQ ID No:14 of WO2005033321), AAVLG-4 / rh.38 (SEQ ID NO:86 of WO2005033321), AAVLG-4 / rh.38 (SEQ ID No:7 of WO2005033321), AAVN721-8 / rh.43 (SEQ ID NO:163 of WO2005033321), AAVN721-8 / rh.43 (SEQ ID No:43 of WO2005033321), AAVpi.1 (SEQ ID NO:28 of WO2005033321), AAVpi.2 (SEQ ID NO:30 of WO2005033321), AAVpi.3 (SEQ ID NO:29 of WO2005033321), AAVrh.38 (SEQ ID NO:86 of WO2005033321), AAVrh.40 (SEQ ID NO:92 of WO2005033321), AAVrh.43 (SEQ ID NO:163 of WO2005033321), AAVrh.44 (SEQ ID NO:34 of WO2005033321), AAVrh.45 (SEQ ID NO:41 of WO2005033321), AAVrh.47 (SEQ ID NO:38 of WO2005033321), AAVrh.48 (SEQ ID NO:115 of WO2005033321), AAVrh.49 (SEQ ID NO:103 of WO2005033321), AAVrh.50 (SEQ ID NO:108 of WO2005033321), AAVrh.51 (SEQ ID NO:104 of WO2005033321), AAVrh.52 (SEQ ID NO:96 of WO2005033321), AAVrh.53 (SEQ ID NO:97 of WO2005033321), AAVrh.55 (SEQ ID NO:37 of WO2005033321), AAVrh.56 (SEQ ID NO:152 of WO2005033321), AAVrh.57 (SEQ ID NO:105 of WO2005033321), AAVrh.58 (SEQ ID NO:106 of WO2005033321), AAVrh.59 (SEQ ID NO:42 of WO2005033321), AAVrh.60 (SEQ ID NO:31 of WO2005033321), AAVrh.61 (SEQ ID NO:107 of WO2005033321), AAVrh.62 (SEQ ID NO: 114 of WO2005033321), AAVrh.64 (SEQ ID NO: 99 of WO2005033321), AAVrh.65 (SEQ ID NO: 35 of WO2005033321), AAVrh.68 (SEQ ID NO: WO2005033321 NO:16), AAVrh.69 (WO2005033321 SEQ ID NO:39), AAVrh.70 (WO2005033321 SEQ ID NO:20), AAVrh.72 (WO2005033321 SEQ ID NO:9), or variants thereof, including but not limited to AAVrh.2, AAVrh.3, AAVrh.4, AAVrh.5, AAVrh.6, AAVrh.12, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.25 / 42 15, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrh14. Non-limiting examples of variants include SEQ ID NOs: 13, 15, 17, 19, 24, 36, 40, 45, 47, 48, 51-54, 60-62, 64-77, 79, 80, 82, 89, 90, 93-95, 98, 100, 101, 109-113, 118-120, 124, 126, 131, 139, 142, 151, 154, 158, 161, 162, 165-183, 202, 204-212, 215, 219, 224-236 of WO2005033321, the contents of which are incorporated herein by reference in their entirety.
[0223] In some embodiments, the AAV serotype can be or have a sequence described in International Publication No. WO2015168666, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAVrh8R (SEQ ID NO: 9 of WO2015168666), AAVrh8R A586R mutant (SEQ ID NO: 10 of WO2015168666), AAVrh8R R533A mutant (SEQ ID NO: 11 of WO2015168666), or variants thereof.
[0224] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Patent No. US9233131, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAVhE1.1 (SEQ ID NO: 44 of US9233131), AAVhEr1.5 (SEQ ID NO: 45 of US9233131), AAVhER1.14 (SEQ ID NO: 46 of US9233131), AAVhEr1.8 (SEQ ID NO: 47 of US9233131), AAVhEr1.16 (SEQ ID NO: 48 of US9233131), AAVhEr1.18 (SEQ ID NO: 49 of US9233131), AAVhEr1.35 (SEQ ID NO: 50 of US9233131), AAVhEr1.7 (SEQ ID NO: 51 of US9233131), NO: 51), AAVhEr1.36 (SEQ ID NO: 52 of US9233131), AAVhEr2.29 (SEQ ID NO: 53 of US9233131), AAVhEr2.4 (SEQ ID NO: 54 of US9233131), AAVhEr2.16 (SEQ ID NO: 55 of US9233131), AAVhEr2.30 (SEQ ID NO: 56 of US9233131), AAVhEr2.31 (SEQ ID NO: 58 of US9233131), AAVhEr2.36 (SEQ ID NO: 57 of US9233131), AAVhER1.23 (SEQ ID NO: 53 of US9233131), AAVhEr3.1 (SEQ ID NO: 54 of US9233131), NO:59), AAV2.5T (SEQ ID NO:42 of US9233131), or variants thereof.
[0225] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Patent Publication No. US20150376607, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV-PAEC (SEQ ID NO: 1 of US20150376607), AAV-LK01 (SEQ ID NO: 2 of US20150376607), AAV-LK02 (SEQ ID NO: 3 of US20150376607), AAV-LK03 (SEQ ID NO: 4 of US20150376607), AAV-LK04 (SEQ ID NO: 5 of US20150376607), AAV-LK05 (SEQ ID NO: 6 of US20150376607), AAV-LK06 (SEQ ID NO: 7 of US20150376607), NO:7), AAV-LK07 (SEQ ID NO:8 of US20150376607), AAV-LK08 (SEQ ID NO:9 of US20150376607), AAV-LK09 (SEQ ID NO:10 of US20150376607), AAV-LK10 (SEQ ID of US20150376607 NO:11), AAV-LK11 (SEQ ID NO:12 of US20150376607), AAV-LK12 (SEQ ID NO:13 of US20150376607), AAV-LK13 (SEQ ID NO:14 of US20150376607), AAV-LK14 (SEQ ID of US20150376607 NO:15), AAV-LK15 (SEQ ID NO:16 of US20150376607), AAV-LK16 (SEQ ID NO:17 of US20150376607), AAV-LK17 (SEQ ID NO:18 of US20150376607), AAV-LK18 (SEQ ID NO: US20150376607 NO: 19), AAV-LK19 (SEQ ID NO: 20 of US20150376607), AAV-PAEC2 (SEQ ID NO: 21 of US20150376607), AAV-PAEC4 (SEQ ID NO: 22 of US20150376607), AAV-PAEC6 (SEQ ID of US20150376607) NO: 23), AAV-PAEC7 (SEQ ID NO: 24 of US20150376607), AAV-PAEC8 (SEQ ID NO: 25 of US20150376607)ID NO: 25), AAV-PAEC11 (SEQ ID NO: 26 of US20150376607), AAV-PAEC12 (SEQ ID NO: 27 of US20150376607), or variants thereof.
[0226] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Pat. No. 9,163,261, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV-2-pre-miRNA-101 (US9163261 SEQ ID NO: 1).
[0227] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Patent Publication No. US20150376240, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV-8h (SEQ ID NO: 6 of US20150376240), AAV-8b (SEQ ID NO: 5 of US20150376240), AAV-h (SEQ ID NO: 2 of US20150376240), AAV-b (SEQ ID NO: 1 of US20150376240), or variants thereof.
[0228] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Patent Publication No. US20160017295, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV SM 10-2 (SEQ ID NO: 22 of US20160017295), AAV shuffled 100-1 (SEQ ID NO: 23 of US20160017295), AAV shuffled 100-3 (SEQ ID NO: 24 of US20160017295), AAV shuffled 100-7 (SEQ ID NO: 25 of US20160017295), AAV shuffled 10-2 (SEQ ID NO: 34 of US20160017295), AAV shuffled 10-6 (SEQ ID NO: 35 of US20160017295), AAV shuffled 10-8 (SEQ ID NO: 40 of US20160017295), AAV shuffled 10-9 (SEQ ID NO: 41 of US20160017295), AAV shuffled 10-10 (SEQ ID NO: 42 of US20160017295), AAV shuffled 10-11 (SEQ ID NO: 43 of US20160017295), AAV shuffled 10-12 (SEQ ID NO: 44 of US20160017295), AAV shuffled 10-13 (SEQ ID NO: 45 of US20160017295), AAV shuffled 10-14 (SEQ ID NO: 46 of US20160017295), AAV shuffled 10-15 ( NO:36), AAV shuffled 100-2 (SEQ ID NO:37 of US20160017295), AAV SM 10-1 (SEQ ID NO:38 of US20160017295), AAV SM 10-8 (SEQ ID NO:39 of US20160017295), AAV SM 100-3 (SEQ ID NO:40 of US20160017295), AAV SM 100-10 (SEQ ID NO:41 of US20160017295), or variants thereof.
[0229] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Patent Publication No. US20150238550, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, BNP61 AAV (SEQ ID NO: 1 of US20150238550), BNP62 AAV (SEQ ID NO: 3 of US20150238550), BNP63 AAV (SEQ ID NO: 4 of US20150238550), or variants thereof.
[0230] In some embodiments, the AAV serotype may be or may have a sequence described in U.S. Patent Publication No. US20150315612, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAVrh.50 (SEQ ID NO: 108 of US20150315612), AAVrh.43 (SEQ ID NO: 163 of US20150315612), AAVrh.62 (SEQ ID NO: 114 of US20150315612), AAVrh.48 (SEQ ID NO: 115 of US20150315612), AAVhu.19 (SEQ ID NO: 133 of US20150315612), AAVhu.11 (SEQ ID NO: 153 of US20150315612), AAVhu.53 (SEQ ID NO: 116 ...hu.62 (SEQ ID NO: 114 of US20150315612), AAVhu.62 (SEQ ID NO: 114 of US20150315612), AAVhu.62 (SEQ ID NO: 114 of US20150315612), AAVhu.62 NO:186), AAV4-8 / rh.64 (SEQ ID No:15 of US20150315612), AAVLG-9 / hu.39 (SEQ ID No:24 of US20150315612), AAV54.5 / hu.23 (SEQ ID No:60 of US20150315612), AAV54.2 / hu.22 (SEQ ID No:67 of US20150315612), AAV54.7 / hu.24 (SEQ ID No:66 of US20150315612), AAV54.1 / hu.21 (SEQ ID No:65 of US20150315612), AAV54.4R / hu.27 (SEQ ID No:68 of US20150315612). No: 64), AAV46.2 / hu.28 (SEQ ID No: 68 of US20150315612), AAV46.6 / hu.29 (SEQ ID No: 69 of US20150315612), AAV128.1 / hu.43 (SEQ ID No: 80 of US20150315612) or variants thereof.
[0231] In some embodiments, the AAV serotype can be or have the sequence described in International Publication No. WO2015121501, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, true type AAV (ttAAV) (SEQ ID NO: 2 of WO2015121501), "UPenn AAV10" (SEQ ID NO: 8 of WO2015121501), "Japanese AAV10" (SEQ ID NO: 9 of WO2015121501), or variants thereof.
[0232] According to the present invention, the selection or use of AAV capsid serotypes can be from a variety of species. In one embodiment, the AAV can be an avian AAV (AAAV). The AAAV serotype can be or have a sequence described in U.S. Patent No. US 9238800, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAAV (SEQ ID NOs: 1, 2, 4, 6, 8, 10, 12, and 14 of US 9,238,800) or variants thereof.
[0233] In one embodiment, AAV can be bovine AAV (BAAV). The BAAV serotype can be or have the sequence described in U.S. Patent No. US 9,193,769, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, BAAV (SEQ ID NOs: 1 and 6 of US9193769) or variants thereof. The BAAV serotype can be or have the sequence described in U.S. Patent No. US7427396, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, BAAV (SEQ ID NOs: 5 and 6 of US7427396) or variants thereof.
[0234] In one embodiment, the AAV may be a goat AAV. The goat AAV serotype may be or have the sequence described in U.S. Pat. No. 7,427,396, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, goat AAV (SEQ ID NO: 3 of US7,427,396) or a variant thereof.
[0235] In other embodiments, the AAV can be engineered into a hybrid AAV from two or more parental serotypes. In one embodiment, the AAV can be AAV2G9, which comprises sequences from AAV2 and AAV9. The AAV2G9 AAV serotype can be or have the sequence described in U.S. Patent Publication No. US20160017005, the contents of which are incorporated herein by reference in their entirety.
[0236] In one embodiment, the AAV can be a serotype having mutations in amino acids 390-627 (VP1 numbering) generated from an AAV9 capsid library as described by Pulicherla et al. (Molecular Therapy 19(6): 1070-1078 (2011)), the contents of which are incorporated herein by reference in their entirety. The serotype and corresponding nucleotide and amino acid substitutions can be, but are not limited to, AAV9.1 (G1594C; D532H), AAV6.2 (T1418A and T1436X; V473D and I479K), AAV9.3 (T1238A; F413Y), AAV9.4 (T1250C and A1617T; F417S), AAV9.5 (A1235G, A1314T, A1642G, C1760T; Q412R, T548A, A587V), AAV9.6 (T1231A; F411I), AAV9.9 (G1203A; F413Y), AAV9.4 (T1250C and A1617T; F417S), AAV9.5 (A1235G, A1314T, A1642G, C1760T; Q412R, T548A, A587V), AAV9.6 (T1231A; F411I), AAV9.9 (G1203A; , G1785T; W595C), AAV9.10 (A1500G, T1676C; M559T), AAV9.11 (A1425T, A1702C, A1769T; T568P, Q590L), AAV9.13 (A1369C, A1720T; A AV9.26 (A1337G, A1769C; Y446C, Q590P), AAV9.33 (A1667C; D556A), AAV9.34 (A1534G, C1794T; N512D), AAV9.35 (A1289T, T1450A, C 1494T, A1515T, C1794A, G1816A; Q430L, Y484N, N98K, V606I), AAV9.40 (A1694T, E565V), AAV9.41 (A1348T, T1362C; T450S), AAV9.4 4(A1684C, A1701T, A1737G; N562H, K567N), AAV9.45 (A1492T, C1804T; N498Y, L602F), AAV9.46 (G1441C, T1525C, T1549G; G481R, W5 09R, L517V), 9.47 (G1241A, G1358A, A1669G, C1745T; S414N, G453D, K557E, T582I), AAV9.48 (C1445T, A1736T; P482L, Q579L), AAV9.50 (A1638T, C1683T, T1805A; Q546H, L602H), AAV9.53 (G1301A, A1405C, C1664T, G1811T; R134Q, S469R, A555V, G604V), AAV9.54 (C1531A, T1609A; L511I, L537M), AAV9.55 (T1605A; F535L), AAV9.58 (C1475T, C1579A; T492I, H527N), AAV.59 (T1336C; Y446H), AAV9.61 (A1493T; N498I), AAV9.64 (C1531A, A1617T; L511I), AAV9.65 (C1335T, T1530C, C1568A; A523D), AAV9.68 (C1510A; P504T), AAV9.80 (G1441A; G481R), AAV9.83 (C1402A, A1500T; P468T, E500D), AAV9.87 (T1464C, T1468C; S490P), AAV9.90 (A1196T; Y399F), AAV9.91 (T1316G, A1583T, C1782G, T1806C; L439R, K528I), AAV9.93 (A1273G, A1421G, A1638C, C1712T, G1732A, A1744T, A1832T; S425G, Q474R, Q546H, P571L, G578R, T582S, D611V), AAV9.94 (A1675T; M559L) and AAV9.95 (T1605A; F535L). [[ID=I]]
[0237] In some embodiments, the AAV serotype may be or have a sequence as described in International Publication No. WO2016049230, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAVF1 / HSC1 (SEQ ID NOs: 2 and 20 of WO2016049230), AAVF2 / HSC2 (SEQ ID NOs: 3 and 21 of WO2016049230), AAVF3 / HSC3 (SEQ ID NOs: 5 and 22 of WO2016049230), AAVF4 / HSC4 (SEQ ID NOs: 6 and 23 of WO2016049230), AAVF5 / HSC5 (SEQ ID NOs: 11 and 25 of WO2016049230), AAVF6 / HSC6 (SEQ ID NOs: 7 and 24 of WO2016049230), AAVF7 / HSC7 (SEQ ID NOs: 11 and 26 of WO2016049230), AAVF8 / HSC9 (SEQ ID NOs: 11 and 12 of WO2016049230), AAVF9 / HSC10 (SEQ ID NOs: 11 and 12 of WO2016049230), AAVF11 / HSC12 (SEQ ID NOs: 11 and 12 of WO2016049230), AAVF12 / HSC13 (SEQ ID NOs: 11 and 12 of WO2016049230), AAVF13 / HSC14 (SEQ ID NOs: 11 and 12 of WO2016049230), AAVF14 / HSC15 (SEQ ID NOs: 11 and 12 of WO201 NO: 8 and 27), AAVF8 / HSC8 (SEQ ID NO: 9 and 28 of WO2016049230), AAVF9 / HSC9 (SEQ ID NO: 10 and 29 of WO2016049230), AAVF11 / HSC11 (SEQ ID NO: 4 and 26 of WO2016049230), AAVF12 / HSC12 (SEQ ID NO: 12 and 30 of WO2016049230), AAVF13 / HSC13 (SEQ ID NO: 14 and 31 of WO2016049230), AAVF14 / HSC14 (SEQ ID NO: 15 and 32 of WO2016049230), AAVF15 / HSC15 (SEQ ID NO: 16 and 17 of WO2016049230), AAVF16 / HSC17 (SEQ ID NO: 17 and 18 of WO2016049230), AAVF17 / HSC18 (SEQ ID NO: 19 and 20 of WO2016049230), AAVF18 / HSC19 (SEQ ID NO: 21 and 22 of WO2016049230), NO: 16 and 33), AAVF16 / HSC16 (SEQ ID NO: 17 and 34 of WO2016049230), AAVF17 / HSC17 (SEQ ID NO: 13 and 35 of WO2016049230) or variants or derivatives thereof.
[0238] In some embodiments, the AAV serotype can be or have a sequence described in U.S. Patent No. 8,734,809, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV CBr-E1 (SEQ ID NOs: 13 and 87 of U.S. Patent No. 8,734,809), AAV CBr-E2 (SEQ ID NOs: 14 and 88 of U.S. Patent No. 8,734,809), AAV CBr-E3 (SEQ ID NOs: 15 and 89 of U.S. Patent No. 8,734,809), AAV CBr-E4 (SEQ ID NOs: 16 and 90 of U.S. Patent No. 8,734,809), AAV CBr-E5 (SEQ ID NOs: 17 and 91 of U.S. Patent No. 8,734,809), AAV CBr-e5 (SEQ ID NOs: 18 and 92 of U.S. Patent No. 8,734,809), AAV CBr-E6 (SEQ ID NOs: 19 and 93 of U.S. Patent No. 8,734,809), AAV CBr-E7 (SEQ ID NOs: 19 and 104 of U.S. Patent No. 8,734,809), ID NOs: 20 and 94), AAV CBr-E8 (SEQ ID NOs: 21 and 95 of US8734809), AAV CLv-D1 (SEQ ID NOs: 22 and 96 of US8734809), AAV CLv-D2 (SEQ ID NOs: 23 and 97 of US8734809), AAV CLv-D3 (SEQ ID NOs: 24 and 98 of US8734809), AAV CLv-D4 (SEQ ID NOs: 25 and 99 of US8734809), AAV CLv-D5 (SEQ ID NOs: 26 and 100 of US8734809), AAV CLv-D6 (SEQ ID NOs: 27 and 101 of US8734809), AAV CLv-D7 (SEQ ID NOs: 28 and 102 of US8734809), AAV CLv-D8 (SEQ ID NOs: 29 and 103 of US8734809), AAV CLv-E1 (SEQ ID NOs: 13 and 87 of US8734809), AAV CLv-R1 (SEQ ID NOs: 30 and 104 of US8734809), AAV CLv-R2 (SEQ ID NOs: 31 and 105 of US8734809), AAV CLv-R3 (SEQ ID NOs: 32 and 106 of US8734809), AAV CLv-R4 (SEQ ID NOs: 33 and 107 of US8734809), AAV CLv-R5 (SEQ ID NOs: 34 and 108 of US8734809), AAV CLv-R6 (SEQ ID NOs: 35 and 109 of US8734809), AAVCLv-R7 (SEQ ID NOs: 36 and 110 of US8734809), AAV CLv-R8 (SEQ ID NOs: 37 and 111 of US8734809), AAV CLv-R9 (SEQ ID NOs: 38 and 112 of US8734809), AAV CLg-F1 (SEQ ID NOs: 39 and 113 of US8734809), AAV CLg-F2 (SEQ ID NOs: 40 and 114 of US8734809), AAV CLg-F3 (SEQ ID NOs: 41 and 115 of US8734809), AAV CLg-F4 (SEQ ID NOs: 42 and 116 of US8734809), AAV CLg-F5 (SEQ ID NOs: 43 and 117 of US8734809), AAV CLg-F6 (SEQ ID NOs: 43 and 117 of US8734809), AAV CLg-F7 (SEQ ID NOs: 44 and 118 of US8734809), AAV CLg-F8 (SEQ ID NOs: 43 and 117 of US8734809), AAV CSp-1 (SEQ ID NOs: 45 and 119 of US8734809), AAV CSp-10 (SEQ ID NOs: 46 and 120 of US8734809), AAV CSp-11 (SEQ ID NOs: 47 and 121 of US8734809), AAV CSp-2 (SEQ ID NOs: 48 and 122 of US8734809), AAV CSp-3 (SEQ ID NOs: 49 and 123 of US8734809), AAV CSp-4 (SEQ ID NOs: 49 and 124 of US8734809), AAV CSp-5 (SEQ ID NOs: 50 and 51 of US8734809), AAV CSp-6 (SEQ ID NOs: 51 and 52 of US8734809), AAV CSp-7 (SEQ ID NOs: 52 and 53 of US8734809), AAV CSp-8 (SEQ ID NOs: 53 and 54 of US8734809), AAV CSp-9 (SEQ ID NOs: 54 and 55 of US8734809), AAV CSp-10 (SEQ ID NOs: 55 and 56 of US8734809), AAV CSp-11 (SEQ ID NOs: 56 and 57 of US8734809), AAV CSp-12 809), AAV CSp-7 (SEQ ID NOs: 52 and 126 of US8734809), AAV CSp-8 (SEQ ID NOs: 53 and 127 of US8734809), AAV CSp-9 (SEQ ID NOs: 54 and 128 of US8734809), AAV CSp-2 (SEQ ID NOs: 55 and 129 of US8734809), AAV CSp-3 (SEQ ID NOs: 56 and 130 of US8734809), AAV CKd-1 (SEQ ID NOs: 57 and 131 of US8734809), AAV CKd-10 (SEQ ID NOs: 58 and 132 of US8734809), AAV CKd-2 (SEQ ID NOs: 59 and 140 of US8734809), AAV CKd-3 (SEQ ID NOs: 51 and 141 of US8734809), AAV CKd-4 (SEQ ID NOs: 52 and 142 of US8734809), AAV CKd-5 (SEQ ID NOs: 53 and 143 of US8734809), AAV CKd-6 (SEQ ID NOs: 51 and 125 of US8734809), AAV CKd-7 (SEQ ID NOs: 52 and 126 of US8734809), AAV CKd-8 (SEQ ID NOs: 53 and 127 of US8734809), AAV CKd-9 (SEQ ID NOs: 54 and 128 of US8734809), NO: 59 and 133), AAVCKd-3 (SEQ ID NOs: 60 and 134 of US8734809), AAV CKd-4 (SEQ ID NOs: 61 and 135 of US8734809), AAV CKd-6 (SEQ ID NOs: 62 and 136 of US8734809), AAV CKd-7 (SEQ ID NOs: 63 and 137 of US8734809), AAV CKd-8 (SEQ ID NOs: 64 and 138 of US8734809), AAV CLv-1 (SEQ ID NOs: 35 and 139 of US8734809), AAV CLv-12 (SEQ ID NOs: 66 and 140 of US8734809), AAV CLv-13 (SEQ ID NOs: 67 and 141 of US8734809), AAV CLv-2 (SEQ ID NOs: 68 and 142 of US8734809), AAV CLv-3 (SEQ ID NOs: 69 and 150 of US8734809), AAV CLv-4 (SEQ ID NOs: 61 and 155 of US8734809), AAV CLv-5 (SEQ ID NOs: 69 and 156 of US8734809), AAV CLv-6 (SEQ ID NOs: 61 and 157 of US8734809), AAV CLv-7 (SEQ ID NOs: 63 and 137 of US8734809), AAV CLv-8 (SEQ ID NOs: 64 and 138 of US8734809), AAV CLv-1 (SEQ ID NOs: 35 and 139 of US8734809), AAV CLv-1 NO: 68 and 142), AAV CLv-3 (SEQ ID NO: 69 and 143 of US8734809), AAV CLv-4 (SEQ ID NO: 70 and 144 of US8734809), AAV CLv-6 (SEQ ID NO: 71 and 145 of US8734809), AAV CLv-8 (SEQ ID NO: 72 and 146 of US8734809), AAV CKd-B1 (SEQ ID NO: 73 and 147 of US8734809), AAV CKd-B2 (SEQ ID NO: 74 and 148 of US8734809), AAV CKd-B3 (SEQ ID NO: 75 and 149 of US8734809), AAV CKd-B4 (SEQ ID NO: 76 and 150 of US8734809), AAV CKd-B5 (SEQ ID NOs: 77 and 151 of US8734809), AAV CKd-B6 (SEQ ID NOs: 78 and 152 of US8734809), AAV CKd-B7 (SEQ ID NOs: 79 and 153 of US8734809), AAV CKd-B8 (SEQ ID NOs: 80 and 154 of US8734809), AAV CKd-H1 (SEQ ID NOs: 81 and 155 of US8734809), AAV CKd-H2 (SEQ ID NOs: 82 and 156 of US8734809), AAV CKd-H3 (SEQ ID NOs: 83 and 157 of US8734809), AAV CKd-H4 (SEQ ID NOs: 84 and 158 of US8734809), AAV CKd-H5 (SEQ ID NO: 85 and 159 of US8734809), AAVCKd-H6 (SEQ ID NOs: 77 and 151 of US8734809), AAV CHt-1 (SEQ ID NOs: 86 and 160 of US8734809), AAVCLv1-1 (SEQ ID NO: 171 of US8734809), AAV CLv1-2 (SEQ ID NO: 172 of US8734809), AAVCLv1-3 (SEQ ID NO: 173 of US8734809), AAV CLv1-4 (SEQ ID NO: 174 of US8734809), AAVClv1-7 (SEQ ID NO: 175 of US8734809), AAVClv1-8 (SEQ ID NO: 176 of US8734809), AAVClv1-9 (SEQ ID NO: 177 of US8734809), AAV Clv1-10 (SEQ ID NO: 178 of US8734809), AAV.VR-355 (SEQ ID NO: 181 of US8734809), AAV.hu.48R3 (SEQ ID NO: 183 of US8734809), or variants or derivatives thereof.
[0239] In some embodiments, the AAV serotype may be or have a sequence described in International Publication No. WO2016065001, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV CHt-P2 (SEQ ID NOs: 1 and 51 of WO2016065001), AAV CHt-P5 (SEQ ID NOs: 2 and 52 of WO2016065001), AAV CHt-P9 (SEQ ID NOs: 3 and 53 of WO2016065001), AAV CBr-7.1 (SEQ ID NOs: 4 and 54 of WO2016065001), AAV CBr-7.2 (SEQ ID NOs: 5 and 55 of WO2016065001), AAV CBr-7.3 (SEQ ID NOs: 6 and 56 of WO2016065001), AAV CBr-7.4 (SEQ ID NOs: 7 and 8 of WO2016065001), NO: 7 and 57), AAV CBr-7.5 (SEQ ID NO: 8 and 58 of WO2016065001), AAV CBr-7.7 (SEQ ID NO: 9 and 59 of WO2016065001), AAV CBr-7.8 (SEQ ID NO: 10 and 60 of WO2016065001), AAV CBr-7.10 (SEQ ID NOs: 11 and 61 of WO2016065001), AAV CKd-N3 (SEQ ID NOs: 12 and 62 of WO2016065001), AAV CKd-N4 (SEQ ID NOs: 13 and 63 of WO2016065001), AAV CKd-N9 (SEQ ID NOs: 14 and 64 of WO2016065001), AAV CLv-L4 (SEQ ID NOs: 15 and 65 of WO2016065001), AAV CLv-L5 (SEQ ID NOs: 16 and 66 of WO2016065001), AAV CLv-L6 (SEQ ID NOs: 17 and 67 of WO2016065001), AAV CLv-K1 (SEQ ID NOs: 18 and 68 of WO2016065001), AAV CLv-K3 (SEQ ID NOs: 19 and 69 of WO2016065001), AAV CLv-K6 (SEQ ID NOs: 20 and 70 of WO2016065001), AAV CLv-M1 (SEQ ID NOs: 21 and 71 of WO2016065001), AAV CLv-M11 (SEQ ID NOs: 22 and 72 of WO2016065001), AAV CLv-M2 (SEQ ID NOs: 23 and 73 of WO2016065001), AAV CLv-M5 (SEQ ID NOs: 24 and 74 of WO2016065001), AAV CLv-M6 (SEQ ID NOs: 25 and 75 of WO2016065001), AAV CLv-M7 (SEQ ID NOs: 26 and 27 of WO2016065001), NO: 26 and 76), AAV CLv-M8 (SEQ ID NO: 27 and 77 of WO2016065001), AAV CLv-M9 (SEQ ID NO: 28 and 78 of WO2016065001), AAV CHt-P1 (SEQ ID NO: 29 and 79 of WO2016065001), AAV CHt-P6 (SEQ ID NO: 30 and 80 of WO2016065001), AAV CHt-P8 (SEQ ID NO: 31 and 81 of WO2016065001), AAV CHt-6.1 (SEQ ID NO: 32 and 82 of WO2016065001), AAV CHt-6.10 (SEQ ID NO: 33 and 83 of WO2016065001), AAV CHt-6.5 (SEQ ID NO: 34 and 35 of WO2016065001), AAV CHt-6.7 (SEQ ID NO: 35 and 36 of WO2016065001), AAV CHt-6.8 (SEQ ID NO: 36 and 37 of WO2016065001), AAV CHt-6.9 (SEQ ID NO: 37 and 38 of WO2016065001), AAV CHt-7.10 (SEQ ID NO: 38 and 39 of WO2016065001), AAV CHt-7.11 (SEQ ID NO: 39 and 40 of WO2016065001), AAV CHt-7.12 (SEQ ID NO: 39 and 41 of WO2016065001), AAV CHt-7.13 (SEQ ID NO: 39 and 42 of WO NO:34 and 84), AAV CHt-6.6 (SEQ ID NOs: 35 and 85 of WO2016065001), AAV CHt-6.7 (SEQ ID NOs: 36 and 86 of WO2016065001), AAV CHt-6.8 (SEQ ID NOs: 37 and 87 of WO2016065001), AAV CSp-8.10 (SEQ ID NOs: 38 and 88 of WO2016065001), AAV CSp-8.2 (SEQ ID NOs: 39 and 89 of WO2016065001), AAV CSp-8.4 (SEQ ID NOs: 40 and 90 of WO2016065001), AAV CSp-8.5 (SEQ ID NOs: 41 and 91 of WO2016065001), AAV CSp-8.6 (SEQ ID NOs: 42 and 92 of WO2016065001), AAV CSp-8.7 (SEQ ID NOs: 43 and 93 of WO2016065001), AAV CSp-8.8 (SEQ ID NOs: 44 and 94 of WO2016065001), AAV CSp-8.9 (SEQ ID NOs: 45 and 95 of WO2016065001), AAV CBr-B7.3 (SEQ ID NOs: 46 and 96 of WO2016065001), AAV CBr-B7.4 (SEQ ID NOs: 47 and 97 of WO2016065001), AAV3B (SEQ ID NOs: 48 and 98 of WO2016065001), AAV4 (SEQ ID NOs: 49 and 99 of WO2016065001), AAV5 (SEQ ID NOs: 50 and 100 of WO2016065001), or variants or derivatives thereof.
[0240] In some embodiments, the AAV serotype can be or have modifications described in U.S. Publication No. US20160361439, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, Y252F, Y272F, Y444F, Y500F, Y700F, Y704F, Y730F, Y275F, Y281F, Y508F, Y576F, Y612G, Y673F, and Y720F of wild-type AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, and hybrids thereof.
[0241] In some embodiments, the AAV serotype may be or have mutations described in U.S. Pat. No. 9,546,112, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, at least two, but not all, F129L, D418E, K531E, L584F, V598A, and H642N mutations in the sequence of AAV6 (SEQ ID NO: 4 of U.S. Pat. No. 9,546,112), AAV1 (SEQ ID NO: 6 of U.S. Pat. No. 9,546,112), AAV2, AAV3, AAV4, AAV5, AAV7, AAV9, AAV10, or AAV11, or derivatives thereof. In yet another embodiment, the AAV serotype may be or have an AAV6 sequence comprising a K53IE mutation (SEQ ID NO: 5 of U.S. Pat. No. 9,546,112).
[0242] In some embodiments, the AAV serotype may be or have a mutation in the AAV1 sequence described in U.S. Publication No. US20130224836, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, preferably substitution of at least one surface-exposed tyrosine residue at positions 252, 273, 445, 701, 705, and 731 of AAV1 (SEQ ID NO: 2 of US20130224836) with another amino acid, preferably with a phenylalanine residue. In one embodiment, the AAV serotype may be or have a mutation in the AAV9 sequence, such as, but not limited to, preferably substitution of at least one surface-exposed tyrosine residue at positions 252, 272, 444, 500, 700, 704, and 730 of AAV2 (SEQ ID NO: 4 of US 20130224836) with another amino acid, preferably with a phenylalanine residue. In one embodiment, the tyrosine residue at position 446 of AAV9 (SEQ ID NO: 6 of US20130224836) is substituted with a phenylalanine residue.
[0243] In some embodiments, the serotype may be AAV2 or a variant thereof as described in International Publication No. WO2016130589, which is incorporated herein by reference in its entirety. The amino acid sequence of AAV2 may comprise N587A, E548A, or N708A mutations. In one embodiment, the amino acid sequence of any AAV may comprise a V708K mutation.
[0244] In one embodiment, the AAV can be a serotype selected from any of the serotypes present in Table 1.
[0245] In one embodiment, the AAV may comprise a sequence, fragment, or variant of the sequence in Table 1.
[0246] In one embodiment, the AAV may be encoded by a sequence, fragment, or variant described in Table 1.
[0247] Table 1. AAV serotypes
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255]
[0256]
[0257]
[0258]
[0259]
[0260]
[0261]
[0262]
[0263]
[0264]
[0265]
[0266]
[0267]
[0268]
[0269]
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294]
[0295]
[0296]
[0297]
[0298]
[0299] Each patent, application, and / or publication listed in Table 1 is incorporated herein by reference in its entirety.
[0300] In one embodiment, the AAV serotype may be or may have a sequence as described in International Patent Publication No. WO2015038958, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV9 (SEQ ID NOs: 2 and 11 of WO2015038958 or SEQ ID NOs: 127 and 126, respectively, herein), PHP.B (SEQ ID NOs: 8 and 9 of WO2015038958, SEQ ID NOs: 868 and 869, respectively, herein), G2B-13 (SEQ ID NO: 12 of WO2015038958, SEQ ID NO: 870, herein), G2B-26 (SEQ ID NO: 13 of WO2015038958, SEQ ID NOs: 868 and 869, respectively, herein), TH1.1-32 (SEQ ID NO: 14 of WO2015038958, SEQ ID NO: 157, herein), or TH1.2 (SEQ ID NO: 16 of WO2015038958, SEQ ID NO: 171, herein). NO:871), TH1.1-35 (SEQ ID NO:15 of WO2015038958, SEQ ID NO:872 herein), or variants thereof. In addition, any targeting peptide or amino acid insert described in WO2015038958 can be inserted into any parent AAV serotype, such as, but not limited to, AAV9 (DNA sequence is SEQ ID NO:126, amino acid sequence is SEQ ID NO:127). In one embodiment, the amino acid insert is inserted between amino acids 586-592 of the parent AAV (e.g., AAV9). In another embodiment, the amino acid insert is inserted between amino acids 588-589 of the parent AAV sequence.The amino acid insert may be, but is not limited to, any of the following amino acid sequences: TLAVPFK (SEQ ID NO: 1 of WO2015038958; SEQ ID NO: 873 herein), KFPVALT (SEQ ID NO: 3 of WO2015038958; SEQ ID NO: 874 herein), LAVPFK (SEQ ID NO: 31 of WO2015038958; SEQ ID NO: 875 herein), AVPFK (SEQ ID NO: 32 of WO2015038958; SEQ ID NO: 876 herein), VPFK (SEQ ID NO: 33 of WO2015038958; SEQ ID NO: 877 herein), TLAVPF (SEQ ID NO: 34 of WO2015038958; SEQ ID NO: 878 herein), TLAVP (SEQ ID NO: 35 of WO2015038958; SEQ ID NO: 879 herein), NO: 879), TLAV (SEQ ID NO: 36 of WO2015038958; SEQ ID NO: 880 herein), SVSKPFL (SEQ ID NO: 28 of WO2015038958; SEQ ID NO: 881 herein), FTLTTPK (SEQ ID NO: 29 of WO2015038958; SEQ ID NO: 882 herein), MNATKNV (SEQ ID NO: 30 of WO2015038958; SEQ ID NO: 883 herein), QSSQTPR (SEQ ID NO: 54 of WO2015038958; SEQ ID NO: 884 herein), ILGTGTS (SEQ ID NO: 55 of WO2015038958; SEQ ID NO: 885 herein), TRTNPEA (SEQ ID NO: 56 of WO2015038958; SEQ ID NO: 57 herein), ID NO: 886), NGGTSSS (SEQ ID NO: 58 of WO2015038958; SEQ ID NO: 887 herein), or YTLSQGW (SEQ ID NO: 60 of WO2015038958; SEQ ID NO: 888 herein).Non-limiting examples of nucleotide sequences that can encode the amino acid insert include the following: AAGTTTCCTGTGGCGTTGACT (SEQ ID NO: 3 for WO2015038958; SEQ ID NO: 889 herein), ACTTTGGCGGTGCCTTTTAAG (SEQ ID NOs: 24 and 49 of WO2015038958; SEQ ID NO: 890 herein), AGTGTGAGTAAGCCTTTTTTG (SEQ ID NO: 25 of WO2015038958; SEQ ID NO: 891 herein), TTTACGTTGACGACGCCTAAG (SEQ ID NO: 26 of WO2015038958; SEQ ID NO: 892 herein), ATGAATGCTACGAAGAATGTG (SEQ ID NO: 27 of WO2015038958; SEQ ID NO: 893 herein). NO: 893), CAGTCGTCGCAGACGCCTAGG (SEQ ID NO: 48 of WO2015038958; SEQ ID NO: 894 herein), ATTCTGGGGACTGGTACTTCG (SEQ ID NOs: 50 and 52 of WO2015038958; SEQ ID NO: 895 herein), ACGCGGACTAATCCTGAGGCT (SEQ ID NO: 51 of WO2015038958; SEQ ID NO: 896 herein), AATGGGGGGACTAGTAGTTCT (SEQ ID NO: 53 of WO2015038958; SEQ ID NO: 897 herein), or TATACTTTGTCGCAGGGTTGG (SEQ ID NO: 59 of WO2015038958; SEQ ID NO: 898 herein).
[0301] In one embodiment, the AAV serotype can be engineered to contain at least one AAV capsid CD8+ T cell epitope for AAV2, such as, but not limited to, SADNNNSEY (SEQ ID NO:899), LIDQYLYYL (SEQ ID NO:900), VPQYGYLTL (SEQ ID NO:901), TTSTRTWAL (SEQ ID NO:902), YHLNGRDSL (SEQ ID NO:903), SQAVGRSSF (SEQ ID NO:904), VPANPSTTF (SEQ ID NO:905), FPQSGVLIF (SEQ ID NO:906), YFDFNRFHCHFSPRD (SEQ ID NO:907), VGNSSGNWHCDSTWM (SEQ ID NO:908), QFSQAGASDIRDQSR (SEQ ID NO:909), GASDIRQSRNWLP (SEQ ID NO:910), and GNRQAATADVNTQGV (SEQ ID NO:911).
[0302] In one embodiment, an AAV serotype can be engineered to contain at least one AAV capsid CD8+ T cell epitope for AAV1, such as, but not limited to, LDRLMNPLI (SEQ ID NO: 912), TTSTRTWAL (SEQ ID NO: 902), and QPAKKRLNF (SEQ ID NO: 913).
[0303] In one embodiment, the AAV serotype can be or can have a sequence described in International Patent Publication WO2017100671, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV9 (SEQ ID NO: 45 of WO2017100671, SEQ ID NO: 1861 herein), PHP.N (SEQ ID NO: 46 of WO2017100671, SEQ ID NO: 1859 herein), PHP.S (SEQ ID NO: 47 of WO2017100671, SEQ ID NO: 1860 herein), or variants thereof. In addition, any targeting peptide or amino acid insert described in WO2017100671 can be inserted into any parent AAV serotype, such as, but not limited to, AAV9 (SEQ ID NO: 127 or SEQ ID NO: 1861). In one embodiment, the amino acid insert is inserted between amino acids 586-592 of the parent AAV (e.g., AAV9). In another embodiment, the amino acid insert is inserted between amino acids 588-589 of the parent AAV sequence. The amino acid insert may be, but is not limited to, any of the following amino acid sequences: AQTLAVPFKAQ (SEQ ID NO: 1 of WO2017100671; SEQ ID NO: 2245 herein), AQSVSKPFLAQ (SEQ ID NO: 2 of WO2017100671; SEQ ID NO: 2246 herein), AQFTLTTPKAQ (SEQ ID NO: 3 in the sequence listing of WO2017100671; SEQ ID NO: 2247 herein), DGTLAVPFKAQ (SEQ ID NO: 4 in the sequence listing of WO2017100671; SEQ ID NO: 2248 herein), ESTLAVPFKAQ (SEQ ID NO: 5 of WO2017100671; SEQ ID NO: 2249 herein), GGTLAVPFKAQ (SEQ ID NO: 6 of WO2017100671; SEQ ID NO: 2250 herein), NO: 2250), AQTLATPFKAQ (SEQ ID NOs: 7 and 33 of WO2017100671; SEQ ID NO: 2251 herein), ATTLATPFKAQ (SEQ ID NO: 8 of WO2017100671; SEQ ID NO: 2252 herein), DGTLATPFKAQ (SEQ ID NO: 9 of WO2017100671; SEQ ID NO: 2253 herein), GGTLATPFKAQ (SEQ ID NO: 10 of WO2017100671;NO: 2254 herein), SGSLAVPFKAQ (SEQ ID NO: 11 of WO2017100671; SEQ ID NO: 2255 herein), AQTLAQPFKAQ (SEQ ID NO: 12 of WO2017100671; SEQ ID NO: 2256 herein), AQTLQQPFKAQ (SEQ ID NO: 13 of WO2017100671; SEQ ID NO: 2257 herein), AQTLSNPFKAQ (SEQ ID NO: 14 of WO2017100671; SEQ ID NO: 2258 herein), AQTLAVPFSNP (SEQ ID NO: 15 of WO2017100671; SEQ ID NO: 2259 herein), QGTLAVPFKAQ (SEQ ID NO: 16 of WO2017100671; SEQ ID NO: 2260 herein), NO: 2260), NQTLAVPFKAQ (SEQ ID NO: 17 of WO2017100671; SEQ ID NO: 2261 herein), EGSLAVPFKAQ (SEQ ID NO: 18 of WO2017100671; SEQ ID NO: 2262 herein), SGNLAVPFKAQ (SEQ ID NO: 19 of WO2017100671; SEQ ID NO: 2263 herein), EGTLAVPFKAQ (SEQ ID NO: 20 of WO2017100671; SEQ ID NO: 2264 herein), DSTLAVPFKAQ (SEQ ID NO: 21 in Table 1 of WO2017100671; SEQ ID NO: 2265 herein), AVTLAVPFKAQ (SEQ ID NO: 22 of WO2017100671; SEQ ID NO: 2266 herein), NO: 2266), AQTLSTPFKAQ (SEQ ID NO: 23 of WO2017100671; SEQ ID NO: 2267 herein), AQTLPQPFKAQ (SEQ ID NOs: 24 and 32 of WO2017100671; SEQ ID NO: 2268 herein), AQTLSQPFKAQ (SEQ ID NO: 25 of WO2017100671; SEQ ID NO: 2269 herein), AQTLQLPFKAQ (SEQ ID NO: 26 of WO2017100671;: SEQ ID NO: 2270 herein), AQTLTMPFKAQ (SEQ ID NOs: 27 and 34 of WO2017100671 and SEQ ID NO: 35 in the sequence listing of WO2017100671; SEQ ID NO: 2271 herein), AQTLTTPFKAQ (SEQ ID NO: 28 of WO2017100671; SEQ ID NO: 2272 herein), AQYTLSQGWAQ (SEQ ID NO: 29 of WO2017100671; SEQ ID NO: 2273 herein), AQMNATKNVAQ (SEQ ID NO: 30 of WO2017100671; SEQ ID NO: 2274 herein), AQVSGGHHSAQ (SEQ ID NO: 31 of WO2017100671; SEQ ID NO: 2275 herein), NO: 2275), AQTLTAPFKAQ (SEQ ID NO: 35 in Table 1 of WO2017100671; SEQ ID NO: 2276 herein), AQTLSKPFKAQ (SEQ ID NO: 36 in WO2017100671; SEQ ID NO: 2277 herein), QAVRTSL (SEQ ID NO: 37 in WO2017100671; SEQ ID NO: 2278 herein), YTLSQGW (SEQ ID NO: 38 in WO2017100671; SEQ ID NO: 888 herein), LAKERS (SEQ ID NO: 39 in WO2017100671; SEQ ID NO: 2279 herein), TLAVPFK (SEQ ID NO: 40 in the sequence listing of WO2017100671; SEQ ID NO: 873 herein), SVSKPFL (SEQ ID NO: 41 in Table 1 of WO2017100671; SEQ ID NO: 2279 herein), NO:41; SEQ ID NO:881 herein), FTLTTPK (SEQ ID NO:42 of WO2017100671; SEQ ID NO:882 herein), MNSTKNV (SEQ ID NO:43 of WO2017100671; SEQ ID NO:2280 herein), VSGGHHS (SEQ ID NO:44 of WO2017100671; SEQ ID NO:2281 herein), SAQTLAVPFKAQAQ (SEQ ID NO:48 of WO2017100671; SEQ ID NO:2282 herein), SXXXLAVPFKAQAQ (SEQ ID NO:49 of WO2017100671, wherein X can be any amino acid;2283 herein), SAQXXXVPFKAQAQ (SEQ ID NO: 50 of WO2017100671, wherein X can be any amino acid; SEQ ID NO: 2284 herein), SAQTLXXXFKAQAQ (SEQ ID NO: 51 of WO2017100671, wherein X can be any amino acid; SEQ ID NO: 2285 herein), SAQTLAVXXXAQAQ (SEQ ID NO: 52 of WO2017100671, wherein X can be any amino acid; SEQ ID NO: 2286 herein), SAQTLAVPFXXXAQ (SEQ ID NO: 53 of WO2017100671, wherein X can be any amino acid; SEQ ID NO: 2287 herein), TNHQSAQ (SEQ ID NO: 65 of WO2017100671; SEQ ID NO: 66 herein). NO: 2288), AQAQTGW (SEQ ID NO: 66 of WO2017100671; SEQ ID NO: 2289 herein), DGTLATPFK (SEQ ID NO: 67 of WO2017100671; SEQ ID NO: 2290 herein), DGTLATPFKXX (SEQ ID NO: 68 of WO2017100671, wherein X can be any amino acid; SEQ ID NO: 2291 herein), LAVPFKAQ (SEQ ID NO: 80 of WO2017100671; SEQ ID NO: 2292 herein), VPFKAQ (SEQ ID NO: 81 of WO2017100671; SEQ ID NO: 2293 herein), FKAQ (SEQ ID NO: 82 of WO2017100671; SEQ ID NO: 2294 herein), NO: 2294), AQTLAV (SEQ ID NO: 83 of WO2017100671; SEQ ID NO: 2295 herein), AQTLAVPF (SEQ ID NO: 84 of WO2017100671; SEQ ID NO: 2296 herein), QAVR (SEQ ID NO: 85 of WO2017100671; SEQ ID NO: 2297 herein), AVRT (SEQ ID NO: 86 of WO2017100671; SEQ ID NO: 2298 herein), VRTS (SEQ ID NO: 87 of WO2017100671; SEQ ID NO: 2299 herein), RTSL (SEQ ID NO: 88 of WO2017100671);SEQ ID NO: 2300 herein), QAVRT (SEQ ID NO: 89 of WO2017100671; SEQ ID NO: 2301 herein), AVRTS (SEQ ID NO: 90 of WO2017100671; SEQ ID NO: 2302 herein), VRTSL (SEQ ID NO: 91 of WO2017100671; SEQ ID NO: 2303 herein), QAVRTS (SEQ ID NO: 92 of WO2017100671; SEQ ID NO: 2304 herein), or AVRTSL (SEQ ID NO: 93 of WO2017100671; SEQ ID NO: 2305 herein). ;
[0304] Non-limiting examples of nucleotide sequences that can encode the amino acid insert include the following: GATGGGACTTTGGCGGTGCCTTTTAAGGCACAG (SEQ ID NO: 54 of WO2017100671; SEQ ID NO: 2306 herein), GATGGGACGTTGGCGGTGCCTTTTAAGGCACAG (SEQ ID NO: 55 of WO2017100671; SEQ ID NO: 2307 herein), CAGGCGGTTAGGACGTCTTTG (SEQ ID NO: 56 of WO2017100671; SEQ ID NO: 2308 herein), CAGGTCTTCACGGACTCAGACTATCAG (SEQ ID NOs: 57 and 78 of WO2017100671; SEQ ID NO: 2309 herein), CAAGTAAAACCTCTACAAATGTGGTAAAATCG (SEQ ID NO: 58 of WO2017100671; SEQ ID NO: 2310 herein). NO: 2310), ACTCATCGACCAATACTTGTACTATCTCTCTAGAAC (SEQ ID NO: 59 of WO2017100671; SEQ ID NO: 2311 of this article), GGAAGTATTCCTTGGTTTTGAACCCA (SEQ ID NO: 60 of WO2017100671; SEQ ID of this article) NO:2312), GGTCGCGGTTTCTTGTTTGTGGAT (SEQ ID NO:61 of WO2017100671; SEQ ID NO:2313 of this article), CGACCTTGAAGCGCATGAACTCCT (SEQ ID NO:62 of WO2017100671; SEQ ID NO:2313 of this article) IDNO:2314), GTATTCCTTGGTTTTGAACCCAACCGGTCTGCGCCTGTGCMNNMNNMNNMNNMNNMNNMNNTTGGGCACTCTGGTGGTTTGTC (SEQ of WO2017100671 ID NO: 63, wherein N may be A, C, T, or G; SEQ ID NO: 2315 herein), GTATTCCTTGGTTTTGAACCCAACCGGTCTGCGCMNNMNNMNNAAAAGGCACCGCCAAAGTTTG (SEQ ID NO: 69 of WO2017100671, wherein N may be A, C, T, or G;: SEQ ID NO: 2316 herein), GTATTCCTTGGTTTTGAACCCAACCGGTCTGCGCCTGTGCMNNMNNMNNCACCGCC AAAGTTTGGGCACT (SEQ ID NO: 70 of WO2017100671, wherein N may be A, C, T, or G; SEQ ID NO: 2317 herein), GTATTCCTTGGTTTTGAACCCAACCGGTCTGCGCCTGTGCCTTAAAMNNMNNMNNC AAAGTTTGGGCACTCTGGTGG (SEQ ID NO: 71 of WO2017100671, wherein N may be A, C, T, or G; SEQ ID NO: 2318 herein), GTATTCCTTGGTTTTGAACCCAACCGGTCTGCGCCTGTGCCTTAAAAGGCACMNNMNNMNNTTGGGCACTCTGGTGGTTTGTG (SEQ ID NO: 2319 of WO2017100671, wherein N may be A, C, T, or G; NO: 72, wherein N can be A, C, T, or G; SEQ ID NO: 2319 herein), ACTTGGCGGTGCCTTTTAAG (SEQ ID NO: 74 of WO2017100671; SEQ ID NO: 890 herein), AGTGTGAGTAAGCTTTTTTG (SEQ ID NO: 75 of WO2017100671; SEQ ID NO: 891 herein), TTTACGTTGACGACGCCTAAG (SEQ ID NO: 76 of WO2017100671; SEQ ID NO: 892 herein), TATACTTTGTCGCAGGGTTGG (SEQ ID NO: 77 of WO2017100671; SEQ ID NO: 898 herein), or CTTGCGAAGGAGCGGCTTTCG (SEQ ID NO: 79 of WO2017100671; SEQ ID NO: 2320 herein). ;
[0305] In one embodiment, the AAV serotype may be or may have a sequence as described in U.S. Pat. No. 9,624,274, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, AAV1 (SEQ ID NO: 181 of U.S. Pat. No. 9,624,274), AAV6 (SEQ ID NO: 182 of U.S. Pat. No. 9,624,274), AAV2 (SEQ ID NO: 183 of U.S. Pat. No. 9,624,274), AAV3b (SEQ ID NO: 184 of U.S. Pat. No. 9,624,274), AAV7 (SEQ ID NO: 185 of U.S. Pat. No. 9,624,274), AAV8 (SEQ ID NO: 186 of U.S. Pat. No. 9,624,274), AAV10 (SEQ ID NO: 187 of U.S. Pat. No. 9,624,274), AAV4 (SEQ ID NO: 188 of U.S. Pat. No. 9,624,274), AAV11 (SEQ ID NO: 189 of U.S. Pat. No. 9,624,274), bAAV (SEQ ID NO: 190 of U.S. Pat. No. 9,624,274), or AAV2 (SEQ ID NO: 191 of U.S. Pat. No. 9,624,274). NO: 190), AAV5 (SEQ ID NO: 191 of US9624274), GPV (SEQ ID NO: 192 of US9624274; SEQ ID NO: 1862 herein), B19 (SEQ ID NO: 193 of US9624274; SEQ ID NO: 1863 herein), MVM (SEQ ID NO: 194 of US9624274; SEQ ID NO: 1864 herein), FPV (SEQ ID NO: 195 of US9624274; SEQ ID NO: 1865 herein), CPV (SEQ ID NO: 196 of US9624274; SEQ ID NO: 1866 herein), or variants thereof. In addition, any of the structural protein inserts described in US 9624274 can be inserted into, but are not limited to, I-453 and I-587 of any parental AAV serotype, such as, but not limited to, AAV2 (SEQ ID NO: 183 of US 9624274). The amino acid insert can be, but is not limited to, any of the following amino acid sequences: VNLTWSRASG (SEQ ID NO: 50 of US 9624274; SEQ ID NO: 2321 herein), EFCINHRGYWVCGD (SEQ ID NO: 55 of US 9624274; SEQ ID NO: 2322 herein), EDGQVMDVDLS (SEQ ID NO: 85 of US 9624274; SEQ ID NO: 2323 herein), EKQRNGTLT (SEQ ID NO: 86 of US 9624274; SEQ ID NO: 2324 herein), EGQVQVDV (SEQ ID NO: 87 of US 9624274; SEQ ID NO: 2325 herein), EGQVQVDV (SEQ ID NO: 88 of US 9624274; SEQ ID NO: 2326 herein), EGQVQVDV (SEQ ID NO: 89 of US 9624274; SEQ ID NO: 2330 herein), EGQVQVDV (SEQ ID NO: 91 of US 9624274; SEQ ID NO: 2331 herein), EGQVQVDV (SEQ ID NO: 92 of US 9624274; SEQ ID NO: 2332 herein), EGQVQVDV (SEQ ID NO: 93 of US 9624274; SEQ ID NO: 2333 herein), EGQVQVDV (SEQ ID NO: 94 of USSEQ ID NO: 2324 herein), TYQCRVTHPHLPRALMR (SEQ ID NO: 87 of US9624274; SEQ ID NO: 2325 herein), RHSTTQPRKTKGSG (SEQ ID NO: 88 of US9624274; SEQ ID NO: 2326 herein), DSNPRGVSAYLSR (SEQ ID NO: 89 of US9624274; SEQ ID NO: 2327 herein), TITCLWDLAPSK (SEQ ID NO: 90 of US9624274; SEQ ID NO: 2328 herein), KTKGSGFFVF (SEQ ID NO: 91 of US9624274; SEQ ID NO: 2329 herein), THPHLPRALMRS (SEQ ID NO: 92 of US9624274; SEQ ID NO: 2330 herein). NO: 2330), GETYQCRVTHPHLPRALMRSTTK (SEQ ID NO: 93 of US9624274; SEQ ID NO: 2331 herein), LPRALMRS (SEQ ID NO: 94 of US9624274; SEQ ID NO: 2332 herein), INHRGYWV (SEQ ID NO: 95 of US9624274; SEQ ID NO: 2333 herein), CDAGSVRTNAPD (SEQ ID NO: 60 of US9624274; SEQ ID NO: 2334 herein), AKAVSNLTESRSESLQS (SEQ ID NO: 96 of US9624274; SEQ ID NO: 2335 herein), SLTGDEFKKVLET (SEQ ID NO: 97 of US9624274; SEQ ID NO: 2336 herein), REAVAYRFEED (SEQ ID NO: 98 of US9624274; SEQ ID NO: 2337 herein), NO:98; SEQ ID NO:2337 herein), INPEIITLDG (SEQ ID NO:99 of US9624274; SEQ ID NO:2338 herein), DISVTGAPVITATYL (SEQ ID NO:100 of US9624274; SEQ ID NO:2339 herein), DISVTGAPVITA (SEQ ID NO:101 of US9624274; SEQ ID NO:2340 herein), PKTVSNLTESSSESVQS (SEQ ID NO:102 of US9624274;NO: 2341 herein), SLMGDEFKAVLET (SEQ ID NO: 103 of US9624274; SEQ ID NO: 2342 herein), QHSVAYTFEED (SEQ ID NO: 104 of US9624274; SEQ ID NO: 2343 herein), INPEIITRDG (SEQ ID NO: 105 of US9624274; SEQ ID NO: 2344 herein), DISLTGDPVITASYL (SEQ ID NO: 106 of US9624274; SEQ ID NO: 2345 herein), DISLTGDPVITA (SEQ ID NO: 107 of US9624274; SEQ ID NO: 2346 herein), DQSIDFEIDSA (SEQ ID NO: 108 of US9624274; SEQ ID NO: 2347 herein), NO: 2347), KNVSEDLPLPTFSPTLLGDS (SEQ ID NO: 109 of US9624274; SEQ ID NO: 2348 herein), KNVSEDLPLPT (SEQ ID NO: 110 of US9624274; SEQ ID NO: 2349 herein), CDSGRVRTDAPD (SEQ ID NO: 111 of US9624274; SEQ ID NO: 2350 herein), FPEHLLVDFLQSLS (SEQ ID NO: 112 of US9624274; SEQ ID NO: 2351 herein), DAEFRHDSG (SEQ ID NO: 65 of US9624274; SEQ ID NO: 2352 herein), HYAAAQWDFGNTMCQL (SEQ ID NO: 113 of US9624274; SEQ ID NO: 2354 herein). NO: 2353), YAAQWDFGNTMCQ (SEQ ID NO: 114 of US9624274; SEQ ID NO: 2354 herein), RSQKEGLHYT (SEQ ID NO: 115 of US9624274; SEQ ID NO: 2355 herein), SSRTPSDKPVAHWANPQAE (SEQ ID NO: 116 of US9624274; SEQ ID NO: 2356 herein), SRTPSDKPVAHWANP (SEQ ID NO: 117 of US9624274; SEQ ID NO: 2357 herein), SSRTPSDKP (SEQ ID NO: 118 of US9624274;SEQ ID NO: 2358 herein), NADGNVDYHMNSVP (SEQ ID NO: 119 of US9624274; SEQ ID NO: 2359 herein), DGNVDYHMNSV (SEQ ID NO: 120 of US9624274; SEQ ID NO: 2360 herein), RSFKEFLQSSLRALRQ (SEQ ID NO: 121 of US9624274; SEQ ID NO: 2361 herein); FKEFLQSSLRA (SEQ ID NO: 122 of US9624274; SEQ ID NO: 2362 herein), or QMWAPQWGPD (SEQ ID NO: 123 of US9624274; SEQ ID NO: 2363 herein).
[0306] In one embodiment, the AAV serotype can be or can have a sequence described in U.S. Pat. No. 9,475,845, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, an AAV capsid protein comprising one or more amino acid modifications at amino acid positions 585 to 590 of a native AAV2 capsid protein. Further modifications can result in, but are not limited to, the amino acid sequences RGNRQA (SEQ ID NO: 3 of US9475845; SEQ ID NO: 2364 herein), SSSTDP (SEQ ID NO: 4 of US9475845; SEQ ID NO: 2365 herein), SSNTAP (SEQ ID NO: 5 of US9475845; SEQ ID NO: 2366 herein), SNSNLP (SEQ ID NO: 6 of US9475845; SEQ ID NO: 2367 herein), SSTTAP (SEQ ID NO: 7 of US9475845; SEQ ID NO: 2368 herein), AANTAA (SEQ ID NO: 8 of US9475845; SEQ ID NO: 2369 herein), QQNTAP (SEQ ID NO: 9 of US9475845; SEQ ID NO: 2370 herein), SAQAQA (SEQ ID NO: 10 of US9475845; SEQ ID NO: 2371 herein), NO: 2371), QANTGP (SEQ ID NO: 11 of US9475845; SEQ ID NO: 2372 herein), NATTAP (SEQ ID NO: 12 of US9475845; SEQ ID NO: 2373 herein), SSTAGP (SEQ ID NOs: 13 and 20 of US9475845; SEQ ID NO: 2374 herein), QQNTAA (SEQ ID NO: 14 of US9475845; SEQ ID NO: 2375 herein), PSTAGP (SEQ ID NO: 15 of US9475845; SEQ ID NO: 2376 herein), NQNTAP (SEQ ID NO: 16 of US9475845; SEQ ID NO: 2377 herein), QAANAP (SEQ ID NO: 17 of US9475845; SEQ ID NO: 2378 herein), SIVGLP (SEQ ID NOs: 13 and 20 of US9475845; SEQ ID NO: 2379 herein), NO: 18; SEQ ID NO: 2379 herein), AASTAA (SEQ ID NO: 19 and 27 of US9475845; SEQ ID NO: 2380 herein), SQNTTA (SEQ ID NO: 21 of US9475845;
[00155] In one embodiment, the amino acid modification is a substitution with a targeting sequence at amino acid positions 262 to 265 in a native AAV2 capsid protein, or corresponding positions in a capsid protein of another AAV. The targeting sequence can be, but is not limited to, any of the following amino acid sequences: NGRAHA (SEQ ID NO: 38 of US9475845; SEQ ID NO: 2387 herein), QPEHSST (SEQ ID NOs: 39 and 50 of US9475845; SEQ ID NO: 2388 herein), VNTANST (SEQ ID NO: 40 of US9475845; SEQ ID NO: 2389 herein), HGPMQKS (SEQ ID NO: 41 of US9475845; SEQ ID NO: 2390 herein), PHKPPLA (SEQ ID NO: 42 of US9475845; SEQ ID NO: 2391 herein), IKNNEMW (SEQ ID NO: 43 of US9475845; SEQ ID NO: 2392 herein), RNLDTPM (SEQ ID NO: 44 of US9475845; SEQ ID NO: 45 herein). NO: 2393), VDSHRQS (SEQ ID NO: 45 of US9475845; SEQ ID NO: 2394 herein), YDSKTKT (SEQ ID NO: 46 of US9475845; SEQ ID NO: 2395 herein), SQLPHQK (SEQ ID NO: 47 of US9475845; SEQ ID NO: 2396 herein), STMQQNT (SEQ ID NO: 48 of US9475845; SEQ ID NO: 2397 herein), TERYMTQ (SEQ ID NO: 49 of US9475845; SEQ ID NO: 2398 herein), DASLSTS (SEQ ID NO: 51 of US9475845);SEQ ID NO: 2399 herein), DLPNKKT (SEQ ID NO: 52 of US9475845; SEQ ID NO: 2400 herein), DLTAARL (SEQ ID NO: 53 of US9475845; SEQ ID NO: 2401 herein), EPHQFNY (SEQ ID NO: 54 of US9475845; SEQ ID NO: 2402 herein), EPQSNHT (SEQ ID NO: 55 of US9475845; SEQ ID NO: 2403 herein), MSSWPSQ (SEQ ID NO: 56 of US9475845; SEQ ID NO: 2404 herein), NPKHNAT (SEQ ID NO: 57 of US9475845; SEQ ID NO: 2405 herein), PDGMRTT (SEQ ID NO: 58 of US9475845; SEQ ID NO: 2406 herein). NO: 2406), PNNNKTT (SEQ ID NO: 59 of US9475845; SEQ ID NO: 2407 herein), QSTTHDS (SEQ ID NO: 60 of US9475845; SEQ ID NO: 2408 herein), TGSKQKQ (SEQ ID NO: 61 of US9475845; SEQ ID NO: 2409 herein), SLKHQAL (SEQ ID NO: 62 of US9475845; SEQ ID NO: 2410 herein), SPIDGEQ (SEQ ID NO: 63 of US9475845; SEQ ID NO: 2411 herein), WIFPWIQL (SEQ ID NOs: 64 and 112 of US9475845; SEQ ID NO: 2412 herein), CDCRGDCFC (SEQ ID NO: 65 of US9475845; SEQ ID NO: 2413 herein). NO: 2413), CNGRC (SEQ ID NO: 66 of US9475845; SEQ ID NO: 2414 herein), CPRECES (SEQ ID NO: 67 of US9475845; SEQ ID NO: 2415 herein), CTTHWGFTLC (SEQ ID NOs: 68 and 123 of US9475845; SEQ ID NO: 2416 herein), CGRRAGGSC (SEQ ID NO: 69 of US9475845; SEQ ID NO: 2417 herein), CKGGRAKDC (SEQ ID NO: 70 of US9475845);NO: 2418 herein), CVPELGHEC (SEQ ID NOs: 71 and 115 of US9475845; SEQ ID NO: 2419 herein), CRRETAWAK (SEQ ID NO: 72 of US9475845; SEQ ID NO: 2420 herein), VSWFSHRYSPFAVS (SEQ ID NO: 73 of US9475845; SEQ ID NO: 2421 herein), GYRDGYAGPILYN (SEQ ID NO: 74 of US9475845; SEQ ID NO: 2422 herein), XXXYXXX (SEQ ID NO: 75 of US9475845; SEQ ID NO: 2423 herein), YXNW (SEQ ID NO: 76 of US9475845; SEQ ID NO: 2424 herein), RPLPPLP (SEQ ID NO: 77 of US9475845; SEQ ID NO: 2425 herein). NO: 2425), APPLPPR (SEQ ID NO: 78 of US9475845; SEQ ID NO: 2426 herein), DVFYPYPYASGS (SEQ ID NO: 79 of US9475845; SEQ ID NO: 2427 herein), MYWYPY (SEQ ID NO: 80 of US9475845; SEQ ID NO: 2428 herein), DITWDQLWDLMK (SEQ ID NO: 81 of US9475845; SEQ ID NO: 2429 herein), CWDDXWLC (SEQ ID NO: 82 of US9475845; SEQ ID NO: 2430 herein), EWCEYLGGYLRCYA (SEQ ID NO: 83 of US9475845; SEQ ID NO: 2431 herein), YXCXXGPXTWXCXP (SEQ ID NO: 84 of US9475845; SEQ ID NO: 2432 herein). ID NO: 2432), IEGPTLRQWLAARA (SEQ ID NO: 85 of US9475845; SEQ ID NO: 2433 herein), LWXXX (SEQ ID NO: 86 of US9475845; SEQ ID NO: 2434 herein), XFXXYLW (SEQ ID NO: 87 of US9475845; SEQ ID NO: 2435 herein), SSIISHFRWGLCD (SEQ ID NO: 88 of US9475845;NO: 2436 herein), MSRPACPPNDKYE (SEQ ID NO: 89 of US9475845; SEQ ID NO: 2437 herein), CLRSGRGC (SEQ ID NO: 90 of US9475845; SEQ ID NO: 2438 herein), CHWMFSPWC (SEQ ID NO: 91 of US9475845; SEQ ID NO: 2439 herein), WXXF (SEQ ID NO: 92 of US9475845; SEQ ID NO: 2440 herein), CSSRLDAC (SEQ ID NO: 93 of US9475845; SEQ ID NO: 2441 herein), CLPVASC (SEQ ID NO: 94 of US9475845; SEQ ID NO: 2442 herein), CGFECVRQCPERC (SEQ ID NO: 95 of US9475845; SEQ ID NO: 2443 herein). NO: 2443), CVALCREACGEGC (SEQ ID NO: 96 of US9475845; SEQ ID NO: 2444 herein), SWCEPGWCR (SEQ ID NO: 97 of US9475845; SEQ ID NO: 2445 herein), YSGKWGW (SEQ ID NO: 98 of US9475845; SEQ ID NO: 2446 herein), GLSGGRS (SEQ ID NO: 99 of US9475845; SEQ ID NO: 2447 herein), LMLPRAD (SEQ ID NO: 100 of US9475845; SEQ ID NO: 2448 herein), CSCFRDVCC (SEQ ID NO: 101 of US9475845; SEQ ID NO: 2449 herein), CRDVVSVIC (SEQ ID NO: 102 of US9475845; SEQ ID NO: 2450 herein). NO: 2450), MARSGL (SEQ ID NO: 103 of US9475845; SEQ ID NO: 2451 herein), MARAKE (SEQ ID NO: 104 of US9475845; SEQ ID NO: 2452 herein), MSRTMS (SEQ ID NO: 105 of US9475845; SEQ ID NO: 2453 herein), KCCYSL (SEQ ID NO: 106 of US9475845; SEQ ID NO: 2454 herein), MYWGDSHWLQYWYE (SEQ ID NO: 107 of US9475845;NO: 2455 herein), MQLPLAT (SEQ ID NO: 108 of US9475845; SEQ ID NO: 2456 herein), EWLS (SEQ ID NO: 109 of US9475845; SEQ ID NO: 2457 herein), SNEW (SEQ ID NO: 110 of US9475845; SEQ ID NO: 2458 herein), TNYL (SEQ ID NO: 111 of US9475845; SEQ ID NO: 2459 herein), WDLAWMFRLPVG (SEQ ID NO: 113 of US9475845; SEQ ID NO: 2460 herein), CTVALPGGYVRVC (SEQ ID NO: 114 of US9475845; SEQ ID NO: 2461 herein), CVAYCIEHHCWTC (SEQ ID NO: 116 of US9475845; SEQ ID NO: 2462 herein). NO: 2462), CVFAHNYDYLVC (SEQ ID NO: 117 of US9475845; SEQ ID NO: 2463 herein), CVFTSNYAFC (SEQ ID NO: 118 of US9475845; SEQ ID NO: 2464 herein), VHSPNKK (SEQ ID NO: 119 of US9475845; SEQ ID NO: 2465 herein), CRGDGWC (SEQ ID NO: 120 of US9475845; SEQ ID NO: 2466 herein), XRGCDX (SEQ ID NO: 121 of US9475845; SEQ ID NO: 2467 herein), PXXX (SEQ ID NO: 122 of US9475845; SEQ ID NO: 2468 herein), SGKGPRQITAL (SEQ ID NO: 124 of US9475845; SEQ ID NO: 2469 herein), NO: 2469), AAAAAAAAAXXXXX (SEQ ID NO: 125 of US9475845; SEQ ID NO: 2470 herein), VYMSPF (SEQ ID NO: 126 of US9475845; SEQ ID NO: 2471 herein), ATWLPPR (SEQ ID NO: 127 of US9475845; SEQ ID NO: 2472 herein), HTMYYHHYQHHL (SEQ ID NO: 128 of US9475845;: SEQ ID NO: 2473 herein), SEVGCRAGPLQWLCEKYFG (SEQ ID NO: 129 of US9475845; SEQ ID NO: 2474 herein), CGLLPVGRPDRNVWRWLC (SEQ ID NO: 130 of US9475845; SEQ ID NO: 2475 herein), CKGQCDRFKGLPWEC (SEQ ID NO: 131 of US9475845; SEQ ID NO: 2476 herein), SGRSA (SEQ ID NO: 132 of US9475845; SEQ ID NO: 2477 herein), WGFP (SEQ ID NO: 133 of US9475845; SEQ ID NO: 2478 herein), AEPMPPHSLNFSQYLWYT (SEQ ID NO: 134 of US9475845; SEQ ID NO: 2479 herein). NO: 2479), WAYXSP (SEQ ID NO: 135 of US9475845; SEQ ID NO: 2480 herein), IELLQAR (SEQ ID NO: 136 of US9475845; SEQ ID NO: 2481 herein), AYTKCSRQWRTCMTTH (SEQ ID NO: 137 of US9475845; SEQ ID NO: 2482 herein), PQNSKIPGPTFLDPH (SEQ ID NO: 138 of US9475845; SEQ ID NO: 2483 herein), SMEPALPDWWWKMFK (SEQ ID NO: 139 of US9475845; SEQ ID NO: 2484 herein), ANTPCGPYTHDCPVKR (SEQ ID NO: 140 of US9475845; SEQ ID NO: 2485 herein), TACHQHVRMVRP (SEQ ID NO: 141 of US9475845; SEQ ID NO: 2486 herein), NO: 141; SEQ ID NO: 2486 herein), VPWMEPAYQRFL (SEQ ID NO: 142 of US9475845; SEQ ID NO: 2487 herein), DPRATPGS (SEQ ID NO: 143 of US9475845; SEQ ID NO: 2488 herein), FRPNRAQDYNTN (SEQ ID NO: 144 of US9475845; SEQ ID NO: 2489 herein), CTKNSYLMC (SEQ ID NO: 145 of US9475845;NO: 2490 herein), CXXTXXXGXGC (SEQ ID NO: 146 of US9475845; SEQ ID NO: 2491 herein), CPIEDRPMC (SEQ ID NO: 147 of US9475845; SEQ ID NO: 2492 herein), HEWSYLAPYPWF (SEQ ID NO: 148 of US9475845; SEQ ID NO: 2493 herein), MCPKHPLGC (SEQ ID NO: 149 of US9475845; SEQ ID NO: 2494 herein), RMWPSSTVNLSAGRR (SEQ ID NO: 150 of US9475845; SEQ ID NO: 2495 herein), SAKTAVSQRVWLPSHRGGEP (SEQ ID NO: 151 of US9475845; SEQ ID NO: 2496 herein). NO: 2496), KSREHVNNSACPSKRITAAL (SEQ ID NO: 152 of US9475845; SEQ ID NO: 2497 herein), EGFR (SEQ ID NO: 153 of US9475845; SEQ ID NO: 2498 herein), AGLGVR (SEQ ID NO: 154 of US9475845; SEQ ID NO: 2499 herein), GTRQGHTMRLGVSDG (SEQ ID NO: 155 of US9475845; SEQ ID NO: 2500 herein), IAGLATPGWSHWLAL (SEQ ID NO: 156 of US9475845; SEQ ID NO: 2501 herein), SMSIARL (SEQ ID NO: 157 of US9475845; SEQ ID NO: 2502 herein), HTFEPGV (SEQ ID NO: 158 of US9475845; SEQ ID NO: 2503 herein). NO: 2503), NTSLKRISNKRIRRK (SEQ ID NO: 159 of US9475845; SEQ ID NO: 2504 herein), LRIKRKRRKRKKTRK (SEQ ID NO: 160 of US9475845; SEQ ID NO: 2505 herein), GGG, GFS, LWS, EGG, LLV, LSP, LBS, AGG, GRR, GGH, and GTV. ;
[0307] In one embodiment, the AAV serotype may be or may have a sequence as described in U.S. Publication No. US20160369298, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, a site-specific mutant capsid protein of AAV2 (SEQ ID NO: 97 of US20160369298; SEQ ID NO: 2506 herein) or a variant thereof, wherein the specific site is at least one site selected from sites R447, G453, S578, N587, N587+1, S662 of VP1 or a fragment thereof.
[0308] In addition, any mutant sequence described in US20160369298 may be or may have, but is not limited to, any of the following sequences: SDSGASN (SEQ ID NO: 1 and SEQ ID NO: 231 of US20160369298; SEQ ID NO: 2507 herein), SPSGASN (SEQ ID NO: 2 of US20160369298; SEQ ID NO: 2508 herein), SHSGASN (SEQ ID NO: 3 of US20160369298; SEQ ID NO: 2509 herein), SRSGASN (SEQ ID NO: 4 of US20160369298; SEQ ID NO: 2510 herein), SKSGASN (SEQ ID NO: 5 of US20160369298; SEQ ID NO: 2511 herein), SNSGASN (SEQ ID NO: 6 of US20160369298; SEQ ID NO: 2512 herein), NO: 2512), SGSGASN (SEQ ID NO: 7 of US20160369298; SEQ ID NO: 2513 herein), SASGASN (SEQ ID NOs: 8, 175, and 221 of US20160369298; SEQ ID NO: 2514 herein), SESGTSN (SEQ ID NO: 9 of US20160369298; SEQ ID NO: 2515 herein), STTGGSN (SEQ ID NO: 10 of US20160369298; SEQ ID NO: 2516 herein), SSAGSTN (SEQ ID NO: 11 of US20160369298; SEQ ID NO: 2517 herein), NNDSQA (SEQ ID NO: 12 of US20160369298; SEQ ID NO: 2518 herein), NO: 2518), NNRNQA (SEQ ID NO: 13 of US20160369298; SEQ ID NO: 2519 herein), NNNKQA (SEQ ID NO: 14 of US20160369298; SEQ ID NO: 2520 herein), NAKRQA (SEQ ID NO: 15 of US20160369298; SEQ ID NO: 2521 herein), NDEHQA (SEQ ID NO: 16 of US20160369298; SEQ ID NO: 2522 herein), NTSQKA (SEQ ID NO: 17 of US20160369298);NO: 2526 herein), YYLSRTNTHSGTHTQSPLHFSQAGA (SEQ ID NO: 27 of US20160369298; SEQ ID NO: 2527 herein), YYLSRTNTPSGTDTQSRLVFSQAGA (SEQ ID NO: 18 of US20160369298; SEQ ID NO: 2528 herein), YYLSRTNTDSGTETQSGLDFSQAGA (SEQ ID NO: 19 of US20160369298; SEQ ID NO: 2529 herein), YYLSRTNTESGTPTQSALEFSQAGA (SEQ ID NO: 20 of US20160369298; SEQ ID NO: 2530 herein), YYLSRTNTHSGTHTQSPLHFSQAGA (SEQ ID NO: 21 of US20160369298; SEQ ID NO: 2531 herein), YYLSRTNTSSGTITISHLIFSQAGA (SEQ ID NO: 22 of US20160369298; SEQ ID NO: 2532 herein), NO: 2528), YYLSRTNTRSGIMTKSSLMFSQAGA (SEQ ID NO: 23 of US20160369298; SEQ ID NO: 2529 herein), YYLSRTNTKSGRKTLSNLSFSQAGA (SEQ ID NO: 24 of US20160369298; SEQ ID NO: 2530 herein), YYLSRTNDGSGPVTPSKLRFSQRGA (SEQ ID NO: 25 of US20160369298; SEQ ID NO: 2531 herein), YYLSRTNAASGHATHSDLKFSQPGA (SEQ ID NO: 26 of US20160369298; SEQ ID NO: 2532 herein), YYLSRTNGQAGSLTMSELGFSQVGA (SEQ ID NO: 27 of US20160369298; SEQ ID NO: 273 herein). NO: 2533), YYLSRTNSTGGNQTTSQLLFSQLSA (SEQ ID NO: 28 of US20160369298; SEQ ID NO: 2534 herein), YFLSRTNNNTGLNTNSTLNFSQGRA (SEQ ID NO: 29 of US20160369298; SEQ ID NO: 2535 herein), SKTGADNNNSEYSWTG (SEQ ID NO: 30 of US20160369298; SEQ ID NO: 2536 herein), SKTDADNNNSEYSWTG (SEQ ID NO: 31 of US20160369298);NO:2537 herein), SKTEADNNNSEYSWTG (SEQ ID NO:32 of US20160369298; SEQ ID NO:2538 herein), SKTPADNNNSEYSWTG (SEQ ID NO:33 of US20160369298; SEQ ID NO:2539 herein), SKTHADNNNSEYSWTG (SEQ ID NO:34 of US20160369298; SEQ ID NO:2540 herein), SKTQADNNNSEYSWTG (SEQ ID NO:35 of US20160369298; SEQ ID NO:2541 herein), SKTIADNNNSEYSWTG (SEQ ID NO:36 of US20160369298; SEQ ID NO:2542 herein), SKTMADNNNSEYSWTG (SEQ ID NO:37 of US20160369298; SEQ ID NO:2543 herein), NO:37 of US20160369298; SEQ ID NO:2543 herein), SKTRADNNNSEYSWTG (SEQ ID NO:38 of US20160369298; SEQ ID NO:2544 herein), SKTNADNNNSEYSWTG (SEQ ID NO:39 of US20160369298; SEQ ID NO:2545 herein), SKTVGRNNNSEYSWTG (SEQ ID NO:40 of US20160369298; SEQ ID NO:2546 herein), SKTADRNNNSEYSWTG (SEQ ID NO:41 of US20160369298; SEQ ID NO:2547 herein), SKKLSQNNNSKYSWQG (SEQ ID NO:42 of US20160369298; SEQ ID NO:2548 herein), SKPTTGNNNSDYSWPG (SEQ ID NO:43 of US20160369298; SEQ ID NO:2550 herein), NO:43; SEQ ID NO:2549 herein), STQKNENNNSNYSWPG (SEQ ID NO:44 of US20160369298; SEQ ID NO:2550 herein), HKDDEGKF (SEQ ID NO:45 of US20160369298; SEQ ID NO:2551 herein), HKDDNRKF (SEQ ID NO:46 of US20160369298; SEQ ID NO:2552 herein), HKDDTNKF (SEQ ID NO:47 of US20160369298);SEQ ID NO: 2553 herein), HEDSDKNF (SEQ ID NO: 48 of US20160369298; SEQ ID NO: 2554 herein), HRDGADSF (SEQ ID NO: 49 of US20160369298; SEQ ID NO: 2555 herein), HGDNKSRF (SEQ ID NO: 50 of US20160369298; SEQ ID NO: 2556 herein), KQGSEKTNVDFEEV (SEQ ID NO: 51 of US20160369298; SEQ ID NO: 2557 herein), KQGSEKTNVDSEEV (SEQ ID NO: 52 of US20160369298; SEQ ID NO: 2558 herein), KQGSEKTNVDVEEV (SEQ ID NO: 53 of US20160369298; SEQ ID NO: 2559 herein), NO: 2559), KQGSDKTNVDDAGV (SEQ ID NO: 54 of US20160369298; SEQ ID NO: 2560 herein), KQGSSKTNVDPREV (SEQ ID NO: 55 of US20160369298; SEQ ID NO: 2561 herein), KQGSRKTNVDHKQV (SEQ ID NO: 56 of US20160369298; SEQ ID NO: 2562 herein), KQGSKGGNVDTNRV (SEQ ID NO: 57 of US20160369298; SEQ ID NO: 2563 herein), KQGSGEANVDNGDV (SEQ ID NO: 58 of US20160369298; SEQ ID NO: 2564 herein), KQDAAADNIDYDHV (SEQ ID NO: 59 of US20160369298; SEQ ID NO: 2565 herein), KQGSKGGNVDTNRV (SEQ ID NO: 51 of US20160369298; SEQ ID NO: 2566 herein), KQGSGEANVDNGDV (SEQ ID NO: 52 of US20160369298; SEQ ID NO: 2567 herein), KQDAAADNIDYDHV (SEQ ID NO: 53 of US20160369298; SEQ ID NO: 2568 herein), KQGSKGGNVDTNRV (SEQ ID NO: 54 of US20160369298; SEQ ID NO: 2569 herein), KQG NO: 59; SEQ ID NO: 2565 herein), KQSGTRSNAAASSV (SEQ ID NO: 60 of US20160369298; SEQ ID NO: 2566 herein), KENTNTNDTELTNV (SEQ ID NO: 61 of US20160369298; SEQ ID NO: 2567 herein), QRGNNVAATADVNT (SEQ ID NO: 62 of US20160369298; SEQ ID NO: 2568 herein), QRGNNEAATADVNT (SEQ ID NO: 63 of US20160369298);NO: 2569 herein), QRGNNPAATADVNT (SEQ ID NO: 64 of US20160369298; SEQ ID NO: 2570 herein), QRGNNHAATADVNT (SEQ ID NO: 65 of US20160369298; SEQ ID NO: 2571 herein), QEENNIAATPGVNT (SEQ ID NO: 66 of US20160369298; SEQ ID NO: 2572 herein), QPPNNMAATHEVNT (SEQ ID NO: 67 of US20160369298; SEQ ID NO: 2573 herein), QHHNNSAATTIVNT (SEQ ID NO: 68 of US20160369298; SEQ ID NO: 2574 herein), QTTNNRAAFNMVET (SEQ ID NO: 69 of US20160369298; SEQ ID NO: 2575 herein), NO: 2575), QKKNNNAASKKVAT (SEQ ID NO: 70 of US20160369298; SEQ ID NO: 2576 herein), QGGNNKAADDAVKT (SEQ ID NO: 71 of US20160369298; SEQ ID NO: 2577 herein), QAAKGGAADDAVKT (SEQ ID NO: 72 of US20160369298; SEQ ID NO: 2578 herein), QDDRAAAANESVDT (SEQ ID NO: 73 of US20160369298; SEQ ID NO: 2579 herein), QQQHDDAAYQRVHT (SEQ ID NO: 74 of US20160369298; SEQ ID NO: 2580 herein), QSSSSLAAVSTVQT (SEQ ID NO: 75 of US20160369298; SEQ ID NO: 2581 herein), NO: 2581), QNNQTTAAIRNVTT (SEQ ID NO: 76 of US20160369298; SEQ ID NO: 2582 herein), NYNKKSDNVDFT (SEQ ID NO: 77 of US20160369298; SEQ ID NO: 2583 herein), NYNKKSENVDFT (SEQ ID NO: 78 of US20160369298; SEQ ID NO: 2584 herein), NYNKKSLNVDFT (SEQ ID NO: 79 of US20160369298);NO: 2585 herein), NYNKKSPNVDFT (SEQ ID NO: 80 of US20160369298; SEQ ID NO: 2586 herein), NYSKKSHCVDFT (SEQ ID NO: 81 of US20160369298; SEQ ID NO: 2587 herein), NYRKTIYVDFT (SEQ ID NO: 82 of US20160369298; SEQ ID NO: 2588 herein), NYKEKKDVHFT (SEQ ID NO: 83 of US20160369298; SEQ ID NO: 2589 herein), NYGHRAIVQFT (SEQ ID NO: 84 of US20160369298; SEQ ID NO: 2590 herein), NYANHQFVVCT (SEQ ID NO: 85 of US20160369298; SEQ ID NO: 2591 herein), NO: 2591), NYDDDPTGVLLT (SEQ ID NO: 86 of US20160369298; SEQ ID NO: 2592 herein), NYDDPTGVLLT (SEQ ID NO: 87 of US20160369298; SEQ ID NO: 2593 herein), NFEQQNSVEWT (SEQ ID NO: 88 of US20160369298; SEQ ID NO: 2594 herein), SQSGASN (SEQ ID NO: 89 and SEQ ID NO: 241 of US20160369298; SEQ ID NO: 2595 herein), NNGSQA (SEQ ID NO: 90 of US20160369298; SEQ ID NO: 2596 herein), YYLSRTNTPSGTTTWSRLQFSQAGA (SEQ ID NO: 91 of US20160369298; SEQ ID NO: 92 herein). NO: 2597), SKTSADNNNSEYSWTG (SEQ ID NO: 92 of US20160369298; SEQ ID NO: 2598 herein), HKDDEEKF (SEQ ID NOs: 93, 209, 214, 219, 224, 234, 239, and 244 of US20160369298; SEQ ID NO: 2599 herein), KQGSEKTNVDIEEV (SEQ ID NO: 94 of US20160369298; SEQ ID NO: 2600 herein), QRGNNQAATADVNT (SEQ ID NO: 95 of US20160369298);SEQ ID NO: 2601 of this article), NYNKKSVNVDFT (SEQ ID NO: 96 of US20160369298; SEQ ID NO: 2602 of this article), SQSGASNYNTPSGTTTQSRLQFSTSADNNNSEYSWTGATKYH (SEQ ID NO: 106 of US20160369298; SEQ ID NO of this article) NO:2603), SASGASNFNSEGGSLTQSSLGFSTDGENNNSDFSWTGATKYH (SEQ ID NO:107 of US20160369298; SEQ ID NO:2604 of this article), SQSGASNYNTPSGTTTQSRLQFSTDGENNNSDFSWTGATKYH (SEQ ID NO:108 of US20160369298; SEQ ID of this article) NO:2605), SASGASNYNTPSGTTTQSRLQFSTSADNNNSEFSWPGATTYH (SEQ ID NO:109 of US20160369298; SEQ ID NO:2606 of this article), SQSGASNFNSEGGSLTQSSLGFSTDGENNNSDFSWTGATKYH (SEQ ID of US20160369298 NO: 110; SEQ ID NO: 2607 of this article), SASGASNYNTPSGSLTQSSLGFSTDGENNNSDFSWTGATKYH (SEQ ID NO: 111 of US20160369298; SEQ ID NO: 2608 of this article), SQSGASNYNTPSGTTTQSRLQFSTSADNNNSDFSWTGATKYH (SEQ ID of US20160369298 NO:112; SEQ ID of this article NO: 2609), SGAGASNFNSEGGSLTQSSLGFSTDGENNNSDFSWTGATKYH (SEQ ID NO: 113 of US20160369298; SEQ ID NO: 2610 herein), SGAGASN (SEQ ID NO: 176 of US20160369298; SEQ ID NO: 2611 herein), NSEGGSLTQSSLGFS (SEQ ID NOs: 177, 185, 193, and 202 of US20160369298; SEQ ID NO: 2612 herein), TDGENNNSDFS (SEQ ID NO: 178 of US20160369298);SEQ ID NO: 2614 herein), TSADNNNSDFSWT (SEQ ID NO: 180 of US20160369298; SEQ ID NO: 2615 herein), SQSGASNY (SEQ ID NO: 181, 187 and 198 of US20160369298; SEQ ID NO: 2616 herein), NTPSGTTTQSRLQFS (SEQ ID NO: 182, 188, 191 and 199 of US20160369298; SEQ ID NO: 2617 herein), TSADNNNSEYSWTGATKYH (SEQ ID NO: 183 of US20160369298; SEQ ID NO: 2618 herein), NO: 2618), SASGASNF (SEQ ID NO: 184 of US20160369298; SEQ ID NO: 2619 herein), TDGENNNSDFSWTGATKYH (SEQ ID NOs: 186, 189, 194, 197, and 203 of US20160369298; SEQ ID NO: 2620 herein), SASGASNY (SEQ ID NOs: 190 and 195 of US20160369298; SEQ ID NO: 2621 herein), TSADNNNSEFSWPGATTYH (SEQ ID NO: 192 of US20160369298; SEQ ID NO: 2622 herein), NTPSGSLTQSSLGFS (SEQ ID NO: 196 of US20160369298; SEQ ID NO: 2623 herein). NO:2623), TSADNNNSDFSWTGATKYH (SEQ ID NO:200 of US20160369298; SEQ ID NO:2624 of this article), SGAGASNF (SEQ ID NO:201 of US20160369298; SEQ ID of this article) NO: 2625), CTCCAGVVSVVSMRSRVCVNSGCAGCTDHCVVSRNSGTCVMSACACAA (SEQ ID NO: 204 of US20160369298; SEQ ID NO: 2626 of this article), CTCCAGAGAGGCAACAGACAAGCAGCTACCGCAGATGTCAACACACAA (SEQ ID NO: 205 of US20160369298;SEQ ID NO: 2627 herein), SAAGASN (SEQ ID NO: 206 of US20160369298; SEQ ID NO: 2628 herein), YFLSRTNTESGSTTQSTLRFSQAG (SEQ ID NO: 207 of US20160369298; SEQ ID NO: 2629 herein), SKTSADNNNSDFS (SEQ ID NOs: 208, 228, and 253 of US20160369298; SEQ ID NO: 2630 herein), KQGSEKTDVDIDKV (SEQ ID NO: 210 of US20160369298; SEQ ID NO: 2631 herein), STAGASN (SEQ ID NO: 211 of US20160369298; SEQ ID NO: 212 herein). NO: 2632), YFLSRTNTTSGIETQSTLRFSQAG (SEQ ID NO: 212 and SEQ ID NO: 247 of US20160369298; SEQ ID NO: 2633 herein), SKTDGENNNSDFS (SEQ ID NO: 213 and SEQ ID NO: 248 of US20160369298; SEQ ID NO: 2634 herein), KQGAAADDVEIDGV (SEQ ID NO: 215 and SEQ ID NO: 250 of US20160369298; SEQ ID NO: 2635 herein), SEAGASN (SEQ ID NO: 216 of US20160369298; SEQ ID NO: 2636 herein), YYLSRTNTPSGTTTQSRLQFSQAG (SEQ ID NO: 217, 232 and 242 of US20160369298; SEQ ID NO: 2637 herein). NO: 2637), SKTSADNNNSEYS (SEQ ID NOs: 218, 233, 238, and 243 of US20160369298; SEQ ID NO: 2638 herein), KQGSEKTNVDIEKV (SEQ ID NOs: 220, 225, and 245 of US20160369298; SEQ ID NO: 2639 herein), YFLSRTNDASGSDTKSTLLFSQAG (SEQ ID NO: 222 of US20160369298; SEQ ID NO: 2640 herein), STTPSENNNSEYS (SEQ ID NO: 223 of US20160369298;SEQ ID NO: 2641 herein), SAAGATN (SEQ ID NO: 226 and SEQ ID NO: 251 of US20160369298; SEQ ID NO: 2642 herein), YFLSRTNGEAGSATLSELRFSQAG (SEQ ID NO: 227 of US20160369298; SEQ ID NO: 2643 herein), HGDDADRF (SEQ ID NO: 229 and SEQ ID NO: 254 of US20160369298; SEQ ID NO: 2644 herein), KQGAEKSDVEVDRV (SEQ ID NO: 230 and SEQ ID NO: 255 of US20160369298; SEQ ID NO: 2645 herein), KQDSGGDNIDIDQV (SEQ ID NO: 235 of US20160369298; SEQ ID NO: 2646 herein). NO: 2646), SDAGASN (SEQ ID NO: 236 of US20160369298; SEQ ID NO: 2647 herein), YFLSRTNTEGGHDTQSTLRFSQAG (SEQ ID NO: 237 of US20160369298; SEQ ID NO: 2648 herein), KEDGGGSDVAIDEV (SEQ ID NO: 240 of US20160369298; SEQ ID NO: 2649 herein), SNAGASN (SEQ ID NO: 246 of US20160369298; SEQ ID NO: 2650 herein), and YFLSRTNGEAGSATLSELRFSQPG (SEQ ID NO: 252 of US20160369298; SEQ ID NO: 2651 herein). Nucleotide sequences that can encode amino acid mutation sites include the following: AGCVVMDCAGGARSCASCAAC (SEQ ID NO: 97 of US20160369298; SEQ ID NO: 2652 herein), AACRACRRSMRSMAGGCA (SEQ ID NO: 98 of US20160369298; SEQ ID NO: 2653 herein), CACRRGGACRRCRMSRRSARSTTT (SEQ ID NO: 99 of US20160369298;SEQ ID NO: 2654 of this article), TATTTCTTGAGCAGAACAAACRVCVVSRSCGGAMNCVHSACGMHSTCAVVSCTTVDSTTTTCTCAGSBCRGSGCG (SEQ ID NO: 100 of US20160369298; SEQ ID NO: 2655 of this article), TCAAMAMMAVNSRVCSRSAACAACAACAGTRASTTCTCGTGGMMAGGA (SEQ ID NO: 101 of US20160369298; SEQ ID NO: 2656 of this article), AAGSAARRCRSCRVSRVARVCRATRYCGMSNHCRVMVRSGTC (SEQ ID NO: 102 of US20160369298; SEQ ID NO: 2657 of this article), CAGVVSVVSMRSRVCVNSGCAGCTDHCVVSRNSGTCVMSACA (SEQ ID NO: 103 of US20160369298; SEQ ID NO: 2658 of this article), AACTWCRVSVASMVSVHSDDTGTGSWSTKSACT (SEQ ID NO: 104 of US20160369298; SEQ ID NO: 2659 of this article), TTGTTGAACATCACCACGTGACGCACGTTC (SEQ ID NO: 256 of US20160369298; SEQ ID NO: 2660 of this article), TCCCCGTGGTTCTACTACATAATGTGGCCG (SEQ ID NO: 257 of US20160369298; SEQ ID NO: 2661 of this article), TTCCACACTCCGTTTTGGATAATGTTGAAC (SEQ ID NO: 258 of US20160369298; SEQ ID NO: 2662 of this article), AGGGACATCCCCAGCTCCATGCTGTGGTCG (SEQ ID NO: 259 of US20160369298; SEQ ID NO: 2663 of this article), AGGGACAACCCCTCCGACTCGCCCTAATCC (SEQ ID NO: 260 of US20160369298; SEQ ID NO: 2664 of this article), TCCTAGTAGAAGACACCCTCTCACTGCCCG (SEQ ID NO: 261 of US20160369298;SEQ ID NO: 2665 herein), AGTACCATGTACACCCACTCTCCCAGTGCC (SEQ ID NO: 262 of US20160369298; SEQ ID NO: 2666 herein), ATATGGACGTTCATGCTGATCACCATACCG (SEQ ID NO: 263 of US20160369298; SEQ ID NO: 2667 herein), AGCAGGAGCTCCTTGGCCTCAGCGTGCGAG (SEQ ID NO: 264 of US20160369298; SEQ ID NO: 2668 herein), ACAAGCAGCTTCACTATGACAACCACTGAC (SEQ ID NO: 265 of US20160369298; SEQ ID NO: 2669 herein), NO:2669), CAGCCTAGGAACTGGCTTCCTGGACCCTGTTACCGCCAGCAGAGAGTCTCAAMAMMAVNSRVCSRSAACAACAGTRASTTCTCCTGGMMAGGAGCTACCAAGTACCACCTCAATGGCAGAGACTCTCTGGTGAATCCCGGACC AGCTATGGCAAGCCACRRGGACRRCRMSRRSARSTTTTTTCCTCAGAGCGGGGTTCTCATCTTTGGGAAGSAARRCRSCRVSRVARVCRATRYCGMSNHCRVMVRSGTCATGATTACAGACGAAGAGGAGATCTGGAC(SEQ of US20160369298 ID NO: 266; SEQ ID NO: 2670 of this article), TGGGACAATGGCGGTCGTCTCTCAGAGTTKTKKT (SEQ ID NO: 267 of US20160369298; SEQ ID of this article) NO: 2671), AGAGGACCKKTCCTCGATGGTTCATGGTGGAGTTA (SEQ ID NO: 268 of US20160369298; SEQ ID NO: 2672 herein), CCACTTAGGGCCTGGTCGATACCGTTCGGTG (SEQ ID NO: 269 of US20160369298; SEQ ID NO: 2673 herein), and TCTCGCCCCAAGAGTAGAAACCCTTCSTTYYG (SEQ ID NO: 270 of US20160369298; SEQ ID NO: 2674 herein). ;
[0309] In some embodiments, the AAV serotype may comprise an ocular cell targeting peptide as described in International Patent Publication No. WO2016134375, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, SEQ ID NO: 9 and SEQ ID NO: 10 of WO2016134375. In addition, any ocular cell targeting peptide or amino acid described in WO2016134375 may be inserted into any parent AAV serotype, such as, but not limited to, AAV2 (SEQ ID NO: 8 of WO2016134375; SEQ ID NO: 2675 herein) or AAV9 (SEQ ID NO: 11 of WO2016134375; SEQ ID NO: 2676 herein). In some embodiments, modifications, such as insertions, are made at AAV2 protein P34-A35, T138-A139, A139-P140, G453-T454, N587-R588, and / or R588-Q589. In certain embodiments, the insertion is made at D384, G385, I560, T561, N562, E563, E564, E565, N704, and / or Y705 of AAV9. The ocular cell targeting peptide may be, but is not limited to, any of the following amino acid sequences: GSTPPPM (SEQ ID NO: 1 of WO2016134375; SEQ ID NO: 2677 herein) or GETRAPL (SEQ ID NO: 4 of WO2016134375; SEQ ID NO: 2678 herein).
[0310] In some embodiments, the AAV serotypes can be modified as described in U.S. Publication No. US20170145405, the contents of which are incorporated herein by reference in their entirety. The AAV serotypes can include modified AAV2 (e.g., modifications at Y444F, Y500F, Y730F, and / or S662V), modified AAV3 (e.g., modifications at Y705F, Y731F, and / or T492V), and modified AAV6 (e.g., modifications at S663V and / or T492V).
[0311] In some embodiments, the AAV serotype can be modified as described in International Publication No. WO2017083722, the contents of which are incorporated herein by reference in their entirety. AAV serotypes may include AAV1 (Y705+731F+T492V), AAV2 (Y444+500+730F+T491V), AAV3 (Y705+731F), AAV5, AAV 5 (Y436+693+719F), AAV6 (VP3 variant Y705F / Y731F / T492V), AAV8 (Y733F), AAV9, AAV9 (VP3 variant Y731F), and AAV10 (Y733F).
[0312] In some embodiments, the AAV serotype may comprise an engineered epitope as described in International Patent Publication No. WO2017015102, the contents of which are incorporated herein by reference in their entirety, comprising amino acids SPAKFA (SEQ ID NO: 24 of WO2017015102; SEQ ID NO: 2679 herein) or NKDKLN (SEQ ID NO: 2 of WO2017015102; SEQ ID NO: 2680 herein). The epitope may be inserted into the region of amino acids 665 to 670 based on the numbering of the VP1 capsid of AAV8 (SEQ ID NO: 3 of WO2017015102) and / or residues 664 to 668 of AAV3B (SEQ ID NO: 3).
[0313] In one embodiment, the AAV serotype may be or may have a sequence as described in International Patent Publication No. WO2017058892, the contents of which are incorporated herein by reference in their entirety, such as, but not limited to, an AAV variant having a capsid protein that may comprise a substitution at one or more (e.g., 2, 3, 4, 5, 6, or 7) of amino acid residues 262-268, 370-379, 451-459, 472-473, 493-500, 528-534, 547-552, 588-597, 709-710, 716-722 (in any combination) of AAV1 or the equivalent amino acid residues of AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAVrh32.33, bovine AAV, or avian AAV. The amino acid substitution may be, but is not limited to, any amino acid sequence described in WO2017058892.In one embodiment, the AAV may comprise amino acid substitutions at the following residues: 256L, 258K, 259Q, 261S, 263A, 264S, 265T, 266G, 272H, 385S, 386Q, S472R, V473D, N500E, 547S, 709A, 710N, 716D, 717N, 718N, 720L, A456T, Q457T, N458Q, K459S, T492S, K493A, S586R, S587G, S588N, T589R and / or 722T (in any combination) of AAV1 (SEQ ID NO: 1 of WO2017058892); 53P, 535N, 536P, 537G, 538T, 539T, 540A, 541T, 542Y, 543L, 546N, 653V, 654P, 656S, 697Q, 698F, 704D, 705S, 706T, 707G, 708E, 709Y and / or 710R (in any combination) of AAV5 (SEQ ID NO: 5); NO: 5) 248R, 316V, 317Q, 318D, 319S, 443N, 530N, 531S, 532Q 533P, 534A, 535N, 540A, 541T, 542Y, 543L, 545G, 546N, 697Q, 704D, 706T, 708E, 709Y and / or 710R (in any combination); 264S, 266G, 269N, 272H, 457Q, 588S and / or 589I (in any combination) of AAV6 (SEQ ID NO: 6WO2017058892); NO:8WO2017058892) of 457T, 459N, 496G, 499N, 500N, 589Q, 590N and / or 592A (in any combination); 451I, 452N, 453G, 454S, 455G, 456Q, 457N and / or 458Q (in any combination) of AAV9 (SEQ ID NO:9WO2017058892).
[0314] In some embodiments, the AAV may comprise the amino acid sequence at positions 155, 156, and 157 of VP1 or positions 17, 18, 19, and 20 of VP2 as described in International Publication No. WO 2017066764, the contents of which are incorporated herein by reference in their entirety. The amino acid sequence may be, but is not limited to, NSS, SXS, SSY, NXS, NSY, SXY, and NXY, wherein N, X, and Y are independently, but are not limited to, non-serine or non-threonine amino acids, and wherein the AAV may be, but is not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12. In some embodiments, the AAV may comprise a deletion of at least one amino acid at position 156, 157, or 158 of VP1 or position 19, 20, or 21 of VP2, wherein the AAV may be, but is not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, and AAV12.
[0315] In one embodiment, peptides contained in AAV serotypes can be identified using the method described by Hui et al. (Molecular Therapy–Methods & Clinical Development (2015) 2, 15029 doi: 10.1038 / mtm.2015.29; the contents of which are incorporated herein by reference in their entirety). As a non-limiting example, the method includes isolating human splenocytes, restimulating the splenocytes in vitro with individual peptides spanning the amino acid sequence of the AAV capsid protein, performing an IFN-γ ELISpot using the individual peptides used for in vitro restimulation, bioinformatics analysis to determine the HLA restriction of the 15-mer recognized by the IFN-γ ELISpot, identifying candidate reactive 9-mer epitopes for a given HLA allele, synthesizing candidate 9-mers, performing a second IFN-γ ELISpot screen on splenocytes from subjects carrying the HLA allele to which the expected recognized AAV epitope binds, determining AAV capsid reactive CD8+ T cell epitopes, and determining the frequency of responses in subjects to the given AAV epitope.
[0316] In one embodiment, the AAV can be a serotype generated by Cre-recombination-based AAV targeted evolution (CREATE) described by Deverman et al. (Nature Biotechnology 342): 204-209 (2016), the contents of which are incorporated herein by reference in their entirety. In one embodiment, the AAV serotype generated in this manner has improved CNS transduction and / or neuronal and astrocyte tropism compared to other AAV serotypes. As non-limiting examples, the AAV serotypes can be PHP.B, PHP.B2, PHP.B3, PHP.A, G2A12, G2A15. In one embodiment, these AAV serotypes can be AAV9 (SEQ ID NOs: 126 and 127) derivatives having a 7 amino acid insert between amino acids 588-589. Non-limiting examples of these 7 amino acid insertions include LAVPFK (SEQ ID NO:873), SVSKPFL (SEQ ID NO: 1249), FTLTTPK (SEQ ID NO:882), YTLSQGW (SEQ ID NO:888), QAVRTSL (SEQ ID NO:914), and / or LAKERLS (SEQ ID NO:915).
[0317] In one embodiment, the AAV serotype can be as described in Jackson et al. (Frontiers in Molecular Neuroscience 9:154 (2016)), the contents of which are incorporated herein by reference in their entirety. In some embodiments, the AAV serotype is PHP.B or AAV9. In some embodiments, the AAV serotype is paired with the synapsin promoter to enhance neuronal transduction compared to using more common promoters (i.e., CBA or CMV).
[0318] In one embodiment, peptides contained within an AAV serotype can be identified by isolating human splenocytes, restimulating the splenocytes in vitro with individual peptides spanning the amino acid sequence of an AAV capsid protein, performing an IFN-γ ELISpot using the individual peptides used for in vitro restimulation, bioinformatics analysis to determine the restriction of a given allele for the 15-mer recognized by the IFN-γ ELISpot, identifying candidate reactive 9-mer epitopes for a given allele, synthesizing candidate 9-mers, performing a second IFN-γ ELISpot screen on splenocytes from subjects carrying the specific allele to which the expected recognized AAV epitope binds, determining AAV capsid-reactive CD8+ T cell epitopes, and determining the frequency with which subjects respond to a given AAV epitope.
[0319] AAV particles containing regulatory polynucleotides encoding siRNA molecules can be prepared or derived from a variety of AAV serotypes, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV9.47, AAV9 (hu14), AAV10, AAV11, AAV12, AAVrh8, AAVrh10, AAV-DJ8 and AAV-DJ. In some cases, AAVs of different serotypes can be mixed together or mixed with other types of viruses to produce chimeric AAV particles. As a non-limiting example, the AAV particles are derived from the AAV9 serotype.
[0320] viral genome
[0321] In one embodiment, the AAV particle comprises a viral genome having a payload region, as shown.
[0322] In one embodiment, the viral genome may comprise Figure 1 The components shown. The payload region 110 is located within the viral genome 100. At least one inverted terminal repeat (ITR) 120 may be present at the 5' and / or 3' end of the viral genome 100. Between the 5' ITR 120 and the payload region 110, a promoter region 130 may be present. In one embodiment, the payload region may comprise at least one regulatory polynucleotide.
[0323] In one embodiment, the viral genome 100 may comprise Figure 2 The components shown. The payload region 110 is located within the viral genome 100. At least one inverted terminal repeat (ITR) 120 may be present at the 5' and / or 3' end of the viral genome 100. Between the 5' ITR 120 and the payload region 110, a promoter region 130 may be present. Between the promoter region 130 and the payload region 110, an intron region 140 may be present. In one embodiment, the payload region may comprise at least one regulatory polynucleotide.
[0324] In one embodiment, the viral genome 100 may comprise Figure 3 At least one inverted terminal repeat (ITR) 120 may be present at the 5' and / or 3' end of the viral genome 100. In the viral genome 100, there may be an enhancer region 150, a promoter region 130, an intron region 140, and a payload region 110. In one embodiment, the payload region may comprise at least one regulatory polynucleotide.
[0325] In one embodiment, the viral genome 100 may comprise Figure 4The components shown. At least one inverted terminal repeat (ITR) 120 may be present at the 5' and / or 3' end of the viral genome 100. In the viral genome 100, there may be an enhancer region 150, a promoter region 130, an intron region 140, a payload region 110, and a polyadenylation signal sequence region 160. In one embodiment, the payload region may include at least one regulatory polynucleotide.
[0326] In one embodiment, the viral genome 100 may comprise Figure 5 Components shown. At the 5' and / or 3' end of the viral genome 100, there may be at least one inverted terminal repeat (ITR) 120. In the viral genome 100, there may be at least one MCS region 170, an enhancer region 150, a promoter region 130, an intron region 140, a payload region 110, and a polyadenylation signal sequence region 160. In one embodiment, the payload region may comprise at least one regulatory polynucleotide.
[0327] In one embodiment, the viral genome 100 may comprise Figure 6 The components shown. At the 5' and / or 3' end of the viral genome 100, there may be at least one inverted terminal repeat (ITR) 120. Within the viral genome 100, there may be at least one MCS region 170, an enhancer region 150, a promoter region 130, at least one exon region 180, at least one intron region 140, a payload region 110, and a polyadenylation signal sequence region 160. In one embodiment, the payload region may comprise at least one regulatory polynucleotide.
[0328] In one embodiment, the viral genome 100 may comprise Figure 7 and 8 In the viral genome 100, there may be at least one promoter region 130 and one payload region 110. In one embodiment, the payload region may comprise at least one regulatory polynucleotide.
[0329] In one embodiment, the viral genome 100 may comprise Figure 9 In the viral genome 100, there may be at least one promoter region 130, one payload region 110, and one polyadenylation signal sequence region 160. In one embodiment, the payload region may comprise at least one regulatory polynucleotide.
[0330] Viral genome size
[0331] In one embodiment, the viral genome comprising the payload described herein can be a single-stranded or double-stranded viral genome. The size of the viral genome can be small, medium, large, or maximum size. In addition, the viral genome can include a promoter and a polyA tail.
[0332] In one embodiment, the viral genome comprising the payload described herein can be a small single-stranded viral genome. The size of the small single-stranded viral genome can be 2.7 to 3.5 kb, for example, about 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, and 3.5 kb. As a non-limiting example, the size of the small single-stranded viral genome can be 3.2 kb. In addition, the viral genome can include a promoter and a polyA tail.
[0333] In one embodiment, the viral genome comprising the payload described herein can be a small double-stranded viral genome. The size of the small double-stranded viral genome can be 1.3 to 1.7 kb, for example, about 1.3, 1.4, 1.5, 1.6, and 1.7 kb. As a non-limiting example, the size of the small double-stranded viral genome can be 1.6 kb. In addition, the viral genome can include a promoter and a polyA tail.
[0334] In one embodiment, the viral genome comprising the payload described herein can be a medium single-stranded viral genome. The size of the medium single-stranded viral genome can be 3.6 to 4.3 kb, for example, about 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, and 4.3 kb. As a non-limiting example, the size of the medium single-stranded viral genome can be 4.0 kb. In addition, the viral genome can include a promoter and a polyA tail.
[0335] In one embodiment, the viral genome comprising the payload described herein can be a medium double-stranded viral genome. The size of the medium double-stranded viral genome can be 1.8 to 2.1 kb, for example, about 1.8, 1.9, 2.0, and 2.1 kb. As a non-limiting example, the size of the medium double-stranded viral genome can be 2.0 kb. In addition, the viral genome can include a promoter and a polyA tail.
[0336] In one embodiment, the viral genome comprising the payload described herein can be a large single-stranded viral genome. The size of the large single-stranded viral genome may be 4.4 to 6.0 kb, for example, about 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 and 6.0 kb. As a non-limiting example, the size of the large single-stranded viral genome can be 4.7 kb. As another non-limiting example, the size of the large single-stranded viral genome can be 4.8 kb. As another non-limiting example, the size of the large single-stranded viral genome can be 6.0 kb. In addition, the viral genome can include a promoter and a poly A tail.
[0337] In one embodiment, the viral genome comprising the payload described herein can be a large double-stranded viral genome. The size of the large double-stranded viral genome can be 2.2 to 3.0 kb, for example, about 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 and 3.0 kb. As a non-limiting example, the size of the large double-stranded viral genome can be 2.4 kb. In addition, the viral genome can include a promoter and a polyA tail.
[0338] Viral genome components: Inverted terminal repeats (ITRs)
[0339] The AAV particles of the present invention comprise a viral genome having at least one ITR region and a payload region. In one embodiment, the viral genome comprises two ITRs. These two ITRs flank the payload region at the 5' and 3' ends. The ITRs serve as origins of replication comprising replication recognition sites. The ITRs comprise sequence regions that can be complementary and symmetrically arranged. The ITRs incorporated into the viral genome of the present invention can be composed of naturally occurring polynucleotide sequences or recombinantly derived polynucleotide sequences.
[0340] The ITRs can be derived from the same serotype as the capsid, selected from any serotype listed in Table 1 or a derivative thereof. The ITRs can have a different serotype than the capsid. In one embodiment, the AAV particle has more than one ITR. In a non-limiting example, the AAV particle has a viral genome comprising two ITRs. In one embodiment, the ITRs have the same serotype as each other. In another embodiment, the ITRs have different serotypes. Non-limiting examples include zero, one, or two ITRs having the same serotype as the capsid. In one embodiment, both ITRs of the viral genome of the AAV particle are AAV2 ITRs.
[0341] In one embodiment, the ITR has a length of 140-142 nucleotides. Non-limiting examples of ITR length are 102, 140, 141, 142, 145 nucleotides, and nucleotides with at least 95% identity thereto.
[0342] In one embodiment, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located near the 5' end of the flip ITR in the expression vector. In another embodiment, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located near the 3' end of the flip ITR in the expression vector. In yet another embodiment, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located near the 5' end of the flop ITR in the expression vector. In yet another embodiment, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located near the 3' end of the flop ITR in the expression vector. In one embodiment, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located between the 5' end of the flip ITR and the 3' end of the flop ITR in the expression vector. In one embodiment, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located between the 3' end of the flip ITR and the 5' end of the flop ITR in the expression vector (e.g., between the 5' end of the flip ITR and the 3' end of the flop ITR or between the 3' end of the flop ITR and the 5' end of the flip ITR). As a non-limiting example, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more than 30 nucleotides downstream of the 5' or 3' end of the ITR (e.g., Flip or Flop ITR) in the expression vector. As a non-limiting example, an AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more 30 nucleotides upstream of the 5' or 3' end of an ITR (e.g., Flip or Flop ITR) in the expression vector. As another non-limiting example, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located within 1-5, 1-10, 1-15, 1-20, 1-25, 1-30, 5-10, 5-15, 5-20, 5-25, 5-30, 10-15, 10-20, 10-25, 10-30, 15-20, 15-25, 15-30, 20-25, 20-30, or 25-30 nucleotides downstream of the 5' or 3' end of the ITR (e.g., Flip or Flop ITR) in the expression vector.As another non-limiting example, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located within 1-5, 1-10, 1-15, 1-20, 1-25, 1-30, 5-10, 5-15, 5-20, 5-25, 5-30, 10-15, 10-20, 10-25, 10-30, 15-20, 15-25, 15-30, 20-25, 20-30, or 25-30 nucleotides upstream of the 5' or 3' end of an ITR (e.g., Flip or Flop ITR) in the expression vector. As a non-limiting example, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located within the first 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or more than 25% of the nucleotides upstream of the 5' or 3' end of the ITR (e.g., Flip or Flop ITR) in the expression vector. As another non-limiting example, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located within the first 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or more than 25% of the nucleotides downstream of the 5' or 3' end of the ITR (e.g., Flip or Flop ITR) in the expression vector.
[0343] Viral genome components: promoters
[0344] In one embodiment, the payload region of the viral genome comprises at least one element that enhances transgene target specificity and expression (see, e.g., Powell et al., Viral Expression Cassette Elements to Enhance Transgene Target Specificity and Expression in Gene Therapy, 2015; the contents of which are incorporated herein by reference in their entirety). Non-limiting examples of elements that enhance transgene target specificity and expression include promoters, endogenous miRNAs, post-transcriptional regulatory elements (PREs), polyadenylation (PolyA) signal sequences and upstream enhancers (USEs), CMV enhancers, and introns.
[0345] Those skilled in the art will recognize that expression of the polypeptides of the present invention in target cells may require specific promoters, including but not limited to species-specific, inducible, tissue-specific, or cell-cycle-specific promoters (Parr et al., Nat. Med. 3:1145-9 (1997); the contents of which are incorporated herein by reference in their entirety).
[0346] In one embodiment, a promoter is considered effective when it drives expression of a polypeptide encoded in the payload region of the viral genome of an AAV particle.
[0347] In one embodiment, the promoter is one that is recognized to be effective in driving expression of a regulatory polynucleotide.
[0348] In one embodiment, the promoter is one that is considered efficient when it drives expression in the cell to be targeted.
[0349] In one embodiment, the promoter drives the expression of the payload in the target tissue for a period of time. The expression driven by the promoter can last for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 15 days, 16 days, 17 days, 18 days, 19 days , 20 days, 3 weeks, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years or more than 10 years. Expression can persist for 1-5 hours, 1-12 hours, 1-2 days, 1-5 days, 1-2 weeks, 1-3 weeks, 1-4 weeks, 1-2 months, 1-4 months, 1-6 months, 2-6 months, 3-6 months, 3-9 months, 4-8 months, 6-12 months, 1-2 years, 1-5 years, 2-5 years, 3-6 years, 3-8 years, 4-8 years, or 5-10 years.
[0350] In one embodiment, the promoter drives expression of the payload for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65 or more years.
[0351] The promoter can be naturally occurring or non-naturally occurring. Non-limiting examples of promoters include viral promoters, plant promoters, and mammalian promoters. In some embodiments, the promoter can be a human promoter. In some embodiments, the promoter can be truncated.
[0352] Promoters that drive or initiate expression in most tissues include, but are not limited to, human elongation factor 1 alpha subunit (EF1α), cytomegalovirus (CMV) immediate early enhancer and / or promoter, chicken beta-actin (CBA) and its derivative CAG, beta glucuronidase (GUSB), or ubiquitin C (UBC). Tissue-specific expression elements can be used to restrict expression to certain cell types, such as, but not limited to, muscle-specific promoters, B cell promoters, monocyte promoters, leukocyte promoters, macrophage promoters, pancreatic acinar cell promoters, endothelial cell promoters, lung tissue promoters, astrocyte promoters, or nervous system promoters, which can be used to restrict expression to neurons, astrocytes, or oligodendrocytes.
[0353] Non-limiting examples of muscle-specific promoters include the mammalian muscle creatine kinase (MCK) promoter, the mammalian desmin (DES) promoter, the mammalian troponin I (TNNI2) promoter, and the mammalian skeletal α-actin (ASKA) promoter (see, e.g., U.S. Patent Publication No. US20110212529, the contents of which are herein incorporated by reference in their entirety).
[0354] Non-limiting examples of neuronal tissue-specific expression elements include neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B chain (PDGF-β), synaptophysin (Syn), methyl-CpG binding protein 2 (MeCP2), Ca 2+ / Calmodulin-dependent protein kinase II (CaMKII), metabotropic glutamate receptor 2 (mGluR2), neurofilament light (NFL) or neurofilament heavy (NFH), β-globin minigene nβ2, preproenkephalin (PPE), enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2) promoter. Non-limiting examples of tissue-specific expression elements for astrocytes include glial fibrillary acidic protein (GFAP) and EAAT2 promoters. Non-limiting examples of tissue-specific expression elements for oligodendrocytes include myelin basic protein (MBP) promoter.
[0355] In one embodiment, the promoter may be less than 1 kb. The length of the promoter may be 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 50 700, 780, 790, 800 or more nucleotides. The promoter may be 200-300, 200-400, 200-500, 200-600, 200-700, 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800, or 700-800 in length.
[0356] In one embodiment, the promoter can be a combination of two or more components of the same or different starting or parent promoters, such as, but not limited to, CMV and CBA. The length of each component can be 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810 0, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 or more. The length of each component can be 200-300, 200-400, 200-500, 200-600, 200-700, 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800, or 700-800. In one embodiment, the promoter is a combination of a 382-nucleotide CMV enhancer sequence and a 260-nucleotide CBA promoter sequence.
[0357] In one embodiment, the viral genome comprises a ubiquitous promoter. Non-limiting examples of ubiquitous promoters include CMV, CBA (including derivatives CAG, CBh, etc.), EF-1α, PGK, UBC, GUSB (hGBp), and UCOE (promoter of HNRPA2B1-CBX3).
[0358] Yu et al. (Molecular Pain 2011, 7:63; the contents of which are incorporated herein by reference in their entirety) evaluated the expression of eGFP in rat DRG cells and primary DRG cells under the CAG, EFIα, PGK, and UBC promoters using lentiviral vectors and found that UBC showed weaker expression than the other three promoters, and only 10-12% glial expression was observed for all promoters. Soderblom et al. (E. Neuro 2015; the contents of which are incorporated herein by reference in their entirety) evaluated the expression of eGFP in AAV8 with CMV and UBC promoters and in AAV2 with CMV promoter after motor cortex injection. Intranasal administration of plasmids containing UBC or EFIα promoters showed stronger sustained airway expression than expression with the CMV promoter (see, e.g., Gill et al., Gene Therapy 2001, Vol. 8, 1539-1546; the contents of which are incorporated herein by reference in their entirety). Husain et al. (Gene Therapy 2009; the contents of which are incorporated herein by reference in their entirety) evaluated HβH constructs with the hGUSB promoter, the HSV-1 LAT promoter, and the NSE promoter and found that the HβH construct showed weaker expression than NSE in the mouse brain. Passini and Wolfe (J. Virol. 2001, 12382-12392, the contents of which are incorporated herein by reference in their entirety) evaluated the long-term effects of the HβH vector after intracerebroventricular injection in newborn mice and found that its expression persisted for at least one year. Xu et al. (Gene Therapy 2001, 8, 1323-1332; the contents of which are incorporated herein by reference in their entirety) found that when the NFL and NFH promoters were used, expression was low in all brain regions compared to CMV-lacZ, CMV-luc, EF, GFAP, hENK, nAChR, PPE, PPE+wpre, NSE (0.3 kb), NSE (1.8 kb), and NSE (1.8 kb+wpre). Xu et al. found that the promoter activity was NSE (1.8 kb), EF, NSE (0.3 kb), GFAP, CMV, hENK, PPE, NFL, and NFH in descending order. NFL is a 650 nucleotide promoter, while NFH is a 920 nucleotide promoter. Neither is present in the liver, but NFH is abundant in sensory proprioceptive neurons, the brain, and the spinal cord, and is present in the heart.Scn8a is a 470-nucleotide promoter that is expressed throughout the DRG, spinal cord, and brain, with particularly high expression in hippocampal neurons and cerebellar Purkinje cells, cortex, thalamus, and hypothalamus (see, e.g., Drews et al., Identification of evolutionary conserved, funtional noncoding elements in the promoter region of the sodium channel gene SCN8A, Mamm Genome (2007) 18:723-731; and Raymond et al., Expression of Alternatively Spliced Sodium Channel α-subunit genes, Journal of Biological Chemistry (2004) 279(44)46234-46241; the entire contents of which are incorporated herein by reference in their entireties).
[0359] Any of the promoters taught by Yu, Soderblom, Gill, Husain, Passini, Xu, Drews, or Raymond, supra, may be used in the present invention.
[0360] In one embodiment, the promoter is not cell-specific.
[0361] In one embodiment, the promoter is the ubiquitin c (UBC) promoter. The UBC promoter can have a size of 300-350 nucleotides. As a non-limiting example, the UBC promoter is 332 nucleotides.
[0362] In one embodiment, the promoter is a β-glucuronidase (GUSB) promoter. The size of the GUSB promoter can be 350-400 nucleotides. As a non-limiting example, the GUSB promoter is 378 nucleotides.
[0363] In one embodiment, the promoter is a neurofilament light peptide (NFL) promoter. The NFL promoter can have a size of 600-700 nucleotides. As a non-limiting example, the NFL promoter is 650 nucleotides. As a non-limiting example, the construct can be AAV-promoter-CMV / globin intron-regulatory polynucleotide-RBG, wherein the AAV can be self-complementary and the AAV can be a DJ serotype.
[0364] In one embodiment, the promoter is a neurofilament heavy peptide (FH) promoter. The NFH promoter can have a size of 900-950 nucleotides. As a non-limiting example, the NFH promoter is 920 nucleotides. As a non-limiting example, the construct can be AAV-promoter-CMV / globin intron-regulatory polynucleotide-RBG, wherein the AAV can be self-complementary and the AAV can be a DJ serotype.
[0365] In one embodiment, the promoter is the scn8a promoter. The size of the scn8a promoter can be 450-500 nucleotides. As a non-limiting example, the scn8a promoter is 470 nucleotides. As a non-limiting example, the construct can be AAV-promoter-CMV / globin intron regulatory polynucleotide-RBG, wherein the AAV can be self-complementary and the AAV can be DJ serotype.
[0366] In one embodiment, the viral genome comprises a Pol III promoter.
[0367] In one embodiment, the viral genome comprises a P1 promoter.
[0368] In one embodiment, the viral genome comprises a FXN promoter.
[0369] In one embodiment, the promoter is the phosphoglycerate kinase 1 (PGK) promoter.
[0370] In one embodiment, the promoter is the chicken beta-actin (CBA) promoter.
[0371] In one embodiment, the promoter is the CAG promoter, which is a construct comprising the cytomegalovirus (CMV) enhancer fused to the chicken beta-actin (CBA) promoter.
[0372] In one embodiment, the promoter is a cytomegalovirus (CMV) promoter.
[0373] In one embodiment, the viral genome comprises a Pol III promoter, such as a Pol III type 3 promoter.
[0374] In one embodiment, the viral genome comprises a U3, U6, U7, 7SK, H1 or MRP, EBER, selenocysteine tRNA, 7SL, adenovirus VA-1 or telomerase gene promoter.
[0375] In one embodiment, the viral genome comprises an H1 promoter.
[0376] In one embodiment, the viral genome comprises a U6 promoter.
[0377] In one embodiment, the promoter is a liver or skeletal muscle promoter. Non-limiting examples of liver promoters include human alpha-1-antitrypsin (hAAT) and thyroxine-binding globulin (TBG). Non-limiting examples of skeletal muscle promoters include desmin, MCK, or synthetic C5-12.
[0378] In one embodiment, the promoter is an RNA pol III promoter. As a non-limiting example, the RNA pol III promoter is U6. As a non-limiting example, the RNA pol III promoter is H1.
[0379] In one embodiment, the promoter is an RNA Pol II promoter, including, for example, a truncated RNA Pol II promoter.
[0380] In one embodiment, the viral genome comprises two promoters. As non-limiting examples, the promoters are the EF1α promoter and the CMV promoter.
[0381] In one embodiment, the viral genome comprises an enhancer element, a promoter and / or a 5'UTR intron. The enhancer element, also referred to herein as an "enhancer," may be, but is not limited to, a CMV enhancer, the promoter may be, but is not limited to, a CMV, CBA, UBC, GUSB, NSE, synapsin, MeCP2, and GFAP promoter, and the 5'UTR / intron may be, but is not limited to, SV40 and CBA-MVM. As non-limiting examples, the enhancers, promoters and / or introns used in combination can be: (1) CMV enhancer, CMV promoter, SV40 5'UTR intron; (2) CMV enhancer, CBA promoter, SV 40 5'UTR intron; (3) CMV enhancer, CBA promoter, CBA-MVM 5'UTR intron; (4) UBC promoter; (5) GUSB promoter; (6) NSE promoter; (7) synapsin promoter; (8) MeCP2 promoter, (9) GFAP promoter, (10) H1 promoter; and (11) U6 promoter.
[0382] In one embodiment, the viral genome comprises an engineered promoter.
[0383] In another embodiment, the viral genome comprises a promoter from a naturally expressed protein.
[0384] Viral genome components: untranslated regions (UTRs)
[0385] By definition, the wild-type untranslated region (UTR) of a gene is transcribed but not translated. Typically, the 5' UTR begins at the transcription start site and ends at the start codon, and the 3' UTR begins immediately after the stop codon and continues until the transcription termination signal.
[0386] Features commonly found in abundantly expressed genes in specific target organs can be engineered into UTRs to enhance stability and protein production. As non-limiting examples, 5'UTRs from mRNAs normally expressed in the liver (e.g., albumin, serum amyloid A, apolipoprotein A / B / E, transferrin, alpha-fetoprotein, erythropoietin, or factor VIII) can be used in the viral genome of the AAV particles of the present invention to enhance expression in hepatocyte cell lines or the liver.
[0387] Without wishing to be bound by theory, the wild-type 5' untranslated region (UTR) includes features that play a role in translation initiation. A Kozak sequence, known to be involved in the process by which ribosomes initiate translation of many genes, is often contained in the 5'UTR. The Kozak sequence has a consensus of CCR(A / G)CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (ATG), followed by another 'G'.
[0388] In one embodiment, the 5'UTR in the viral genome includes a Kozak sequence.
[0389] In one embodiment, the 5'UTR in the viral genome does not include a Kozak sequence.
[0390] Without wishing to be bound by theory, it is known that the wild-type 3'UTR has a stretch of adenosine and uridine embedded within it. These AU-rich features are particularly prevalent in genes with high turnover rates. Based on their sequence characteristics and functional properties, AU-rich elements (AREs) can be divided into three classes (Chen et al., 1995, the contents of which are incorporated herein by reference in their entirety): Class I AREs, such as but not limited to c-Myc and MyoD, contain several dispersed copies of the AUUUA motif within the U-rich region. Class II AREs, such as but not limited to GM-CSF and TNF-α, have two or more overlapping UUAUUUA(U / A)(U / A) nonamers. Class III AREs are less well defined, such as but not limited to c-Jun and myogenin. These U-rich regions do not contain the AUUUA motif. Most proteins that bind to AREs are known to destabilize the messenger, but members of the ELAV family (most notably HuR) have been shown to increase mRNA stability. HuR binds to all three classes of AREs. Engineering a HuR-specific binding site into the 3'UTR of a nucleic acid molecule will result in HuR binding and thereby stabilization of the message in vivo.
[0391] The introduction, removal, or modification of 3'UTR AU-rich elements (AREs) can be used to modulate the stability of polynucleotides. When engineering specific polynucleotides, such as the payload region of a viral genome, one or more copies of AREs can be introduced to reduce the stability of the polynucleotide, thereby reducing translation and reducing the production of the resulting protein. Similarly, AREs can be identified and removed or mutated to increase intracellular stability and thereby increase translation and production of the resulting protein.
[0392] In one embodiment, the 3'UTR of the viral genome may include an oligo(dT) sequence for templated addition of a poly-A tail.
[0393] In one embodiment, the viral genome may include at least one miRNA seed, binding site, or complete sequence. MicroRNA (or miRNA or miR) is a non-coding RNA of 19-25 nucleotides that binds to a nucleic acid target site and downregulates gene expression by reducing the stability of the nucleic acid molecule or inhibiting translation. The microRNA sequence contains a "seed" region, i.e., a sequence in the 2-8 region of the mature microRNA that has perfect Watson-Crick complementarity with the miRNA target sequence of the nucleic acid.
[0394] In one embodiment, the virus can be genetically engineered to contain, alter, or remove at least one miRNA binding site, sequence, or seed region.
[0395] Any UTR from any gene known in the art can be introduced into the viral genome of the AAV particle. These UTRs or portions thereof can be placed in the same orientation as in the gene in which they are selected, or the orientation or position can be changed. In one embodiment, the UTR used in the viral genome of the AAV particle can be reversed, shortened, extended, made with one or more other 5'UTRs or 3'UTRs known in the art. As used herein, the term "alter" when referring to a UTR means that the UTR has been changed in some way relative to a reference sequence. For example, a 3' or 5'UTR can be changed relative to a wild-type or native UTR by a change in orientation or position as described above, or a 3' or 5'UTR can be changed by including additional nucleotides, deletions of nucleotides, exchanges of nucleotides, or transposition.
[0396] In one embodiment, the viral genome of the AAV particle comprises at least one artificial UTR that is not a variant of a wild-type UTR.
[0397] In one embodiment, the viral genome of the AAV particle comprises a UTR selected from a family of transcripts whose proteins share a common function, structure, characteristic, or property.
[0398] Viral genome components: polyadenylation sequence
[0399] In one embodiment, the viral genome of the AAV particle of the invention comprises at least one polyadenylation sequence.The viral genome of the AAV particle may comprise a polyadenylation sequence between the 3' end of the payload encoding sequence and the 5' end of the 3' ITR.
[0400] In one embodiment, the polyadenylation sequence or "polyA sequence" can range in length from absent to about 500 nucleotides. The length of the polyadenylation sequence can be, but is not limited to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 ,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142 、143、144、145、146、147、148、149、150、151、152、153、154、155、156、157、158、159、160、161、162、163、164、165、166、167、168、169、170、171、172、173、174、175、176、177、178、179、180、181、182、183、184、185、186、187、188、189、190、191、192、193、194、195、196、197、198、199、200、201、2 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261,262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、 322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499 and 500 nucleotides.
[0401] In one embodiment, the polyadenylation sequence is 50-100 nucleotides in length.
[0402] In one embodiment, the polyadenylation sequence is 50-150 nucleotides in length.
[0403] In one embodiment, the polyadenylation sequence is 50-160 nucleotides in length.
[0404] In one embodiment, the polyadenylation sequence is 50-200 nucleotides in length.
[0405] In one embodiment, the polyadenylation sequence is 60-100 nucleotides in length.
[0406] In one embodiment, the polyadenylation sequence is 60-150 nucleotides in length.
[0407] In one embodiment, the polyadenylation sequence is 60-160 nucleotides in length.
[0408] In one embodiment, the polyadenylation sequence is 60-200 nucleotides in length.
[0409] In one embodiment, the polyadenylation sequence is 70-100 nucleotides in length.
[0410] In one embodiment, the polyadenylation sequence is 70-150 nucleotides in length.
[0411] In one embodiment, the polyadenylation sequence is 70-160 nucleotides in length.
[0412] In one embodiment, the polyadenylation sequence is 70-200 nucleotides in length.
[0413] In one embodiment, the polyadenylation sequence is 80-100 nucleotides in length.
[0414] In one embodiment, the polyadenylation sequence is 80-150 nucleotides in length.
[0415] In one embodiment, the polyadenylation sequence is 80-160 nucleotides in length.
[0416] In one embodiment, the polyadenylation sequence is 80-200 nucleotides in length.
[0417] In one embodiment, the polyadenylation sequence is 90-100 nucleotides in length.
[0418] In one embodiment, the polyadenylation sequence is 90-150 nucleotides in length.
[0419] In one embodiment, the polyadenylation sequence is 90-160 nucleotides in length.
[0420] In one embodiment, the polyadenylation sequence is 90-200 nucleotides in length.
[0421] In one embodiment, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located upstream of a polyadenylation sequence in the expression vector. Additionally, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located downstream of a promoter (e.g., but not limited to, CMV, U6, CAG, CBA, or a CBA promoter with an SV40 intron or a human beta globin intron) in the expression vector. As a non-limiting example, the AAV particle comprises a nucleic acid sequence encoding an siRNA molecule, which can be located within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more than 30 nucleotides downstream of the promoter and / or upstream of the polyadenylation sequence in the expression vector. As another non-limiting example, the AAV particles comprise a nucleic acid sequence encoding an siRNA molecule, which in the expression vector can be located within 1-5, 1-10, 1-15, 1-20, 1-25, 1-30, 5-10, 5-15, 5-20, 5-25, 5-30, 10-15, 10-20, 10-25, 10-30, 15-20, 15-25, 15-30, 20-25, 20-30, or 25-30 nucleotides downstream of a promoter and / or upstream of a polyadenylation sequence. As a non-limiting example, an AAV particle comprises a nucleic acid sequence encoding an siRNA molecule that can be located within the first 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or more than 25% of the nucleotides downstream of a promoter and / or upstream of a polyadenylation sequence in an expression vector. As another non-limiting example, an AAV particle comprises a nucleic acid sequence encoding an siRNA molecule that can be located within the first 1-5%, 1-10%, 1-15%, 1-20%, 1-25%, 5-10%, 5-15%, 5-20%, 5-25%, 10-15%, 10-20%, 10-25%, 15-20%, 15-25%, or 20-25% of the nucleotides downstream of a promoter and / or upstream of a polyadenylation sequence in an expression vector.
[0422] In one embodiment, the AAV particle comprises a rabbit globin polyadenylation (poly A) signal sequence.
[0423] In one embodiment, the AAV particles comprise a human growth hormone polyadenylation (poly A) signal sequence.
[0424] Viral genome components: introns
[0425] In one embodiment, the payload region includes at least one expression-enhancing element, such as one or more introns or portions thereof. Non-limiting examples of introns include MVM (67-97 bp), F.IX truncated intron 1 (300 bp), β-globulin SD / immunoglobulin heavy chain splice acceptor (250 bp), adenovirus splice donor / immunoglobulin splice acceptor (500 bp), SV40 late splice donor / splice acceptor (19S / 16S) (180 bp), and hybrid adenovirus splice donor / IgG splice acceptor (230 bp).
[0426] In one embodiment, the length of the intron or intron portion can be 100-500 nucleotides. The length of the intron can be 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490 or 500. The intron may be 80-100, 80-120, 80-140, 80-160, 80-180, 80-200, 80-250, 80-300, 80-350, 80-400, 80-450, 80-500, 200-300, 200-400, 200-500, 300-400, 300-500, or 400-500 in length.
[0427] In one embodiment, the AAV viral genome may comprise a promoter, such as, but not limited to, CMV or U6. As a non-limiting example, the promoter of the AAV comprising the nucleic acid sequence of the siRNA molecule of the present invention is the CMV promoter. As another non-limiting example, the promoter of the AAV comprising the nucleic acid sequence of the siRNA molecule of the present invention is the U6 promoter.
[0428] In one embodiment, the AAV viral genome may comprise a CMV promoter.
[0429] In one embodiment, the AAV viral genome may comprise a U6 promoter.
[0430] In one embodiment, the AAV viral genome may comprise CMV and U6 promoters.
[0431] In one embodiment, the AAV viral genome may comprise a Pol III promoter.
[0432] In one embodiment, the AAV viral genome may comprise a Pol III type 3 promoter.
[0433] In one embodiment, the AAV viral genome may comprise an H1 promoter.
[0434] In one embodiment, the AAV viral genome may comprise a U6 promoter.
[0435] In one embodiment, the AAV viral genome may comprise a CBA promoter.
[0436] In one embodiment, the encoded siRNA molecule can be located downstream of a promoter in the expression vector, such as, but not limited to, CMV, U6, H1, CBA, CAG, or a CBA promoter with introns (e.g., SV40 or other introns known in the art). In addition, the encoded siRNA molecule can also be located upstream of a polyadenylation sequence in the expression vector. As non-limiting examples, the encoded siRNA molecule can be located within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more than 30 amino acids downstream of the promoter and / or upstream of the polyadenylation sequence in the expression vector. As non-limiting examples, the encoded siRNA molecule can be located within 1-5, 1-10, 1-15, 1-20, 1-25, 1-30, 5-10, 5-15, 5-20, 5-25, 5-30, 10-15, 10-20, 10-25, 10-30, 15-20, 15-25, 15-30, 20-25, 20-30, or 25-30 nucleotides downstream of the promoter and / or upstream of the polyadenylation sequence in the expression vector. As non-limiting examples, the encoded siRNA molecule can be located within the first 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, or more than 25% of the nucleotides downstream of the promoter and / or upstream of the polyadenylation sequence in the expression vector. As a non-limiting example, the encoded siRNA molecule can be located within the first 1-5%, 1-10%, 1-15%, 1-20%, 1-25%, 5-10%, 5-15%, 5-20%, 5-25%, 10-15%, 10-20%, 10-25%, 15-20%, 15-25% or 20-25% of the nucleotides downstream of the promoter and / or upstream of the polyadenylation sequence in the expression vector.
[0437] Viral genome components: filler sequences
[0438] In one embodiment, the viral genome comprises one or more stuffer sequences.
[0439] In one embodiment, the viral genome comprises one or more stuffer sequences to bring the length of the viral genome to an optimal size for packaging. As a non-limiting example, the viral genome comprises at least one stuffer sequence to bring the length of the viral genome to approximately 2.3 kb. As a non-limiting example, the viral genome comprises at least one stuffer sequence to bring the length of the viral genome to approximately 4.6 kb.
[0440] In one embodiment, the viral genome comprises one or more stuffer sequences to reduce the possibility that the hairpin structure of the vector genome (e.g., a regulatory polynucleotide as described herein) can be read as an inverted terminal repeat (ITR) during expression and / or packaging. As a non-limiting example, the viral genome comprises at least one stuffer sequence to make the length of the viral genome about 2.3 kb. As a non-limiting example, the viral genome comprises at least one stuffer sequence to make the length of the viral genome about 4.6 kb.
[0441] In one embodiment, the viral genome is a single-stranded (ss) viral genome and comprises one or more stuffer sequences having a length of about 0.1 kb to 3.8 kb, such as, but not limited to, 0.1 kb, 0.2 kb, 0.3 kb, 0.4 kb, 0.5 kb, 0.6 kb, 0.7 kb, 0.8 kb, 0.9 kb, 1 kb, 1.1 kb, 1.2 kb, 1.3 kb, 1.4 kb, In some embodiments, the full-length filler sequence in the vector genome is 3.1kb. In some embodiments, the full-length filler sequence in the vector genome is 2.7kb. In some embodiments, the full-length filler sequence in the vector genome is 0.8kb. In some embodiments, the full-length filler sequence in the vector genome is 0.4kb. In some embodiments, the full-length filler sequence in the vector genome is 0.8kb. In some embodiments, the full-length filler sequence in the vector genome is 0.8kb. In some embodiments, the full-length filler sequence in the vector genome is 0.4kb. In some embodiments, the full-length filler sequence in the vector genome is 0.8kb. As a non-limiting example, each stuffer sequence in the vector genome is 0.4 kb in length.
[0442] In one embodiment, the viral genome is a self-complementary (sc) viral genome and comprises one or more filler sequences having a length of about 0.1 kb-1.5 kb, such as, but not limited to, 0.1 kb, 0.2 kb, 0.3 kb, 0.4 kb, 0.5 kb, 0.6 kb, 0.7 kb, 0.8 kb, 0.9 kb, 1 kb, 1.1 kb, 1.2 kb, 1.3 kb, 1.4 kb or 1.5 kb. As a non-limiting example, the full-length filler sequence in the vector genome is 0.8 kb. As a non-limiting example, the full-length filler sequence in the vector genome is 0.4 kb. As a non-limiting example, the length of each filler sequence in the vector genome is 0.8 kb. As a non-limiting example, the length of each filler sequence in the vector genome is 0.4 kb.
[0443] In one embodiment, the viral genome comprises any portion of the stuffer sequence. The viral genome may comprise 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% of the stuffer sequence.
[0444] In one embodiment, the viral genome is a single-stranded (ss) viral genome and comprises one or more stuffer sequences so that the length of the viral genome is about 4.6 kb. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located at the 3' end of the 5' ITR sequence. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located at the 5' end of the promoter sequence. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located at the 3' end of the polyadenylation signal sequence. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located at the 5' end of the 3' ITR sequence. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located between two intron sequences. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located within an intron sequence. As a non-limiting example, the viral genome comprises two stuffer sequences, and the first stuffer sequence is located at the 3' end of the 5' ITR sequence, and the second stuffer sequence is located at the 3' end of the polyadenylation signal sequence. As a non-limiting example, the viral genome comprises two stuffer sequences, and the first stuffer sequence is located 5' to the promoter sequence, and the second stuffer sequence is located 3' to the polyadenylation signal sequence. As a non-limiting example, the viral genome comprises two stuffer sequences, and the first stuffer sequence is located 3' to the 5' ITR sequence, and the second stuffer sequence is located 5' to the 5' ITR sequence.
[0445] In one embodiment, the viral genome is a self-complementary (sc) viral genome and comprises one or more stuffer sequences so that the length of the viral genome is about 2.3 kb. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located at the 3' end of the 5' ITR sequence. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located at the 5' end of the promoter sequence. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located at the 3' end of the polyadenylation signal sequence. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located at the 5' end of the 3' ITR sequence. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located between two intron sequences. As a non-limiting example, the viral genome comprises at least one stuffer sequence, and the stuffer sequence is located within an intron sequence. As a non-limiting example, the viral genome comprises two stuffer sequences, and the first stuffer sequence is located at the 3' end of the 5' ITR sequence, and the second stuffer sequence is located at the 3' end of the polyadenylation signal sequence. As a non-limiting example, the viral genome comprises two stuffer sequences, and the first stuffer sequence is located 5' to the promoter sequence, and the second stuffer sequence is located 3' to the polyadenylation signal sequence. As a non-limiting example, the viral genome comprises two stuffer sequences, and the first stuffer sequence is located 3' to the 5' ITR sequence, and the second stuffer sequence is located 5' to the 5' ITR sequence.
[0446] In one embodiment, the viral genome can include one or more stuffing sequences between one of the multiple regions of the viral genome. In one embodiment, the stuffing region can be located before a region such as, but not limited to, a payload region, an inverted terminal repeat (ITR), a promoter region, an intron region, an enhancer region, a polyadenylation signal sequence region, a multiple cloning site (MCS) region, and / or an exon region. In one embodiment, the stuffing region can be located after a region such as, but not limited to, a payload region, an inverted terminal repeat (ITR), a promoter region, an intron region, an enhancer region, a polyadenylation signal sequence region, a multiple cloning site (MCS) region, and / or an exon region. In one embodiment, the stuffing region can be located before and after a region such as, but not limited to, a payload region, an inverted terminal repeat (ITR), a promoter region, an intron region, an enhancer region, a polyadenylation signal sequence region, a multiple cloning site (MCS) region, and / or an exon region.
[0447] In one embodiment, the viral genome may include one or more stuffer sequences that fork at least one region of the viral genome. The bifurcated region of the viral genome may include 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% of the region to the 5' end of the stuffer sequence region. As a non-limiting example, the stuffer sequence may fork at least one region so that 10% of the region is located at the 5' end of the stuffer sequence and 90% of the region is located at the 3' end of the stuffer sequence. As a non-limiting example, the stuffer sequence may fork at least one region so that 20% of the region is located at the 5' end of the stuffer sequence and 80% of the region is located at the 3' end of the stuffer sequence. As a non-limiting example, the stuffing sequence may fork at least one region such that 30% of the region is located at the 5' end of the stuffing sequence and 70% of the region is located at the 3' end of the stuffing sequence. As a non-limiting example, the stuffing sequence may fork at least one region such that 40% of the region is located at the 5' end of the stuffing sequence and 60% of the region is located at the 3' end of the stuffing sequence. As a non-limiting example, the stuffing sequence may fork at least one region such that 50% of the region is located at the 5' end of the stuffing sequence and 50% of the region is located at the 3' end of the stuffing sequence. As a non-limiting example, the stuffing sequence may fork at least one region such that 60% of the region is located at the 5' end of the stuffing sequence and 40% of the region is located at the 3' end of the stuffing sequence. As a non-limiting example, the stuffing sequence may fork at least one region such that 70% of the region is located at the 5' end of the stuffing sequence and 30% of the region is located at the 3' end of the stuffing sequence. As a non-limiting example, the stuffing sequence may fork at least one region such that 80% of the region is located at the 5' end of the stuffing sequence and 20% of the region is located at the 3' end of the stuffing sequence. As a non-limiting example, the stuffer sequence may bifurcate at least one region such that 90% of the region is located 5' to the stuffer sequence and 10% of the region is located 3' to the stuffer sequence.
[0448] In one embodiment, the viral genome comprises a stuffer sequence after the 5' ITR.
[0449] In one embodiment, the viral genome comprises a stuffer sequence after the promoter region. In one embodiment, the viral genome comprises a stuffer sequence after the payload region. In one embodiment, the viral genome comprises a stuffer sequence after the intron region. In one embodiment, the viral genome comprises a stuffer sequence after the enhancer region. In one embodiment, the viral genome comprises a stuffer sequence after the polyadenylation signal sequence region. In one embodiment, the viral genome comprises a stuffer sequence after the MCS region. In one embodiment, the viral genome comprises a stuffer sequence after the exon region.
[0450] In one embodiment, the viral genome comprises a stuffer sequence before the promoter region. In one embodiment, the viral genome comprises a stuffer sequence before the payload region. In one embodiment, the viral genome comprises a stuffer sequence before the intron region. In one embodiment, the viral genome comprises a stuffer sequence before the enhancer region. In one embodiment, the viral genome comprises a stuffer sequence before the polyadenylation signal sequence region. In one embodiment, the viral genome comprises a stuffer sequence before the MCS region. In one embodiment, the viral genome comprises a stuffer sequence before the exon region.
[0451] In one embodiment, the viral genome comprises a stuffer sequence before the 3' ITR.
[0452] In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the 5'ITR and the promoter region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the 5'ITR and the payload region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the 5'ITR and the intron region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the 5'ITR and the enhancer region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the 5'ITR and the polyadenylation signal sequence region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the 5'ITR and the MCS region.
[0453] In one embodiment, a stuffer sequence may be located between two regions, such as but not limited to a 5' ITR and an exonic region.
[0454] In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, the promoter region and the payload region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, the promoter region and the intron region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, the promoter region and the enhancer region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, the promoter region and the polyadenylation signal sequence region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, the promoter region and the MCS region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, the promoter region and the exon region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, the promoter region and the 3' ITR.
[0455] In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the payload region and the intron region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the payload region and the enhancer region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the payload region and the polyadenylation signal sequence region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the payload region and the MCS region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the payload region and the exon region.
[0456] In one embodiment, a stuffer sequence may be located between two regions, such as, but not limited to, the payload region and the 3' ITR.
[0457] In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an intron region and an enhancer region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an intron region and a polyadenylation signal sequence region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an intron region and a MCS region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an intron region and an exon region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an intron region and a 3' ITR. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an enhancer region and a polyadenylation signal sequence region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an enhancer region and a MCS region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an enhancer region and an exon region. In one embodiment, the stuffing sequence may be located between two regions, such as, but not limited to, an enhancer region and a 3' ITR.
[0458] In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the polyadenylation signal sequence region and the MCS region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the polyadenylation signal sequence region and the exon region. In one embodiment, the stuffer sequence can be located between two regions, such as, but not limited to, the polyadenylation signal sequence region and the 3' ITR.
[0459] In one embodiment, the stuffer sequence may be located between two regions, such as but not limited to the MCS region and the exon region. In one embodiment, the stuffer sequence may be located between two regions, such as but not limited to the MCS region and the 3' ITR.
[0460] In one embodiment, a stuffer sequence may be located between two regions, such as but not limited to an exon region and a 3' ITR.
[0461] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the promoter region and the payload region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the promoter region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the promoter region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the promoter region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the promoter region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the promoter region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the intron region and the enhancer region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the promoter region, and the second stuffer sequence may be located between the MCS region and the 3'ITR.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5' ITR and the promoter region, and the second stuffer sequence may be located between the exon region and the 3' ITR.
[0462] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the promoter region and the payload region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the promoter region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the promoter region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the promoter region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the promoter region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the promoter region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the payload region and the 3'ITR.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the MCS region and the exon region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the payload region, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0463] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the promoter region and the payload region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the promoter region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the promoter region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the promoter region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the promoter region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the promoter region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the intron region and the enhancer region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the intron region, and the second stuffer sequence may be located between the MCS region and the 3'ITR.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5' ITR and the intron region, and the second stuffer sequence may be located between the exon region and the 3' ITR.
[0464] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the promoter region and the payload region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the promoter region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the promoter region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the promoter region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the promoter region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the promoter region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the intron region and the enhancer region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the enhancer region, and the second stuffer sequence may be located between the MCS region and the 3'ITR.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5' ITR and the enhancer region, and the second stuffer sequence may be located between the exon region and the 3' ITR.
[0465] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the promoter region and the payload region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the promoter region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the promoter region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the promoter region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the promoter region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the promoter region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the exon region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0466] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the promoter region and the payload region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the promoter region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the promoter region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the promoter region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the promoter region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the promoter region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the intron region and the enhancer region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the MCS region, and the second stuffer sequence may be located between the MCS region and the 3'ITR.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5' ITR and the MCS region, and the second stuffer sequence may be located between the exon region and the 3' ITR.
[0467] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the promoter region and the payload region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the promoter region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the promoter region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the promoter region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the promoter region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the promoter region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the intron region and the enhancer region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5'ITR and the exon region, and the second stuffer sequence may be located between the MCS region and the 3'ITR.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the 5' ITR and the exon region, and the second stuffer sequence may be located between the exon region and the 3' ITR.
[0468] In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the payload region and the 3' ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the intron region and the 3' ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the enhancer region and the MCS region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the payload region, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0469] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the enhancer region and the exon region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the intron region, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0470] In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the payload region and the 3' ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the intron region and the 3' ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the enhancer region and the exon region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the enhancer region, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0471] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the payload region and the 3' ITR. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the enhancer region and the MCS region.In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the polyadenylation signal sequence region, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0472] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the enhancer region and the exon region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the exon region, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0473] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the payload region and the 3' ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the intron region and the 3' ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the enhancer region and the exon region.In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the MCS region, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0474] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the payload region and the intron region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the payload region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the payload region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the payload region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the payload region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the payload region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the intron region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the enhancer region and the MCS region.In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may contain two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the MCS region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the MCS region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the promoter region and the 3'ITR, and the second stuffer sequence may be located between the exon region and the 3'ITR.
[0475] In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the intron region and the enhancer region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the intron region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the intron region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the intron region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the intron region and the 3' ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the enhancer region and the polyadenylation signal sequence region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the enhancer region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the enhancer region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the enhancer region and the 3'ITR. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the MCS region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may be located between the payload region and the intron region, and the second stuffer sequence may be located between the polyadenylation signal sequence region and the exon region. In one embodiment, the viral genome may comprise two stuffer sequences, the first stuffer sequence may ...
Claims
1. An adeno-associated virus (AAV) viral genome comprising a nucleic acid sequence located between two inverted terminal repeats (ITRs), wherein the nucleic acid sequence from 5' to 3' comprises: (i)(a) a first 5' flanking region, a nucleotide sequence encoding a first sense strand sequence, a first loop region, a nucleotide sequence encoding a first antisense strand sequence, and a first 3' flanking region; or (b) a first 5' flanking region, a nucleotide sequence encoding a first antisense strand sequence, a first loop region, a nucleotide sequence encoding a first sense strand sequence, and a first 3' flanking region, and (ii) (a) a second 5' flanking region, a nucleotide sequence encoding a second sense strand sequence, a second loop region, and a nucleotide sequence encoding a second antisense strand sequence; or (b) a second 5' flanking region, a nucleotide sequence encoding a second antisense strand sequence, a second loop region, a nucleotide sequence encoding a second sense strand sequence, and a second 3' flanking region; in: The first 5' flanking region comprises the nucleotide sequence of any one of SEQ ID NOs: 1503-1509, 1692 or 1782; and the second 5' flanking region comprises the nucleotide sequence of any one of SEQ ID NOs: 1503-1509, 1692 or 1782; The first loop region comprises the nucleotide sequence of any one of SEQ ID NOs: 1510-1517 or 1693-1694, and the second loop region comprises the nucleotide sequence of any one of SEQ ID NOs: 1510-1517 or 1693-1694, and The first 3' flanking region comprises the nucleotide sequence of any one of SEQ ID NOs: 1518-1522, 1695 or 1783; and the second 3' flanking region comprises the nucleotide sequence of any one of SEQ ID NOs: 1518-1522, 1695 or 1783.
2. The AAV viral genome of claim 1, wherein the first antisense strand sequence is complementary to the mRNA of the first target gene and / or the second antisense strand sequence is complementary to the mRNA of the second target gene.
3. The AAV viral genome of claim 1, further comprising: i) a first promoter located 5' relative to the first 5' flanking region; ii) a first promoter located 5' relative to the first 5' flanking region, and a second promoter located 5' relative to the second 5' flanking region; iii) introns; iv) filling sequence; and / or v) Polyadenylation (polyA) sequence.
4. An adeno-associated virus (AAV) particle comprising the viral genome and AAV capsid protein described in any one of claims 1-3.
5. The AAV particle of claim 4, wherein the AAV capsid protein is an AAV9 capsid protein or a variant thereof or an AAV5 capsid protein or a variant thereof.
6. A cell comprising the AAV viral genome of any one of claims 1-3, optionally wherein the cell is a mammalian cell, a HEK293 cell, an insect cell, an Sf9 cell, a cell of the central nervous system, a neuron, a medium spiny neuron, a motor neuron or an astrocyte.
7. A pharmaceutical composition comprising the AAV particles of claim 4 and a pharmaceutically acceptable excipient.
8. Use of the AAV particles of claim 4 in the preparation of a medicament for inhibiting the expression of one or more target genes in a cell.
9. Use of the AAV particles of claim 4 in the preparation of a medicament for treating a disease of the central nervous system (CNS).
10. A method for producing recombinant adeno-associated virus (AAV) particles, comprising providing a cell having a polynucleotide comprising the AAV viral genome of any one of claims 1-3, at least one polynucleotide encoding an AAV rep gene, and at least one polynucleotide encoding an AAV cap gene; and harvesting recombinant AAV from the cell.
